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ABSTRACT 
 
The HIV-1 pandemic continues to cause millions of new infections and AIDS-related 
deaths each year, and a majority of these occur in regions of the world with limited access to 
antiretroviral therapy. Therefore, an HIV-1 vaccine is still desperately needed. The most 
successful HIV-1 clinical trial to date used a non-replicating canarypox viral vector and protein 
boosting, yet its modest efficacy left room for improvement. Efforts to derive novel vectors which 
can be both safe and immunogenic, have spawned a new era of live, viral vectors. One such 
vaccinia virus vector, NYVAC-KC, was specifically designed to replicate in humans and had 
several immune modulators deleted to improve immunogenicity and reduce pathogenicity. Two 
NYVAC-KC vectors were generated: one expressing the Gag capsid, and one with 
deconstructed-gp41 (dgp41), which contains an important neutralizing antibody target, the 
membrane proximal external region (MPER). These vectors were combined with HIV-1 
Gag/dgp41 virus-like particles (VLPs) produced in the tobacco-relative Nicotiana benthamiana. 
Different plant expression vectors were compared in an effort to improve yield. A Geminivirus-
based vector was shown to increase the amount of MPER present in VLPs, thus potentially 
enhancing immunogenicity. Furthermore, these VLPs were shown to interact with the innate 
immune system through Toll-like receptor (TLR) signaling, which activated antigen presenting 
cells to induce a Th2-biased response in a TLR-dependent manner. Furthermore, expression of 
Gag and dgp41 in NYVAC-KC vectors resulted in activation of antiviral signaling pathways reliant 
on TBK1/IRF3, which necessitated the use of higher doses in mice to match the immunogenicity 
of wild-type viral vectors. VLPs and NYVAC-KC vectors were tested in mice, ultimately showing 
that the best antibody and Gag-specific T cell responses were generated when both components 
were administered simultaneously. Thus, plant-produced VLPs and poxvirus vectors represent a 
highly immunogenic HIV-1 vaccine candidate that warrants further study.  
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Chapter 1 
INTRODUCTION 
 
The HIV-1 Pandemic and Treatment Options: Why a Vaccine is Necessary 
Human immunodeficiency virus (HIV-1) was first discovered in 1983 as the causative 
agent of acquired immune deficiency syndrome [AIDS, (Barre-Sinoussi et al., 1983)]. Since then, 
HIV-1 has infected 78 million people and caused an estimated 35 million AIDS-related deaths 
(UNAIDS). Though antiretroviral therapy (ART) has greatly reduced the number of AIDS-related 
deaths, the overall number of HIV-1 infected individuals is still rising, with 2.1 million new 
infections globally in 2015 (Figure 1A). Furthermore, these infections are occurring 
disproportionately in undeveloped regions of the world with limited access to healthcare, and 
Africa accounts for over 66% of all new infections between 1990 and 2015 (Figure 1B). 
Furthermore, regional division of AIDS-related deaths shows a highly similar trend in which Africa 
accounts for 72% of deaths between 1990-2015, while North American and Europe only account 
for approximately 2% (Figure 1C). Comparison of new infections and AIDS-related deaths with 
ART coverage shows the importance of researching an HIV-1 vaccine, because those regions 
which have a majority of deaths and new infections do not receive proportionately higher ART 
coverage (Figure 1D). Over all regions listed, the average ART coverage is only 46% (UNAIDS). 
A recent study known as the strategic timing of antiretroviral treatment (START), highlighted the 
importance of beginning ART in HIV-1 positive patients whose CD4 count is above 500 cells/mL 
versus waiting until the CD4 count drops below 350 cells/mL, the current standard-of-care 
(Lundgren et al., 2015). Starting treatment immediately upon diagnosis reduced the risk of a 
serious AIDS-related event by approximately half. Therefore, this study suggests that pre-
exposure prophylaxis (PrEP) would be extremely beneficial to highly afflicted regions, however, 
such a venture would require large funding efforts to achieve. An intriguing case in which this 
strategy was applied became known as the Mississippi baby, where an infant was placed on ART 
immediately after birth and treatment ceased around 18 months old (Persaud et al., 2013). The 
2 
child had undetectable HIV-1 viremia until two years after cessation of ART when a rebound 
occurred, thus dashing hopes that a functional cure for newborn infants had been discovered. 
The rebound of viremia after cessation of ART or during treatment interruptions has 
routinely shown that targeting the viral reservoir is an essential component of any HIV-1 cure 
(Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997). Simian immunodeficiency virus (SIV) 
infection has been shown to establish reservoirs within 72 hours of the initial infection (Whitney et 
al., 2014), emphasizing the need for either a prophylactic treatment (PrEP) or preventative 
vaccination. Reservoirs are a primary issue with therapeutic treatments because the latent virus 
avoids the immune responses due to limited replication. Certain ART drugs have been developed 
to combat reservoirs (Archin et al., 2012), however, the development of drug resistance often 
precludes use of one drug indefinitely (Clavel  and Hance 2004). More advanced treatments 
directly target the HIV-1 latent provirus by disrupting the genome using CRISPR/Cas9 genomic 
editing technology (Ebina et al., 2013). Other strategies to render infected patients’ cells resistant 
to viral entry and replication are based on the success of the “Berlin patient” who became the first 
person to be cured of HIV-1 after receiving a bone marrow transplant with a natural 32 bp 
deletion in the CCR5 co-receptor (Hütter  et al., 2009). Following the success of the procedure, 
other less invasive strategies were explored to introduce genetic mutations in the CCR5 or 
CXCR4 co-receptor genes used technologies such as CRISPR/Cas9 (Hou et al., 2015; Ye et al., 
2014), Zinc finger nucleases (Tebas et al., 2014), and TALENs (Ye et al., 2014). Though the 
technology is promising, it is still in its early phases, and will likely come with a large price tag. 
Thus, the limited access to treatment, drug resistance, rapid establishment of reservoirs, and the 
time and expense of the proposed genomic editing technologies makes the need for a 
prophylactic HIV-1 vaccine ever more apparent. 
 
Vaccination Strategies and Correlates of Protection 
Since the discovery of HIV-1 in 1983, only a handful of efficacy trials have been 
completed, and none have demonstrated success warranting widespread vaccination (Table 1). 
Strategies have primarily focused on eliciting either protective antibody (Ab) responses, or cell-
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mediated immunity, a less well characterized part of vaccine immunology. Vaccines targeting Ab 
responses mainly target the HIV-1 envelope spike protein gp160/Env, the only protein exposed 
on the virion surface (Briggs and Krausslich, 2011; Engelman and Cherepanov, 2012). However, 
Env spikes are present at low density, and the immunodominant regions are often found in 
hypervariable loops that experience rapid turnover during immune escape, thus resulting in an 
evolutionary arms race with the immune system (Liao et al., 2013b). Furthermore, Ab responses 
to Env are faced with several difficult factors including occlusion of immunodominant regions by 
glycan shields or hypervariable loops and only transient exposure of the conserved neutralization 
sites (Labrijn et al., 2003; Moore et al., 2015; Moscoso et al., 2014; Munro et al., 2014; Pancera 
et al., 2014). Two phase III clinical trials, VAX003 and VAX004, were conducted using 
recombinant gp120 (rgp120) antigen in an effort to design a vaccine with Ab-mediated protection 
(Table 1). Both trials showed a lack of efficacy and an inability to reduce viral load or boost CD4 
counts in vaccinees that subsequently became infected (Flynn et al., 2005; Pitisuttithum et al., 
2006). The Ab responses which most closely correlated with decreased infection risk in 
vaccinated subjects were those that blocked CD4 binding (Gilbert et al., 2005). 
The second major approach is based on T cell responses stemming from studies on elite 
controllers or long-term non-progressors (LTNPs), which have shown that the immune system is 
capable of naturally controlling HIV-1 infection and have provided insight into correlates of 
protection that vaccines should target (Betts et al., 2006; Deeks and Walker, 2007; Feinberg and 
Ahmed, 2012; Mudd et al., 2012). Additionally, these epitopes are known to have a strong HLA 
(human leukocyte antigen) genetic component, resulting control of replication only in the subsets 
of the population that express these alleles (Migueles et al., 2000). The Gag capsid protein 
contains many of these epitopes, and escape from cytotoxic T lymphocyte (CTL) control is almost 
always preceded by one or more mutations in these regions, but at a severe fitness cost to the 
virus (Boutwell et al., 2009; Kelleher et al., 2001; Prado et al., 2009; Schneidewind et al., 2007). 
Several of the protective epitopes were also shown to be isolated to structurally critical regions 
within the capsid protein, thus deterring viral escape mutations (Pereyra et al., 2014). Protective 
Gag epitopes are also presented earlier than those from other proteins, facilitating rapid CD8-
4 
mediated killing of infected cells (Kloverpris et al., 2013). Therefore, there seems to be an 
advantage of a vaccine eliciting Gag-specific CD8 T cell responses. 
The first clinical trial using a cell-mediated immunity approach was the Step Trial 
(HVTN502, Table 1). This study utilized a recombinant adenovirus (rAd5) expressing Gag-Pol-
Nef (GPN) antigens and elicited robust CD4 T cell responses with exceedingly low CD8 T cell 
responses (< 1.0%), which were primarily directed at the Pol protein (Buchbinder et al., 2008; 
McElrath et al., 2008). Furthermore, in the vaccinated group, uncircumcised men that had 
preexisting Ad5 immunity had an increased risk of infection, resulting in no significant vaccine 
efficacy (Buchbinder et al., 2008). It has been hypothesized that this is due to the expansion of 
Ad5-specific CD4 T cells expressing mucosal homing markers, though there are conflicting 
reports on this (Benlahrech et al., 2009; Hutnick et al., 2009). Despite this disagreement, it is 
clear that preexisting Ad5 immunity does reduce the magnitude of the CD8 T cell response (Zak 
et al., 2012), thus Ad5 serostatus is an important factor influencing use of this vaccine. A second 
trial, HVTN505, attempted to improve the rAd5 immunity by first priming with a DNA vaccine 
(Hammer et al., 2013). Unfortunately, this trial was halted before completion due to lack of 
efficacy despite high response rates for CD4 and CD8 T cells and close to 100% Ab response 
rate. Though the T cell response rate was high and polyfunctional (> 60%), the T cell frequency 
was low for both CD4 (0.1%) and CD8 (0.2%). The CD4 response was primarily directed at Gag, 
while the CD8 response was dominated by Env-specific cells (Hammer et al., 2013). However, 
despite the lackluster results, the DNA/rAd5 regimen did not display the same increased risk of 
infection as the Step Trial (Huang et al., 2015), thus offering hope for future use of similar vectors. 
One clinical trial sought to combine both strategies to elicit both T cell and Ab responses. 
The RV144 Thai Trial, enrolled 16,000 participants to test a non-replicating canarypox vector 
(ALVAC) followed by a combinatorial boost with AIDSVAX (B/E) used in the VAX003 trial, and 
was the first to show any clinical efficacy at approximately 31% (Rerks-Ngarm et al., 2009). The 
limited success of this vaccine regimen resulted in numerous follow-up studies to identify 
correlates of protection (listed in Table 1). T cell response rates were lower than for the rAd5 
studies, at 19.7% versus > 70% in the Step Trial, though the responses in RV144 were primarily 
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CD8-dominated with a higher proportion of Env-specific than Gag-specific cells (Rerks-Ngarm et 
al., 2009). A later analysis identified a polyfunctional CD4-subset expressing CD40L, IL-2, IL-4, 
IFN-γ, and TNF-α, which were associated with reduced risk of infection (Lin et al., 2015). 
Poxvirus-specific CD4 T cells are not present at mucosal sites, and therefore this does not offer 
the same concern with enhancing infection risk as it did with the rAd5 vector (Perreau et al., 
2011). Interestingly, Ab responses identified two correlates of risk: serum IgG for the V1-V2 loop 
of Env was inversely correlated with risk, while serum IgA to Env was directly correlated with 
infection risk (Haynes et al., 2012). It was later shown that V1-V2-specific IgG3 was the Ab 
isotype associated with reduced infection risk and these Abs demonstrated multiple effector 
functions, including antibody-dependent cell-mediated cytotoxicity [ADCC, (Chung et al., 2014; 
Yates et al., 2014)]. However, the IgG3 response was transient, thus accounting for the waning 
efficacy of the vaccine over time (Yates et al., 2014). An interesting note is that in the VAX003 
trial, multiple boosting actually shifted from an IgG3 response toward IgG4, which interfered with 
IgG3 effector functions (Chung et al., 2014), suggesting that the canarypox prime used in RV144 
may have actually improved the quality of the response though the magnitude was lower. 
Furthermore, a significant genetic component was found to be responsible for the induction of 
non-protective serum IgA over the protective V1-V2 IgG (Prentice et al., 2015). In the vaccinated 
population, individuals expressing HLA allele DPB1*13 had significantly higher V1-V2 IgG 
protection correlated with reduced risk of infection, and vaccine efficacy for this population subset 
was estimated at 71% (Prentice et al., 2015). Therefore, a successful HIV-1 vaccine must not 
only elicit both T cell and Ab responses, but also take into account subject genotype, quality of 
the Ab response, and proclivity for selectively eliciting responses to protective T cell epitopes. 
In an effort to improve upon the results of the Thai Trial, other poxvirus-based vectors 
were pursued using attenuated vaccinia virus (VACV). The goal of the work presented here is to 
enhance immunogenicity of a similar HIV-1 vaccine by utilizing a replication-competent VACV 
vector in combination with plant-produced HIV-1 virus-like particles (VLPs), which more 
accurately display proteins in their native context for elicitation of broadly neutralizing Abs 
(bnAbs), to be further discussed below. 
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Vaccinia Virus as a Vaccine Vector 
The moderate success of the RV144 trial enhanced interest in other poxvirus vectors that 
are attenuated for increased safety, yet display high immunogenicity. ALVAC was shown to be 
inherently safe due to its avian origin preventing replication in humans (Taylor and Paoletti, 1988; 
Taylor et al., 1988), and thus was chosen for the initial vaccine trials. However, in addition to 
ALVAC, two vaccine strains that have been widely studied for use as HIV-1 vaccine vectors are 
modified vaccinia virus Ankara (MVA) and New York vaccinia virus (NYVAC) [see these 
extensive reviews (Esteban, 2014; Gomez et al., 2012a; Jacobs et al., 2009; Pantaleo et al., 
2010)]. MVA was generated by passaging in chicken embryonic fibroblasts, resulting in a non-
replicating strain with demonstrated safety in animal models and humans (Garcia et al., 2011; 
Goepfert et al., 2011; Keefer et al., 2011; McCurdy et al., 2004), and even in immune-
compromised individuals (Greenough et al., 2008). NYVAC was genetically engineered from the 
Copenhagen (Cop) strain to be replication incompetent in humans through specific deletion of 18 
open reading frames (ORFs) thought to be associated with host-range and pathogenicity 
(Tartaglia et al., 1992b). NYVAC has a similar safety profile as described for MVA (Bart et al., 
2008; Harari et al., 2012; McCormack et al., 2008). Furthermore, NYVAC is capable of generating 
similar, if not somewhat higher, responses when compared to ALVAC (Garcia-Arriaza et al., 
2015; Hel et al., 2002), though ALVAC elicits a different cytokine profile than MVA and NYVAC 
upon immunization (Teigler et al., 2014), thus the vectors have distinct traits, which should be 
considered when choosing one for any given vaccine trial. Due to their demonstrated safety and 
high immunogenicity, multiple phase I/II clinical trials for both MVA and NYVAC expressing Gag-
Pol-Nef (GPN) and gp120/Env have been conducted [reviewed in (Gomez et al., 2012a)]. While 
MVA has also demonstrated success, this study focuses on the use of NYVAC-based vectors, 
thus only these will be discussed further. 
The phase I/II clinical trials involving NYVAC are summarized in Table 2. These trials 
were sponsored primarily by EuroVacc (www.eurovacc.org), an organization supporting studies of 
NYVAC and MVA expressing GPN/gp120 antigens. NYVAC is immunogenic on its own, though 
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the response rate and magnitude can be greatly improved when priming with DNA before a 
NYVAC antigen-matched boost, as demonstrated by the EV01 and EV02 safety and 
immunogenicity trials (Bart et al., 2008; McCormack et al., 2008). While Ab responses are 
improved when priming with DNA, the response rate does not quite reach 100% (Table 2). 
However, CD4 responses are robust (100% response rate with DNA prime) while CD8 responses 
are detectable, but have a less than 50% response rate (Table 2). Both T cell subsets are 
dominated by Env-specific cells with lesser responses to GPN. However, these responses have 
been shown to be polyfunctional, broad (recognizing 4 epitopes on average), and durable, with 
detectable circulating antigen-specific T cells almost one year after the final immunization (Harari 
et al., 2008). Furthermore, more recent studies with DNA/NYVAC regimens have shown the 
induction of HIV-specific T cells that express mucosal homing markers, and are found in the gut 
(Perreau et al., 2011). Studies in macaques revealed that NYVAC can also induce HIV-specific 
CD8 T cells and IgG Ab secretion in breast milk (Wilks et al., 2010), an important note for 
protection from mother-to-child transmission. All of these characteristics are important for HIV-1 
vaccines because mucosal sites represent the primary mode of transmission for HIV-1, and 
broad, polyfunctional T cell responses are necessary to prevent viral escape. 
NYVAC was recently assessed for immunogenicity and safety in a trial testing 
prime/boost schedules with NYVAC and rAd5 [HVTN078, (Bart et al., 2014)]. In this study, 
participants received three injections of viral vectors: two NYVAC followed by one rAd5, or one 
rAd5 (tested at three different doses) followed by two NYVAC. Interestingly, NYVAC served as a 
much better booster than as a priming vector, showing more robust Ab and T cell responses 
when used to boost rAd5 responses (Bart et al., 2014). Additionally, with increasing doses of 
rAd5 prime, CD8 T cell responses and Ab responses improved while CD4 responses declined 
(Bart et al., 2014), suggesting that the dosing of viral vectors can drastically alter the quality of the 
immune response, and must be optimized. Lastly, NYVAC was used in a therapeutic vaccination 
trial in HIV-1 infected patients undergoing ART, and showed the ability to safely generate de novo 
T cell responses in addition to boosting preexisting immunity (Harari et al., 2012). Therefore, 
NYVAC shows great promise as both a preventative and therapeutic vaccine, which can induce 
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robust, polyfunctional T cell responses, neutralizing Abs (nAbs), and is safe even in immune-
compromised individuals, making it an excellent HIV-1 vaccine candidate. However, NYVAC is a 
non-replicating vector and a majority of the T cell responses were Env-specific CD4 T cells, which 
have not been protective through any of the HIV-1 efficacy trials (Table 1), and Gag-specific CD8 
cells are known to be associated with control as discussed above. Thus, it was hypothesized that 
these immune responses could be improved by designing a replication competent, yet highly 
attenuated viral vector. 
To achieve an attenuated, replicating VACV vector, Kibler et al. reinserted two host-range 
genes, K1L and C7L, into the NYVAC genome (NYVAC-KC), thus restoring replication in human 
tissue without compromising safety (Kibler et al., 2011). Both K1L and C7L are known to be 
antagonists of type I interferon (IFN) signaling, and loss of either of these genes significantly 
reduces host-range and virulence (Liu et al., 2013; Meng et al., 2009). K1L has specifically been 
shown to interfere with NFκB activation (Shisler and Jin, 2004), while C7L has been implicated as 
an inhibitor of apoptosis through an unidentified mechanism (Najera et al., 2006). Several studies 
have demonstrated the importance of C7L in the absence of K1L for NYVAC replication, 
ultimately enhancing immune responses (Najera et al., 2010; Sanchez-Sampedro et al., 2016). 
Furthermore, NYVAC-KC displayed improved antigen presentation, dendritic cell (DC) 
maturation, and increased CD8 T cell responses compared to NYVAC (Quakkelaar et al., 2011), 
thus reaffirming the use of a replication competent vector for enhanced immunogenicity. 
Additional modifications have been made to NYVAC-KC to further enhance immunogenicity, such 
as deletion of the soluble IFN-α/β receptor B19R (Symons et al., 1995), and the IFN-γ binding 
protein B8R (Verardi et al., 2001). Deletion of these genes also greatly increases the breadth of 
innate immune signaling, IFN production, and the magnitude of CD8 T cell responses (Delaloye 
et al., 2015; Gomez et al., 2012b; Quakkelaar et al., 2011). Deletion of A46R, an NFκB/IRF3 
inhibitor of Toll-like receptor (TLR) signaling (Bowie et al., 2000), resulted in similar improvements 
in immunogenicity (Perdiguero et al., 2013). 
Interestingly, during generation of viral vectors used in studies described here, severe 
toxicity to the cells and viral vector were noted when expressing HIV-1 antigens. It was 
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hypothesized that overexpression of recombinant protein may trigger ER stress and/or antiviral 
signaling pathways resulting in the observed toxicity. However, VACV encodes many immune 
modulators capable of inhibiting these pathways (Seet et al., 2003; Taylor and Barry, 2006). One 
such inhibitor is K3L, an eIF2α homolog, which prevents phosphorylation of eIF2α and the 
shutdown of protein translation in response to dsRNA activation of protein kinase R (PKR) or ER 
stress activation of PKR-like ER kinase [PERK, (Carroll et al., 1993)]. Multiple immune 
modulators of VACV are dedicated to the interference with IFN signaling (Smith et al., 2013), 
however, one of these inhibitors (C6L) is missing from NYVAC-KC. C6L is an inhibitor of TANK 
binding kinase 1 (TBK1), which is an upstream kinase of IRF3 (Unterholzner et al., 2011), thus its 
absence can result in activation of IRF3 antiviral signaling pathways and potentially cause the 
reduced viral titers. The importance of these pathways and the absence of C6L and many other 
immune modulators, in regard to NYVAC-KC HIV-1 vectors, is explored in Chapter 4. 
Though all clinical trials for NYVAC involved virus alone or in combination with a DNA 
prime, the success of RV144 has been partially attributed to the combination of a viral vector with 
protein boosting. NYVAC was shown to elicit some Ab responses, but these are greatly improved 
when priming with rAd5 (Bart et al., 2014). Interestingly, poxviruses have been used to produce 
HIV-1 VLPs either with or without Env (gp140) spikes for elicitation of Ab responses in vivo 
(Bridge et al., 2011; Chen et al., 2005; Goepfert et al., 2011; Perdiguero et al., 2015). 
Additionally, vaccination with rgp120 in the absence of a viral vector in VAX003 and VAX004, 
resulted in non-protective, though robust, Ab responses (Table 1). Distinct differences in IgG 
isotypes were identified, noting that effector functions of IgG3 were important for the transient 
protection seen in RV144, and in VAX003 these responses were inhibited by IgG4 that was 
increased upon multiple protein boosts (Chung et al., 2014). Therefore, a combinatorial viral 
vector and protein boost is more protective than protein alone or a single viral vector administered 
alone. Recent studies assessed the use of NYVAC-GPN/gp140 VLP-producing vectors in 
combination with DNA prime/NYVAC+protein boost (Asbach et al., 2016) or 
NYVAC/NYVAC+protein regimen (Garcia-Arriaza et al., 2015). Results revealed significantly 
improved CD4 T cell responses with modest CD8 enhancement, and Abs with moderate ADCC 
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activity and low neutralization were induced. Additionally, no differences in T cell or Ab responses 
were detected when altering number or timing of prime/boosts (Asbach et al., 2016). 
Furthermore, the breadth of nAb responses and T cell responses to Env can be improved when 
using engineered mosaic gp120 sequences in a DNA/NYVAC/protein immunization scheme 
(Hulot et al., 2015). Overall, these studies suggest that utilizing VLP-producing viral vectors in 
combination with recombinant protein boosts can improve immune responses, however results 
can still be enhanced potentially through use of VLP boosting for more robust Ab production and 
a replication-competent viral vector in an effort to more drastically enhance CD8 T cell responses. 
This study proposes the use of NYVAC-KC vectors expressing Gag and deconstructed-
gp41 (dgp41) as a safe, immunogenic, replication competent vector for in vivo trials. Of note, in 
all studies listed above, when Env is included in the vector, the T cell response is dominated by 
Env-specific CD4 T cells, which only accounted for a small portion of the efficacy seen in RV144 
(Lin et al., 2015). Therefore, vectors described here express Gag in an effort to elicit protective 
CD8 T cell responses known to be associated with control of viremia. The other vector expresses 
a deconstructed form of the gp41 (dgp41) transmembrane portion of gp160.  
Dgp41 is truncated just outside of the membrane proximal external region (MPER), a 
portion of gp41 known to elicit broadly neutralizing Abs (bnAbs) such as 2F5, 4E10, and 10E8 
(Huang et al., 2012; Purtscher et al., 1994; Zwick et al., 2001). The MPER is more highly 
conserved than Env [80% vs 66% conserved amino acids, respectively (Modrow et al., 1987)], 
and is largely immunodominant resulting in more potent neutralization (Jacob et al., 2015; 
Montero et al., 2008). However, in the context of gp160, the MPER also suffers from occlusion 
until binding to CD4 and a co-receptor results in its exposure (Montero et al., 2008; Moore et al., 
2015; Pejchal et al., 2009). Therefore, the protein was truncated to better expose the MPER, and 
it has been suggested that in this context gp41 remains in a prefusion state (Gong et al., 2015). 
Furthermore, the MPER region fused to the B subunit of cholera toxin has been shown to elicit 
transcytosis blocking Abs (Matoba et al., 2008), an important mode of transmission for HIV-1. 
Similar results were seen when the MPER was displayed in the surface of a lipid virosome in a 
phase I clinical trial (Leroux-Roels et al., 2013), further supporting the use of HIV-1 VLPs. 
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Additionally, the soluble gp120 antigens used in HIV-1 clinical trials are now known to be 
incapable of interacting with bnAb germline B cell receptors (Hoot et al., 2013; McGuire et al., 
2014). As a result, protein engineering developed germline-targeting antigens with the goal of 
vaccinating with a cascade of gp120 antigens with increasing affinity for the maturing B cells 
(Jardine et al., 2013; Jardine et al., 2015; Liao et al., 2013b). Other strategies involve more 
structurally accurate gp140 trimers, (Billington et al., 2007; Du et al., 2009; Sellhorn et al., 2012; 
Wan et al., 2009), but no clinical trials have been conducted with this antigen to date. It is also 
necessary to display the MPER in the context of a membrane because many of the bnAbs are 
partially autoreactive toward lipids, thus necessitating their close proximity to the MPER and a 
highly immunogenic antigen to overcome immune tolerance (Haynes et al., 2005; Haynes et al., 
2016; Verkoczy et al., 2013; Verkoczy et al., 2010; Williams et al., 2015; Zhang et al., 2016). 
Thus, gp120 is not included in the viral vectors for elicitation of Ab or T cell responses in an effort 
to redirect the immune system towards more highly conserved, protective epitopes in Gag and 
gp41. For the protein component of the vaccine, it was hypothesized that antigen-matched VLPs 
would (i) provide a more structurally accurate context for the MPER for bnAb production, (ii) 
provide higher density of antigenic spikes on the VLP surface, and (iii) serve as a large immune 
complex for increased antigen presentation to induce more robust Ab and T cell responses 
through innate immune cell interactions. 
 
Plant-produced VLPs 
HIV-1 Gag VLPs have been produced in plants (Kessans et al., 2013; Meyers et al., 
2008; Scotti et al., 2009), yeast (Sakuragi et al., 2002; Tsunetsugu-Yokota et al., 2003), and 
baculovirus insect cell cultures (Buonaguro et al., 2006; Deml et al., 2005). Plants are a desirable 
production platform for multiple reasons, including speed of production, attainable high yields 
(gram-level of protein in two weeks), ease of scale-up by regulatory standards, relative cost, and 
the lack of contaminating mammalian pathogens (Ma et al., 2005; Rybicki, 2009; Rybicki, 2014). 
Several plant-based products have been derived for both human and veterinary diseases, 
demonstrating their profound safety and immunogenicity [for extensive reviews see (Chen and 
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Lai, 2013; Daniell et al., 2009; Jacob et al., 2013; Liew and Hair-Bejo, 2015; Rybicki, 2010; Scotti 
and Rybicki, 2013)]. One plant-produced product is now an FDA approved treatment for Gaucher 
disease (Zimran et al., 2011). The primary deterrence for plant-made pharmaceuticals is the 
downstream purification costs, often accounting for approximately 80% of the total production 
expense (Wilken and Nikolov, 2012). One of the main reasons for this is difficulties in plant 
purification techniques for the separation of rubisco, which can account for 30-50% of the total 
soluble protein [TSP, (Feller et al., 2008; Spreitzer and Salvucci, 2002)], whereas recombinant 
protein oftentimes only accounts for 0.7-7% of the TSP (Egelkrout et al., 2012). Therefore, a 
primary goal of work described here was to both increase yield of plant-derived HIV-1 Gag/dgp41 
VLPs and improve the purification strategy. 
Many VLPs have been successfully produced in plants, and all display high 
immunogenicity (Chen and Lai, 2013; Scotti and Rybicki, 2013). Two successful VLP vaccines on 
the market are the human papillomavirus (HPV) vaccines (GlaxoSmithKline, 2014; Merck & Co., 
2006). Though these are not plant-derived, they depict a bright future for VLP-based vaccines as 
safe, immunogenic alternatives to attenuated and/or subunit vaccines. As mentioned above, the 
hypothesis here is that the use of VLPs instead of a subunit vaccine in combination with a 
poxvirus vector will result in enhanced immunogenicity and more protective responses than seen 
with RV144 and other clinical trials. 
The plant-derived VLPs used in studies reported here are made with Gag transgenic 
Nicotiana benthamiana supplemented with transient Agrobacterium tumefaciens-mediated 
expression of dgp41 using viral expression vectors (Kessans et al., 2013). These VLPs were 
shown to be immunogenic in mice as potent inducers of serum and mucosal Ab responses 
(Kessans et al., 2016). Others have demonstrated the proficiency of multiple VLPs for activating 
CD8 T cells through DC interactions (Barth et al., 2005; Buonaguro et al., 2006; Lacasse et al., 
2008; Lenz et al., 2001; Tsunetsugu-Yokota et al., 2003), in addition to boosting T cell responses 
(Pillay et al., 2010). Furthermore, VLPs are capable of activating DCs to transport and present 
antigens to B cells more efficiently than subunit vaccines (Bessa et al., 2012; Link et al., 2012), 
thus demonstrating another advantage for MPER displayed in a VLP format versus the gp120 
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antigen used in RV144. While high yields are achievable in plants, VLPs are complex, large 
antigenic particles, and therefore often have poorer yields than other proteins. Gag VLPs seem to 
be more vulnerable to this than others, with yields for cytoplasmic expression reaching no more 
than 44 μg/kg FW (Meyers et al., 2008). For comparison, plant-derived HPV VLPs can obtain 
yields over 500 mg/kg FW (Maclean et al., 2007). The versatility of plant expression is 
demonstrated in that by switching the targeting of the Gag protein from cytoplasmic to 
chloroplast-based expression, Gag yield can be increased to 350 mg/kg FW (Scotti et al., 2009). 
In this study, an alternative approach of utilizing newly developed viral-based expression vectors 
for Gag and dgp41 expression was tested. 
The most widely used commercially available viral-based expression vector for plant-
based production is known as magnICON® (ICON), and is derived from tobacco mosaic virus 
[TMV, (Gleba et al., 2005; Marillonnet et al., 2004; Marillonnet et al., 2005)]. This expression 
system utilizes three plasmids delivered by A. tumefaciens: a 5’ module containing a signal 
peptide and the TMV RNA-dependent RNA polymerase (RdRp) and movement protein (MP), a 3’ 
module with the recombinant gene, and the integrase expression module which allows in planta 
recombination of the 5’ and 3’ T-DNA regions upon transfer to the nucleus [Figure 2A, 
(Marillonnet et al., 2004)]. The signal peptide can be chosen to target proteins through the 
secretory pathway to the apoplastic space, or alternatively use cytoplasmic expression, which is 
the natural site for Gag production. Upon recombination in the nucleus, mRNA is transported to 
the cytoplasm where it is amplified by the TMV RdRp and transferred to adjoining cells by the 
MP. 
More recent development of a Geminivirus-based vector (Gemini) utilizes deconstructed 
bean yellow dwarf virus (BYDV) in a single-plasmid delivery system (Huang et al., 2009; Mor et 
al., 2003). Geminiviruses are ssDNA viruses which replicate via rolling-circle in the plant nucleus 
(Gutierrez, 1999), which requires Rep/RepA (C1/C2) present in the expression vector. However, 
the Gemini movement protein is not part of this expression system [Figure 2B, (Huang et al., 
2009; Huang et al., 2008; Mor et al., 2003)], thus necessitating more efficient agroinfiltration. 
Geminiviruses are also known to induce gene silencing siRNAs targeting the origin of replication 
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and promoters preferentially (Aregger et al., 2012; Rodriguez-Negrete et al., 2009; Seemanpillai 
et al., 2003), thus p19, the silencing suppressor protein of tomato bushy stunt virus, can be 
included and substantially improves yield (Garabagi et al., 2012; Voinnet et al., 2003). The 
biology of these two viruses differs greatly, and thus the expression kinetics and yield could also 
be influence by vector choice. The direct comparison of these two vectors is discussed in Chapter 
2 for enhancing Gag/dgp41 expression and yield. 
 
VLPs and Innate Immunity 
As noted above, plant-based expression requires the use of the gram-negative bacteria 
A. tumefaciens, and viral expression vectors. Both of these components offer a potential for 
natural adjuvancy if any pathogen associated molecular patterns (PAMPs) are remaining in the 
final VLP preparation. Mammalian innate immune systems are programmed to non-specifically 
recognize PAMPs and trigger a signal cascade ultimately leading to activation of antigen 
presenting cells (APCs), including DCs and macrophages, which then stimulate an adaptive 
response (Hoebe et al., 2004; Iwasaki and Medzhitov, 2015; Janeway and Medzhitov, 2002). 
Harnessing the innate immune system to generate robust adaptive immunity is an area of great 
interest for developing stronger, more durable responses with vaccines (Levitz and Golenbock, 
2012; Pulendran and Ahmed, 2006; van Duin et al., 2006). In the case of plant-based VLPs, it 
was hypothesized in Chapter 3 that components of A. tumefaciens (e.g. LPS, flagellin) or the viral 
expression vector RNA could be incorporated into Gag VLPs upon agroinfiltration. Gag VLPs are 
known to encapsulate cellular RNA and can successfully deliver it to the cytoplasm of other cells 
(Valley-Omar et al., 2011). If these PAMPs are found in the VLP preparations, they could provide 
plant-derived VLPs with a unique adjuvant-like effect not found with other expression systems. 
The specific PAMPs expected from plant-based production would primarily be recognized 
by the Toll-like receptors (TLRs, Table 3). TLRs are exposed at the cell surface for recognition of 
bacterial cell wall components, and are found in endosomes to respond to inappropriate 
localization of nucleic acids, often as a result of an intracellular pathogen invasion (Kawai and 
Akira, 2010; Takeda et al., 2003). Additionally, TLRs are linked to adaptive immunity through the 
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adaptor proteins MyD88 and TICAM (also known as TRIF), which control downstream activation 
of transcription factors NFκB and IRF3, resulting in up-regulation of IFN stimulated genes (ISGs), 
including cytokines, chemokines, and cell surface activation markers (Akira et al., 2001; Schnare 
et al., 2001). TLRs are known to help stimulate both Ab responses (Nemazee et al., 2006; Pasare 
and Medzhitov, 2005) and CD4 T cell help (Pasare and Medzhitov, 2004), thus making them a 
prime activation target for vaccines with the goal of inducing strong Ab responses. Indeed, many 
TLR ligand adjuvants have been explored for their utility in vaccination (Hjelm et al., 2014; Mata-
Haro et al., 2007; Nagpal et al., 2015; Steinhagen et al., 2011; van Duin et al., 2006). Therefore, if 
the plant-produced VLPs contain inherent adjuvancy due to their production mechanism, they 
may be more immunogenic on their own than other protein subunit vaccines, thus requiring lower 
adjuvant doses, and can be strategically supplemented with a complementary adjuvant that 
stimulates separate pathways from those triggered by the VLPs without the need for multiple 
additives. 
VLPs are known to be potent stimulators of the innate immune system (Raghunandan, 
2011). One way of linking innate activation to an adaptive response is through CD4 T helper 
responses. CD4 helper T cells can be stimulated to be Th1 or Th2 based on the nature of signals 
received from the activating antigen (Mosmann and Coffman, 1989), and ultimately lead to 
differential responses in Ab isotype switching (Snapper and Paul, 1987). Ab isotypes are a critical 
factor of importance, as revealed by differences between the protective IgG3 in RV144 and the 
non-protective IgG4 in VAX003 clinical trials using the same rgp120 antigen (Table 1). Th1 CD4 T 
helper responses primarily result in IFN-γ secretion for potent CD8 T cell responses and IgG2a 
production (Fujieda et al., 1995; Snapper and Paul, 1987), a characteristic often attributed to VLP 
interactions with DCs (Lacasse et al., 2008; Tsunetsugu-Yokota et al., 2003). On the other hand, 
Th2 stimulation is often associated with allergic responses, but is a potent inducer of Abs through 
production of IL-4 stimulation of B cells to produce IgG1 (Fujieda et al., 1995). Th1 and Th2 
responses can also be regulated by differential activation of macrophages, where classical 
macrophages activated by IFN-γ and LPS stimulate Th1, and alternatively activated 
macrophages triggered by immune complexes and TLR ligands preferentially induce Th2 
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responses (Gordon, 2003; Martinez and Gordon, 2014). Therefore, the type of activation in 
macrophages and DCs largely regulates the adaptive response for both T cell and B cell 
responses, thus the understanding of how vaccine components interact with these pathways will 
result in improved vaccine design. 
HIV-1 Gag VLPs have been shown to be exceptionally robust stimulators of innate 
immunity (Deml et al., 2005). Interestingly, Gag VLPs produced in baculovirus were shown to 
stimulate DCs, monocytes, and PBMCs toward a Th2-biased CD4 helper response independently 
of TLR2 and TLR4 (Buonaguro et al., 2008; Buonaguro et al., 2006; Speth et al., 2008). However, 
adjuvanting a DNA/Gag VLP prime/boost vaccine with a stimulator of TLR4 was shown to induce 
a Th1 response (Poteet et al., 2015), resembling the responses of an HPV VLP vaccine (Pinto et 
al., 2005; Yan et al., 2005; Yang et al., 2004). Thus suggesting that the immune response can be 
tailored to suit the desired outcome of adaptive immune responses based on the natural biases 
induced by the antigen and adjuvant. In contrast, Gag VLPs produced in yeast were shown to 
stimulate a Th1 response that was dependent upon TLR2 (Tsunetsugu-Yokota et al., 2003). This 
indicates that the host production system may directly influence the pathways their respective 
VLPs can stimulate. Therefore, plant-derived VLPs have potential for stimulating adaptive 
responses through multiple innate pathways, inlcuding (i) interacting with DCs for CD8 T cell 
activation, as previously shown with other expression systems (Buonaguro et al., 2006; Deml et 
al., 2005; Tsunetsugu-Yokota et al., 2003), (ii) classical macrophage activation through LPS of A. 
tumefaciens for a Th1 response, and/or (iii) alternative activation of macrophages through TLR 
ligands being present on VLPs, a type of immune complex, for a Th2 response. The interaction 
between plant-derived VLPs and innate immune signaling pathways has yet to be explored and is 
the subject of Chapter 3.  
 
Dissertation Overview 
This dissertation will overall discuss the use of a replicating poxvirus vector, NYVAC-KC, 
for its use as an HIV-1 vaccine vector in combination with plant-produced VLPs for a more 
structurally accurate display of the important bnAb epitopes present in the MPER of gp41. 
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Chapter 2 describes the enhancement of Gag/dgp41 VLP production and yield in the tobacco-
relative Nicotiana benthamiana, in addition to optimizing purification techniques in an effort to 
derive more enriched VLP preparations with minimal rubisco content. Interactions of HIV-1 VLPs 
with the innate immune system, particularly the Toll-like receptors, are assessed in Chapter 3, 
including the influence of these interactions on overall immunogenicity and potential vaccine 
formulations. Generation of recombinant NYVAC-KC vectors is described in Chapters 4 and 5. 
Chapter 4 will primarily focus on toxicity issues with Gag and dgp41 expression, in addition to the 
ER stress and innate immune signaling pathways potentially responsible for the observed toxicity, 
and the resulting effect on immunogenicity of the viral vectors. Lastly, Chapter 5 will describe the 
immunogenicity of NYVAC-KC and plant-derived VLPs in different prime/boost regimens and 
routes of immunization. The results of the studies described herein should improve future vaccine 
formulations involving plant-derived VLPs and NYVAC-KC viral vectors by (i) providing protocols 
for improving plant-based VLP production, (ii) enhancing knowledge of the natural innate immune 
biases induced by the VLPs, and how this might influence adaptive responses during vaccination, 
(iii) how to improve immunogenicity of NYVAC-KC by preventing toxicity of recombinant protein 
production, and (iv) provide data supporting the choice of prime/boost regimen based on desired 
vaccination outcomes. 
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Figure 1 - Global Statistics for HIV-1 
HIV-1 statistics gathered from UNAIDS (aidsinfo.unaids.org). (A) Plot over time of total people 
living with HIV-1 infection (green), number of AIDS-related deaths (red), and the number of new 
infections (blue) from 1990-2015. Error bars represent the upper and lower limits of the estimated 
counts. (B) Regional division of the number of new infections each year, showing that they occur 
disproportionately in undeveloped regions of the world. Percent of the global number of infections 
is shown. (C) The number of AIDS-related deaths is shown as a percentage of the total by region. 
(D) A combined plot to show percent of new infections (blue), AIDS-related deaths (red), and 
percent of infected population with access to antiretroviral therapy (ART, green). Data shows that 
regions accounting for a majority of HIV-1 infections and deaths do not have proportionately 
higher ART coverage. E – east; C – central; N – north; S – south 
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Figure 2 - Comparison of ICON and Gemini Plant Expression Vectors 
The mechanism of plant-based expression for two deconstructed viral vectors based on tobacco 
mosaic virus (TMV) in the magnICON® system (A), or based on bean yellow dwarf virus (BYDV) 
in the Gemini expression vector (B). (A) ICON requires the use of three plasmid vectors harbored 
in individual A. tumefaciens, which transfers the T-DNA regions to the nucleus of infiltrated plant 
cells. Once in the nucleus, the integrase gene mediates recombination of the 5’ and 3’ modules to 
generate one DNA fragment. The mRNA is transported to the cytoplasm where the TMV RNA-
dependent RNA polymerase (RdRp) amplifies the whole transcript, thus resulting in high 
expression levels of the recombinant gene product. The TMV movement protein (MP) transports 
mRNA to the adjacent cells to spread expression throughout leaf tissue. In this system the signal 
peptide (SP) for protein targeting is included in the 5’ module and can be used for secretory or 
cytoplasmic expression pathways. (B) Geminivirus-based vectors are single plasmid delivery. A. 
tumefaciens mediates T-DNA transfer to the nucleus where expression of the replication proteins 
(C1/C2) amplify the ssDNA via rolling-circle replication by binding to the intergenic regions (IRs). 
This generates high mRNA levels resulting in accumulation of the gene product. Geminiviruses 
can induce gene silencing in which the plant generates siRNAs that are guided by Dicer proteins 
to bind mRNA and recruit the RNA-induced silencing complex (RISC), and result in degradation 
of the vector mRNA and reduced expression. To counteract this problem, the p19 silencing 
suppressor protein of tomato bushy stunt virus can be included. P19 binds the siRNA to prevent 
recognition by Dicer proteins, thereby enhancing expression. 
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Table 1 - HIV-1 Clinical Trials 
Clinical 
Trial 
Immunization Efficacy Primary immune responses & 
correlates of risk 
References 
VAX003 rgp120 
(AIDSVAX, 
B/E) 
0.1%  Ab responses not protective 
 Boosting biased Abs to increase 
IgG4 and decrease IgG3 
 IgG4 inhibits IgG3 Ab effector 
functions 
 
(Pitisuttithum 
et al., 2006) 
VAX004 rgp120 
(AIDSVAX, 
B/B) 
6.0%  CD4 blocking Abs best predictor 
of infection risk 
(Flynn et al., 
2005; Gilbert 
et al., 2005) 
 
Step 
(HVTN502) 
rAd5 (GPN) < 0%  Preexisting Ad5 immunity 
increased infection risk in 
uncircumcised males & reduces 
CD8 responses 
 Polyfunctional CD4 T cell 
responses (Freq.: > 70%; RR: 
41%) 
 Low CD8 responses (Freq.: < 
1.0%; RR: 73%) 
 Transient increase in Ad5-specific 
CD4 cells expressing mucosal 
homing markers 
 
(Benlahrech 
et al., 2009; 
Buchbinder 
et al., 2008; 
Hutnick et al., 
2009; 
McElrath et 
al., 2008; Zak 
et al., 2012) 
RV144 ALVAC (Gag-
Pro, B/E; 
gp120 + gp41 
membrane 
anchor, clade 
B) 
 
AIDSVAX 
rgp120 (B/E) 
31.2%  IgG to V1-V2 of Env decreased 
infection risk 
 IgA to Env increased infection risk 
 CD8/CD4 T cell responses (RR: 
19.7%), primarily directed at Env 
 CD8-dominated responses 
 Transient IgG3 to V1-V2 
associated with enhanced ADCC 
 Polyfunctional Env-CD4 
decreased infection risk: CD40L, 
IL-2, IL-4, IFN-γ, TNF-α 
 HLA-controlled Ab responses 
 
(Chung et al., 
2014; 
Haynes et al., 
2012; Lin et 
al., 2015; 
Prentice et 
al., 2015; 
Rerks-Ngarm 
et al., 2009; 
Yates et al., 
2014) 
HVTN505 DNA (GPN, 
Env) 
 
rAd5 (Gag-Pol, 
Env) 
< 0%  Induced polyfunctional T cells 
 CD4 freq.: 0.1%; RR: 61.5% 
(Gag > Env) 
 CD8 freq.: 0.2%; RR: 64.1% 
(Env-dominant) 
 IgG to V1-V2 was low (RR: 20%) 
 IgA to Env: 43% RR 
 rAd5 after DNA prime did not 
result in increased infection risk, 
but study was halted early due to 
lack of efficacy 
 
(Hammer et 
al., 2013; 
Huang et al., 
2015) 
RR: response rate; HVTN: HIV Vaccine Trial Network; rgp120: recombinant gp120; rAd5: 
recombinant adenovirus 5; freq.: frequency; Ab: antibody; ADCC: antibody-dependent cell-
mediated cytotoxicity; GPN: Gag-Pol-Nef 
 
21 
Table 2 - Phase I/II HIV-1 Vaccine Trials Involving NYVAC 
Regimen Antigens Ab 
responses 
T cell responses References 
EV01 
NYVAC x 2 
GPN, Env 
Clade C 
RR: ~15% 
Mostly IgM to 
Env 
 RR: 50% (60% of which is 
directed at Env) 
 Not durable 
 
(Bart et al., 
2008) 
EV02 
DNA x 2/ 
NYVAC x 2 
 
or 
 
NYVAC x 2 
GPN, Env 
Clade C 
RR: 75% 
 
 
 
 
 
RR: 27% 
Transient & 
non-
neutralizing 
for both 
regimens 
 
 RR: 90% (Env > Gag) 
 CD4 – 100%, CD8 – 47% 
 Broad (4.2 epitopes) 
 Durable to 72 weeks (70%) 
 Polyfunctional (> 50%) 
 
 RR: 33% 
 
 Both regimens: 91% respond to 
Env, 48% to GPN 
(Harari et 
al., 2008; 
McCormack 
et al., 2008) 
EV03 
DNA x 3/ 
NYVAC x 1 
GPN, Env 
Clade C 
ND  RR: near 100% for blood and 
mucosal sites for CD4 and CD8 
 83% of CD4 express α4β7 
integrin 
 CD4 also have high CCR5 
expression 
 
(Perreau et 
al., 2011) 
HVTN078 
NYVAC x 2/ 
rAd5 x 1 
or 
 
rAd5 x 2/ 
NYVAC x 1 
NYVAC: 
GPN, 
gp120; 
rAd5: 
Gag-Pol 
(A/B/C), 
gp140 (B) 
RR: 89.7% 
 
 
 
 
RR: 100% 
(up to 50% to 
V1/V2) 
nAbs: 69.3% 
RR to Tier 1 
Transient (< 
6 months) 
 
 RR: CD4 – 42.9%, CD8 – 65.5% 
 
 
 
 
 RR: CD4 – 85.7%, CD8 – 85.7% 
 Increasing doses of rAd5 lowers 
CD4 response but increases 
CD8 
 Both regimens induce 
polyfunctional CD4 and CD8 
(Bart et al., 
2014) 
Theravac-01* 
NYVAC x 2 
GPN, Env 
Clade B 
ND  Recall and expand preexisting 
HIV-specific CD4 and CD8 
subsets 
 Generated 1-3 new peptide 
responses (mainly to Env) 
 CD4 significantly increased for 
Gag peptides 
 Optimal HLA-dependent Gag 
CD8 epitopes were preferentially 
expanded over other proteins 
 
(Harari et 
al., 2012) 
*Theravac-01 was conducted as a therapeutic vaccination trial in HIV-1 infected patients 
undergoing antiretroviral treatment 
HVTN: HIV Vaccine Trial Network; EV: EuroVacc (www.eurovacc.org); RR: response rate; GPN: 
Gag-Pol-Nef; Env: envelope protein; rAd5: recombinant adenovirus; ND: not determined; Ab: 
antibody 
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Table 3 - Potential TLR Ligands from Plant-produced HIV-1 VLPs 
Localization TLR Canonical 
PAMP 
Adaptor 
Protein 
Transcription 
Factor 
Potential PAMP 
source in Plant 
VLPs 
Cell surface TLR2/6 Lipotechoic 
acids 
 
MyD88 NFκB Plant 
lipids/lipoproteins 
TLR4 LPS 
 
MyD88/TICAM NFκB/IRF3 A. tumefaciens 
TLR5 Flagellin 
 
MyD88 NFκB A. tumefaciens 
Endosomal TLR3 dsRNA 
 
TICAM IRF3 TMV vector 
TLR7 ssRNA 
 
MyD88 NFκB TMV vector 
TLR9 Unmethylated 
CpG motifs 
 
MyD88 NFκB Degraded plant 
DNA due to leaf 
necrosis 
 
TLR: Toll-like receptor; LPS: lipopolysaccharide; PAMP: pathogen associated molecular pattern; 
TMV: tobacco mosaic virus; VLPs: virus-like particles 
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Chapter 2 
ENHANCING EXPRESSION AND YIELD OF HIV-1 GAG/DGP41 VIRUS-LIKE PARTICLES 
PRODUCED IN NICOTIANA BENTHAMIANA WITH TRANSIENT, DECONSTRUCTED TMV 
AND GEMINIVIRUS-BASED VECTORS 
 
Abstract 
Virus-like particles (VLPs) are a safe and immunogenic vaccine platform. HIV-1 VLPs 
have been produced in a variety of expression systems. Plant production offers unique 
advantages based on scalability, safety from mammalian pathogen contamination, speed of 
expression, and platform flexibility. In an effort to increase yield of HIV-1 VLPs, a direct 
comparison was performed between a tobacco mosaic virus (TMV)-based magnICON vector and 
a Geminivirus-based expression vector. Gag yield was improved from previous reports of 
cytoplasmic expression (~44 μg p24/kg) to 1 mg p24/kg while transient dgp41 yields achieved 
levels above 5 mg MPER/kg. Interestingly, comparison of kinetics revealed that Gemini vectors 
express transient proteins earlier, often reaching peak levels 2-3 days post infiltration (dpi) and 
quickly lead to visible necrosis. However, the TMV vector does not express until 4 dpi and has 
much slower onset of necrosis. The silencing suppressor protein p19 was shown to delay 
necrosis and consistently increase expression and yield for Gemini vectors. However, Gemini 
vector yields were more variable than TMV, suggesting even with p19, gene silencing and severe 
necrosis may play drastically alter expression. Overall, simultaneous transient expression of Gag 
and dgp41 in wild-type Nicotiana benthamiana provided the highest VLP yield with a molar ratio 
of MPER:p24 of 1.7 up to 11.8, much higher than an HIV-1 virion. VLPs are immunogenic in mice 
and responses can be increased upon boosting. The higher density of gp41 spikes on Gemini-
produced VLPs compared to TMV-based expression make these an interesting platform to 
pursue for HIV-1 vaccines with the goal of inducing neutralizing antibody responses to the MPER. 
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Introduction 
Virus-like particles (VLPs) are a safe, immunogenic alternative to live or attenuated 
vaccines and more accurately represent the native structure of a virion than subunit vaccines, 
which is critical for eliciting neutralizing antibodies [nAbs, (Kushnir et al., 2012)]. Plant production 
of recombinant proteins and pharmaceuticals offers multiple advantages, including lack of 
contamination by mammalian pathogens, ease of scale-up by regulatory standards, speed of 
expression, and platform flexibility (Daniell et al., 2009; Egelkrout et al., 2012; Horn et al., 2003; 
Ma et al., 2005; Rybicki, 2009; Rybicki, 2010). Many different types of VLPs have been produced 
in plants, which has been thoroughly reviewed (Chen and Lai, 2013; Scotti and Rybicki, 2013). 
Several plant-made products have been tested in human clinical trials (Ma et al., 2005; Yusibov 
et al., 2014) with one product being approved by the FDA for treatment of Gaucher disease 
(Zimran et al., 2011). Economic viability of plant production relies heavily on oftentimes poor 
yields, and downstream processing costs to remove host proteins accounts for approximately 
80% of production expenditures (Egelkrout et al., 2012; Wilken and Nikolov, 2012).  
Several transient deconstructed viral-based vectors for rapid, high level protein 
expression in plants were developed in an effort to improve low protein yields. The tobacco 
mosaic virus (TMV)-based magnICON® system has been extensively used to express 
recombinant proteins in plants since its invention, and was the first to provide gram-levels of 
antigen per kilogram of leaf material (Gleba et al., 2005; Marillonnet et al., 2004; Marillonnet et 
al., 2005). However, newer expression systems such as Geminivirus [Gemini, (Huang et al., 
2009; Mor et al., 2003)] and Cowpea mosaic virus (CPMV)-based pEAQ vectors (Peyret and 
Lomonossoff, 2013; Sainsbury et al., 2009) are less well characterized because they are not 
commercially available. The TMV system requires simultaneous delivery of three plasmids: a 
signal peptide module for targeting the secretory pathway or cytoplasmic expression, the vector 
containing a recombinant gene, and an integrase module for recombination in planta after 
Agrobacterium tumefaciens infiltration (agroinfiltration) mediates the transfer (T)-DNA transport to 
the nucleus (Marillonnet et al., 2004; Marillonnet et al., 2005). Once transcription occurs, the TMV 
RNA-dependent RNA polymerase (RdRp) amplifies mRNA in the cytoplasm and the movement 
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protein transfers the recombinant genes to surrounding cells (Marillonnet et al., 2004). However, 
Gemini vectors are a single plasmid delivery system offering simplicity for agroinfiltration culture 
preparation, yet Gemini vectors lack a movement protein and are known to induce gene silencing 
(Aregger et al., 2012; Rodriguez-Negrete et al., 2009; Seemanpillai et al., 2003), though this can 
be suppressed using the tomato bushy stunt virus p19 protein (Garabagi et al., 2012; Silhavy et 
al., 2002; Voinnet et al., 2003). Furthermore, multiple proteins can be delivered on the same 
plasmid and expressed in separate replicons established by short and long intergenic regions 
[SIR/LIR, (Huang et al., 2009)]. After transfer to the nucleus, Gemini vector T-DNA is amplified via 
rolling-circle mechanism by the C1/C2 (Rep/RepA) proteins (Gutierrez, 1999; Mor et al., 2003). 
Thus, due to differences in amplification stage, it was hypothesized that expression kinetics and 
time to peak expression would differ between the two expression systems. 
HIV-1 VLPs have been produced in plants with low yield, particularly of full-length Gag 
capsid (Kessans et al., 2013; Meyers et al., 2008). Yield can be increased by expressing Gag in 
transgenic chloroplasts (Scotti et al., 2009). In this study, cytoplasmic expression of Gag in 
transgenic Nicotiana benthamiana and transient expression of deconstructed-gp41 (dgp41) was 
used to make enveloped VLPs (Kessans et al., 2013). The gp41 protein of HIV-1 is the 
transmembrane portion of the HIV-1 surface spike, and contains the highly immunogenic 
membrane proximal external region (MPER), a target of many broadly neutralizing antibodies 
[bnAbs, (Huang et al., 2012; Purtscher et al., 1994; Zwick et al., 2001)]. Previous studies have 
shown that VLPs displaying this region can elicit both systemic and mucosal MPER-specific Abs 
(Kessans et al., 2016), and transcytosis blocking Abs are also achievable (Matoba et al., 2008). 
It is imperative to display the MPER in the context of a membrane because many of the 
bnAbs targeting this region are autoreactive for membrane components (Haynes et al., 2005; 
Haynes et al., 2016; Verkoczy et al., 2010; Williams et al., 2015; Zhang et al., 2016). Displaying 
the MPER in a virosome successfully elicited mucosal and systemic Abs in a phase I clinical trial 
(Leroux-Roels et al., 2013). Additionally, VLPs, but not subunit vaccines, properly induce antigen 
presenting cells and low affinity B cells to transport and display antigen for induction of Ab 
responses (Bessa et al., 2012; Link et al., 2012). Therefore, in an effort to improve yield and cost-
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effectiveness of plant-produced HIV-1 Gag/dgp41 VLPs for structurally accurate display of the 
MPER in a membrane context, the TMV vector and newly developed Geminivirus vectors were 
compared for differences in expression kinetics and yield in addition to analysis of the amount of 
MPER co-localizing with Gag VLPs for enhanced immunogenicity. 
 
Materials and Methods 
Cloning Geminivirus-based Vectors 
The TMV-based vector, pTM 602, was previously described (Kessans et al., 2013). 
Geminivirus-based vectors were generously provided by Dr. Hugh Mason (Arizona State 
University) for cloning dgp41 and Gag. Three vectors were generated: pTM 924 (Gemini), pTM 
925 which contains p19 (Gemini +p19), and pTM 901 (Dual Gem. +p19), a dual-replicon vector 
for simultaneous expression of two genes from the same backbone, which also contains p19. 
For cloning into pTM 924 and pTM 925, dgp41 was digested from pTM 602 using NcoI 
and SacI. The barley α-amylase (BAA) signal peptide was digested from pTM 796 using XbaI and 
SacI. The geminivirus backbone for pTM 924 is pTM 890 (formerly pBYR2fb) which was opened 
with XbaI and SacI. A triple ligation with dgp41, BAA, and the opened pTM 890 backbone using 
T4 DNA Ligase (Promega) yielded pTM 924. To derive pTM 925, the backbone pTM 800 was 
linearized using XbaI and SacI and the BAA-dgp41 insert was derived from pTM 924 by digesting 
with XbaI and SacI. The backbone and BAA-dgp41 fragment was ligated to yield pTM 925. 
Colonies were screened and sent for sequencing to confirm no mutations. 
The dual-replicon vector, pTM 901, requires cloning into the XbaI/SacI cut site first due to 
the presence of a KpnI cut site in the multiple cloning site because the second cut site requires 
digestion with BsrGI and KpnI. BAA-dgp41 was excised from pTM 924 using XbaI and SacI while 
pTM 900 (formerly pBYR27p) was linearized using the same restriction sites. After confirming 
BAA-dgp41 insertion into the first cloning site, Gag was amplified from pTM 488 via PCR using 
AccuStart Taq DNA Polymerase HiFi (Quanta Biosciences) using oTM 776 (5’ – 
GAGATGTACAATGGGAGCTAGAGCCTCT – 3’) and oTM 777 (5’ – 
GAGAGGTACCTTATTGAGAGGAAGGGT – 3’) for addition of a 5’ BsrGI and 3’ KpnI cut site, 
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shown in italics, and ligated to a TOPO TA backbone (Invitrogen). The Gag gene contained a 
BsrGI cut site which was removed via mutagenesis using whole plasmid replication with the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) per manufacturer’s protocol. 
The first reaction changed a TTG codon to CTG using primers oTM 827 (5’ - 
GAGGAGCTTAGGTCTCTGTACAACACAGTGGCT – 3’) and oTM 828 (5’ - 
AGCCACTGTGTTGTACAGAGACCTAAGCTCCTC – 3’), where the mutated nucleotide is 
underlined. However, this introduces a non-synonymous codon, so an additional change from 
CTG to CTC was performed using oTM 829 (5’ - 
GAGGAGCTTAGGTCTCTCTACAACACAGTGGCT – 3’) and oTM 830 (5’ - 
AGCCACTGTGTTGTAGAGAGACCTAAGCTCCTC – 3’). Upon sequence confirmation this 
plasmid was named pTM 923. From this point, pTM 923 and pTM 901 with BAA-dgp41 inserted 
were both digested using BsrGI and KpnI and then ligated together to derive the complete pTM 
901. Sequences were confirmed for both Gag and dgp41 prior to use. 
Each vector was transformed into GV3101 A. tumefaciens and colony-screened to 
confirm transformation. An isolated colony was grown and used to start infiltration cultures for 
each of the three Geminivirus-based vectors. 
 
Kinetics Time Course 
Six-week old N. benthamiana plants were vacuum infiltrated with an OD600 = 0.1 of A. 
tumefaciens resuspended in infiltration buffer (10 mM MES, 10 mM magnesium sulfate 
heptahydrate, pH 5.5). Bacteria harboring pTM 602, 924, or 925 were infiltrated into Gag 
transgenic plants, while pTM 901 was used in wild-type plants. Leaves were collected in triplicate 
every day for one week following infiltration. Collected leaves were scanned to monitor necrosis 
prior to flash-freezing 200 mg tissue samples in liquid nitrogen for expression analysis. Upon 
time-course completion, frozen tissue samples were homogenized in 1X SDS sample buffer 
without dye (60 mM Tris-HCl, 100 mM DTT, 1.6% SDS (w/v), 5% glycerol) using a ceramic bead 
in a Fast Prep-24 (MP Biomedicals, Solon, OH) machine twice for 30 s each. Homogenized 
samples were clarified by centrifugation at 14,000 xg for 10 min at 4° C. Supernatant was 
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collected and analyzed by Bradford assay (Bio-Rad) to determine total soluble protein (TSP) 
concentration. Equivalent TSP (20 μg) was loaded for each leaf sample into their respective lanes 
on a 12% polyacrylamide gel for SDS-PAGE followed by immunoblot as previously described 
(Kessans et al., 2013). Immunoblots for Gag were probed with primary polyclonal anti-p24 rabbit 
serum and goat anti-rabbit IgG-HRP (Santa Cruz), while dgp41 blots were probed with human 
anti-gp41 2F5 (AIDS Reagents Program) and goat anti-human IgG-HRP (Sigma). Coomassie 
staining was also performed to ensure equal protein loading for each lane. 
To quantify expression over time, ImageJ software (Schneider et al., 2012) was used to 
measure band density. For each replicate, the peak day (highest density) for Gag and dgp41 was 
identified and each subsequent days’ band densities are expressed as a percentage of the peak 
day. 
 
Optimization of VLP Purification 
Two strategies for removing rubisco from VLP preparations were tested. In the first 
experiment, flash-frozen leaf tissue harvested on peak expression day was homogenized in a 
blender in extraction buffer (25 mM sodium phosphate, 100 mM NaCl, 1 mM EDTA, 50 mM 
sodium ascorbate, 1 mM PMSF, pH 7.8), strained through miracloth, and insoluble protein was 
removed by centrifugation at 14,000 xg for 20 min at 4° C. The supernatant was collected and 
subjected to sequential ammonium sulfate precipitation at 20% followed by an increase to 40% 
with VLPs pelleted at 36,000 xg for 30 min at 4° C between precipitations. To remove rubisco 
using pH changes, after pelleting insoluble proteins, the supernatant was titrated to pH 5.5 to 
pellet rubisco, followed by adjustment to pH 5.0. After each pH change, protein was pelleted at 
36,000 xg for 30 min at 4° C. The remaining pH 5.0 supernatant was subjected to a 40% 
ammonium sulfate precipitation to pellet all remaining VLPs and rubisco. All pellets were 
resuspended in 1X PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). 
Samples were analyzed via Bradford assay and protein loaded equally into each lane for 
Coomassie and SDS-PAGE, as above. 
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Large-scale VLP Production and Purification 
Six-week old N. benthamiana plants were infiltrated at OD600 = 0.1 with each of the four 
vectors. At peak expression day, as determined by the kinetics time course, leaf material was 
harvested in 20 g batches and flash frozen in liquid nitrogen and stored at -80° C until extraction. 
VLPs were purified using 20% ammonium sulfate precipitation, as described above. Following 
precipitation VLPs were resuspended in 1X PBS and separated via iodixanol density gradient as 
previously described (Kessans et al., 2013). Purification progress was monitored by immunoblot 
by loading 5 μg TSP per lane for each step of the extraction and density gradient. Gels were used 
for Coomassie staining, Gag expression, and dgp41 expression, as described above and in 
(Kessans et al., 2013). 
 
VLP Quantification 
VLP-containing fractions were concentrated on a 300 kDa molecular weight cut-off 
membrane (Sartorius), and quantified via immunoblot for total Gag and dgp41 content using 
bacterially-produced p24-CTA2 and CTB-MPER purified protein standards, respectively, as 
previously described (Kessans et al., 2016). Ammonium sulfate pellets were directly quantified 
prior to density gradients without concentrating each sample. Briefly, μg/mL amounts for both 
proteins were calculated by comparing serial dilutions of concentrated VLP gradient fractions and 
ammonium sulfate pellets to known concentrations of purified p24-CTA2 or CTB-MPER using 
ImageJ software to determine band density (Schneider et al., 2012). The total calculated p24 and 
MPER protein amount was then divided by kilograms of fresh leaf weight (FW) to determine 
μg/kg yield for Gag and dgp41. Molar ratio of MPER to p24 was determined by relative protein 
sizes (MPER = 15 kDa; p24 = 24 kDa) for a molecular weight ratio of 1.6 p24 to MPER. 
 
Mouse Immunizations 
All animal studies were conducted under the approval of the Arizona State University 
Institutional Animal Care and Use Committee. 
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Four to six-week old C57BL/6 mice (Jackson Laboratories; n = 3) were injected i.p. on 
days 0 and 45 with 2 μg p24 and 1.2 μg MPER gradient-purified VLPs mixed with Ribi adjuvant 
(Sigma) per manufacturer’s protocol. Serum was collected every 2 weeks for analysis of p24 and 
MPER-specific IgG by ELISA as previously described (Kessans et al., 2016). Results are 
reported as OD 490 nm over time for the 1:50 dilution (lowest dilution tested). 
 
Results 
Construction of Transient Geminivirus Vectors 
The commercial development of TMV-based vectors (MagnICON®) for transgene 
expression in plants has been extensively described (Gleba et al., 2005; Marillonnet et al., 2004; 
Marillonnet et al., 2005). A TMV vector for transiently expressing dgp41 for making HIV-1 VLPs 
was previously described [(Kessans et al., 2013), Figure 3A]. Two Geminivirus vectors were 
cloned to transiently express dgp41 with or without the silencing suppressor protein p19 (Figure 
3B-C). Geminiviruses are known to induce gene silencing both during natural infection and with 
expression of transgenes, which primarily targets the replication origin and promoter regions 
(Aregger et al., 2012; Rodriguez-Negrete et al., 2009; Seemanpillai et al., 2003). The p19 protein 
has been shown to increase expression of recombinant proteins in plants by preventing gene 
silencing (Garabagi et al., 2012; Voinnet et al., 2003), thus co-expression of p19 in transient 
expression vectors is hypothesized to increase yield. A third Geminivirus vector was designed to 
co-express Gag and dgp41 from the same T-DNA fragment, but in separate Geminivirus 
replicons separated by LIR/SIRs (Figure 3D). These replicons are amplified by the replication 
proteins C1/C2 in the nucleus after Agrobacterium-mediated T-DNA transfer (Gutierrez, 1999; 
Huang et al., 2009; Mor et al., 2003). Expression in all Geminivirus vectors is under control of the 
Cauliflower mosaic virus (CMV) 35S promoter with two enhancer (2e) binding sites to improve 
transcription efficiency. 
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Geminivirus Vectors Display Accelerated Expression 
After the three Geminivirus vectors were cloned into A. tumefaciens, expression kinetics 
was analyzed over the course of seven days in six-week old N. benthamiana plants. Three 
vectors (TMV, Gemini, and Gemini +p19) were infiltrated into Gag transgenic plants to transiently 
express dgp41 for VLP production while the fourth vector (Dual Gemini +p19) was infiltrated into 
wild-type (WT) plants for transient co-expression of Gag and dgp41. Triplicate leaf samples were 
collected and monitored for necrosis over seven days (Figure 4). All Geminivirus-based vectors 
display necrosis around 3-4 dpi, which is earlier than the TMV vector which shows visible 
necrosis around 6 dpi. The inclusion of p19 with Geminivirus vectors appears to delay the onset 
of necrosis by 1-2 days. However, all Geminivirus infiltrated plants had severe necrosis at 7 dpi 
that prevented further sampling. 
Quantitation of western blot band densities was used to measure Gag and dgp41 
expression and revealed distinct differences between TMV and Geminivirus vectors (Figure 5A-
B). Gemini and Gemini +p19 vectors display a gradual decrease in transgenic Gag levels over 
the seven days, and including p19 increased expression levels by 26.5% on average after 2 dpi 
(Figure 5A & Figure 6B-C, compare red squares with green triangles). This could be a result of 
reduced gene silencing for both transient dgp41 and the Gag transgene leading to a decrease in 
necrosis. The TMV vector maintains steady levels in Gag expression with variability across plants 
and no clear peak day (Figure 5A & Figure 6A, blue circles), consistent with transgenic steady-
state expression in the absence of gene silencing. Transient expression of Gag by the Dual 
Gemini +p19 vector shows a clear peak at 2 dpi followed by a steady decline with little to no 
expression after 4 dpi (Figure 5A & Figure 6D), correlating with onset of necrosis (Figure 4). 
Transient expression of dgp41 in the TMV vector shows initial expression at 3 dpi with a 
steady increase over time, peaking at 7 dpi (Figure 5B & Figure 6A). The two Geminivirus vectors 
expressing dgp41 alone began expression much earlier at 2 dpi with peak expression between 2-
4 dpi (Figure 5B & Figure 6B-C). Interestingly, there is a decrease in dgp41 expression in both 
vectors at 5 dpi despite equivalent protein loading into the gels (Figure 6), and this is far more 
drastic in the vector without p19. Dual Gemini +p19 initiates detectable expression at 2 dpi with a 
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steady decline similar to that seen with Gag expression by the same vector (Figure 5B & Figure 
6D). Based on the combined necrosis and Gag/dgp41 expression levels during the time course, 
peak expression day was determined to be 4 dpi for TMV and 2-3 dpi for all Gemini vectors. 
 
Removal of Rubisco in VLP Preparations 
Two strategies were employed in an effort to reduce rubisco in VLP preparations. 
Rubisco bands were detected by Coomassie staining, with large bands around 50 and 25 kDa 
corresponding to the large and small subunits of rubisco, respectively. Gag (55 kDa) and dgp41 
(23 kDa) were detected by western blot. A majority of VLPs were found to pellet with addition of 
20% ammonium sulfate as determined by Gag and dgp41 presence (Figure 7B-C, 20% P), while 
the major rubisco band around 50 kDa remains in the 20% supernatant (SN, Figure 7A). The 
rubisco can be precipitated with further increase to 40% ammonium sulfate (Figure 7A, 40% P), 
along with any remaining Gag/dgp41 VLPs (Figure 7B-C). The second strategy utilized pH 
changes where a majority of the VLPs pellet at pH 5.5 and a further reduction to pH 5.0 did not 
result in detection of Gag or dgp41 (Figure 7B-C, pH 5.5 & 5.0 P). Ammonium sulfate was added 
to a concentration of 40% in the remaining pH 5.0 SN, and a large band around 50 kDa was 
visible after Coomassie staining with no detectable Gag and little dgp41, indicating this likely 
represents a majority of the rubisco (Figure 7, 5.0 – 40% P). Based on this data, the 20% 
ammonium sulfate precipitation appears cleaner with fewer protein contaminants, including 
rubisco, and was therefore chosen as the method of purification for subsequent experiments. 
 
VLP Purification and Yield 
Large-scale purifications were performed for each of the four vectors by harvesting at 
peak expression day and processing in 20 g batches. VLPs for all samples were primarily isolated 
to the 20% iodixanol fraction, with some large particles or aggregates accumulating in the 50% 
fraction (Figure 8). Comparison of Gag and dgp41 band intensity on equivalently loaded gels 
indicates that Gemini +p19 and Dual Gemini +p19 vectors qualitatively have the highest yield of 
both Gag and dgp41 (Figure 8C-D). After running density gradients, both the 20% ammonium 
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sulfate pellets and the 20% iodixanol gradient fractions were quantified by immunoblot as 
previously described (Kessans et al., 2016). 
Total expression of Gag reached a maximum around 1 mg/kg fresh leaf weight for both 
Dual Gemini +p19 transient expression and with the TMV vector in stable transgenics (Table 4). 
Transient expression of Gag and dgp41 was lowest in the Gemini vector without p19 at 0.62 
mg/kg and 0.82 mg/kg, respectively (Table 4). The highest transient dgp41 expression was seen 
with the Dual Gemini +p19 at 5.5 mg/kg (Table 4). Both Geminivirus vectors which include p19 
had higher dgp41 expression than the TMV-based vector, however, the yields are less consistent. 
Interestingly, Gag yield in the VLP gradient fraction was similar for the TMV and Dual Gemini 
+p19, but the TMV vector had lower dgp41 yield (Table 5). A similar phenomenon was seen with 
the Gemini ± p19 vectors, where inclusion of p19 during expression resulted in an increase in 
dgp41 yield within the VLP fraction (Table 5). Furthermore, the higher dgp41 expression in both 
the Gemini +p19 and Dual Gemini +p19 vectors corresponds to a higher molar ratio of 
MPER:p24, with an average of 2.8 and 3.3, respectively (Table 5). This indicates more dgp41 per 
Gag in each VLP particle, thus presenting a potentially better immunogen with more 
neutralization targets. 
 
VLPs Elicit Gag and Dgp41-specific Antibodies in Mice 
C57BL/6 mice (n = 3) were immunized with Gag/dgp41 VLPs produced using the TMV-
based vector at Day 0 and 45. Two weeks after the first dose, p24-specific IgG was detectable in 
the serum, wheras MPER-specific Abs were below detection limit (Figure 9). One week after the 
second immunization, a 100% response rate was observed for both p24- and MPER-specific 
serum IgG. This indicates the plant-produced VLPs are immunogenic in mice, generate memory 
responses which can be recalled upon boosting, and can elicit Abs specific to the MPER bnAb 
target in the dgp41 protein. 
 
34 
Discussion 
The use of plants as vaccine antigen production platforms has been extensively reviewed 
(Chen and Lai, 2013; Daniell et al., 2009; Ma et al., 2005; Rybicki, 2009; Rybicki, 2010; Rybicki, 
2014; Sala et al., 2003). The primary roadblocks to plant-produced pharmaceuticals revolve 
around both purification and low yield/expression levels (Wilken and Nikolov, 2012). Recombinant 
protein often accounts for only 0.7-7% of TSP (Egelkrout et al., 2012), whereas rubisco is the 
most prominent soluble protein, and the most abundant protein in the world, at 30-50% of the 
plant TSP (Feller et al., 2008; Spreitzer and Salvucci, 2002). Removal of rubisco has plagued the 
plant-produced pharmaceutical field, however, recent developments show great promise at 
removing rubisco with inexpensive chromatography and precipitation methods (Arfi et al., 2016; 
Buyel and Fischer, 2014; Buyel et al., 2013). One such study reports the ability to remove up to 
92% of rubisco from plant extractions using polyethylene glycol (PEG) precipitation (Arfi et al., 
2016). In this study, the removal of the primary large and small subunit bands of rubisco from 
VLP preparations was accomplished by a rapid, inexpensive method using 20% ammonium 
sulfate precipitation (Figure 7). These are critical advancements because the economic 
advantage of using plants over other expression systems is deterred by downstream processing 
accounting for up to 80% of production costs (Wilken and Nikolov, 2012). 
VLPs are thought to be a safe alternative to live attenuated vaccines, yet highly 
immunogenic and more structurally accurate compared to subunit vaccines (Kushnir et al., 2012) 
and plants have been used to produce VLPs of multiple varieties (Chen and Lai, 2013; Scotti and 
Rybicki, 2013; Yildiz et al., 2011). The use of plants for HIV-1 vaccines has grown in interest as 
there is no current HIV-1 vaccine candidate and plants provide unique advantages (Horn et al., 
2003; Rosales-Mendoza et al., 2012). HIV-1 VLPs and other antigens are successfully produced 
in plants (Kessans et al., 2013; Matoba et al., 2009; Meyers et al., 2008; Rosales-Mendoza et al., 
2013; Scotti et al., 2009) and many of these have been shown to be immunogenic in animals 
(Kessans et al., 2016; Matoba et al., 2009; Meyers et al., 2008). 
In particular, for HIV-1 VLPs, the low expression of full-length Gag has proven 
problematic (Meyers et al., 2008), and the highest yields are achieved with transplastomic 
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expression of Gag, reaching levels of 350 mg/kg FW (Scotti et al., 2009). Here improved 
expression was sought by comparing the TMV-based magnICON® system with more recently 
developed Geminivirus-based replicons. Previously, transient cytoplasmic expression of Gag 
yielded a maximum of 44 μg p24/kg FW (Meyers et al., 2008), while here, levels up to 1 mg 
p24/kg FW were reported using both the TMV and Dual Gemini +p19 vectors (Table 4). It is 
possible that this increase is due to transient co-expression of dgp41 as a similar phenomenon 
was previously reported using the TMV-based vector (Kessans et al., 2013). Furthermore, 
gradient-purified VLPs yielded an average up to 343 μg p24/kg FW (Table 5). Again, the Gag 
yield was similar between TMV and Dual Gemini +p19. Though this represents only a fraction of 
the total expression, yields are still far higher than previous reports, thus these vectors hold 
promise for larger-scale production. Additionally, transient genes were consistently expressed at 
higher levels with inclusion of p19 in Geminivirus replicons (Table 4 & Table 5), thus confirming 
the utility of the p19 protein for enhancing transient expression (Garabagi et al., 2012; Silhavy et 
al., 2002; Voinnet et al., 2003). Dual Gemini +p19 also produced the highest dgp41 levels with 
total average expression around 5.5 mg MPER/kg, and the highest yield in VLP fractions with a 
mean of 84 μg MPER/kg (Table 4 & Table 5). Overall, these results suggest transient expression 
of both Gag and dgp41 simultaneously results in the highest VLP yields. 
It is interesting to note that analysis of peak expression for TMV and Gemini-based 
vectors show distinct differences (Figure 5 & Figure 6). All Gemini vectors have an early peak in 
transient dgp41 expression with or without p19, while the TMV vector may be delayed in 
detection of dgp41 but shows a gradual increase over time (Figure 5B). However, this contrasts 
sharply to the pattern seen with transgenic Gag expression (Figure 5A). Gemini and Gemini +p19 
display an early peak in Gag levels corresponding to the peak in dgp41 levels, and Gag 
expression almost completely disappears around the time of severe necrosis (Figure 4 & Figure 
6). What is intriguing is that the TMV vector shows no peak Gag expression with consistent 
variation across the entire time course (Figure 5A). It is likely that this difference is due to the 
gene silencing induced by Geminivirus vectors and not TMV vectors, thus the transgenic Gag and 
transient dgp41 disappear over time, though p19 makes this effect less severe. Additionally, it is 
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possible that gene silencing accounts for the larger variation seen with Gemini vectors, thus 
making harvesting prior to visible necrosis more critical. Therefore, Gemini vectors provide more 
rapid, though more variable, expression. 
One of the major characteristics of HIV-1 responsible for the difficulty of neutralization is 
the low density of gp160 spikes on the virion, with approximately 10 envelope trimers per particle 
(Briggs and Krausslich, 2011). This corresponds to a molar ratio of 0.02 MPER:p24 on a native 
HIV-1 virion (2500 Gag proteins per 10 Env trimers at a molar ratio of 1.6 p24:MPER). The plant-
produced VLPs range from molar ratios of 0.47 to 11.8 (Table 5) and are immunogenic in mice 
[Figure 9 and (Kessans et al., 2016)]. The prospect of increasing the frequency of the bnAb 
MPER target in the context of the enveloped, native Gag matrix is exciting because many bnAbs 
which recognize the MPER are autoreactive towards lipid membrane components (Haynes et al., 
2005; Haynes et al., 2016; Verkoczy et al., 2010; Williams et al., 2015; Zhang et al., 2016), thus 
the MPER epitope must be in the context of a membrane in order to target bnAb lineages. 
Here it was demonstrated that plant-made HIV-1 VLPs can be produced at high yields 
with maximum Gag expression around 1 mg/kg FW and dgp41 up to an average of 5.5 mg/kg, 
and transient Gemini-based vectors +p19 provided the highest yields (Table 4 & Table 5). The 
most exciting result is the consistently higher ratio of MPER on the surface of Gemini-produced 
VLPs compared to the TMV-produced VLPs, which are currently in immunization trials for 
heterologous prime-boosting to determine ability to elicit nAbs. Immunogenicity of the VLPs in this 
study revealed higher responses can be achieved upon boosting, with 100% response rates 
(Figure 9). Plant-produced vaccines and VLPs are gradually breaking through regulatory 
guidelines, thus vastly improving the chances of successful approval of a plant-produced product 
for human use (Fischer et al., 2012; Ma et al., 2005; Spok et al., 2008). The FDA-approved 
enzyme replacement therapy for Gaucher disease is a prime example of the potential for success 
of plant-produced pharmaceuticals (Zimran et al., 2011). Thus, results describe here show 
promise for plant-produced VLPs to be used alone or in combination with other prime-boost 
systems (see Chapter 5), as a cost-effective, scalable production system for an HIV-1 vaccine. 
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Figure 3 - T-DNA Regions of TMV and Geminivirus-based Transient Expression Vectors 
Four transient deconstructed viral expression vectors were compared in this study. (A) A TMV-
based vector, pTM 602, transiently expresses dgp41 after recombining with two other plasmids 
as part of the ICON expression system (Kessans et al., 2013; Marillonnet et al., 2004). (B-D) 
Vectors based on the Geminivirus bean yellow dwarf virus (BYDV) express dgp41 in a replicon, 
bordered by LIRs, in pTM 924 (B) and simultaneously with the silencing suppressor protein p19 in 
pTM 925 (C). These vectors contain the barley α-amylase signal peptide 5’ of dgp41 for targeting 
to the secretory pathway which is under control of the cauliflower mosaic virus 35S promoter 
(P35) containing 2 transcription enhancer binding sites (2e). ICON systems recombine to add the 
signal peptide in planta and express dgp41 under the control of the TMV promoter in the in planta 
recombined construct. Additionally, the last Geminivirus vector contains two replicons separated 
by an SIR and LIR for simultaneous expression of Gag and dgp41 in addition to p19 in pTM 901 
(D). The size of the full plasmid is indicated. For replicon amplification, Geminivirus-based 
systems also contain the viral replication proteins C1 and C2 (Rep and RepA, respectively). SIR – 
short intergenic region; BAA – barley α-amylase; T-DNA – transfer DNA; P – promoter, LIR – long 
intergenic region; 2e – 2 enhancer binding sites; NosT – nos terminator; 3’ UTR – untranslated 
region; nptIII – kanamycin resistance gene 
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Figure 4 - Leaf Necrosis Over Seven-day Kinetics Time Course 
Four transient expression constructs were analyzed for expression of dgp41 alone in Gag 
transgenic N. benthamiana (A-C) or simultaneously transient expression of Gag and dgp41 in WT 
plants (D). Leaf samples were collected in triplicate over seven days and images scanned to 
monitor leaf necrosis. (A) The TMV-based vector expressing dgp41 displays onset of necrosis 
around 5 dpi. Geminivirus-based transient expression of dgp41 in Gag plants displays necrosis 
more rapidly, around 3 dpi, without the silencing suppressor protein p19 (Gemini, B) than the 
Gemini vector which expresses dgp41 and p19 (Gemini +p19) from the same construct, which 
shows onset of necrosis around 4 dpi (C). WT plants infiltrated with the dual-replicon Gemini 
vector (Dual Gem. +p19) simultaneously express Gag, dgp41, and p19 from the same construct, 
and results in visible necrosis around 4 dpi (D). dpi - days post infiltration 
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Figure 5 - Expression Kinetics of Gag and Dgp41 with TMV and Geminivirus-based Vectors 
Homogenized leaf tissue was analyzed in triplicate for Gag (A) and dgp41 (B) expression by 
immunoblot over the seven-day time course and percent of peak expression day calculated 
through band intensity. For each replicate, the band with the highest intensity was set to 100% 
and every other day for that replicate calculated as a percent of the peak day. Peak day varied 
between replicates, and therefore some vectors do not have a consistent day for 100% between 
the replicates. Stable Gag expression and transient dgp41 expression was assessed for three 
vectors in Gag transgenic N. benthamiana: TMV, Gemini, and Gemini +p19. A fourth dual-
replicon Gemini vector +p19 transiently expresses Gag, dgp41, and p19 simultaneously in wild-
type plants. Peak expression day was determined for each vector as the day with highest Gag 
and dgp41 expression prior to severe necrosis. Data are the means of three replicates shown 
with standard error. dpi - days post infiltration 
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Figure 6 - Expression of Gag and Dgp41 with TMV and Geminivirus-based Vectors 
Leaf samples pictured in Figure 4 were homogenized for each vector and 20 μg TSP was loaded 
in each lane (dpi 1-7). Three vectors were compared for dgp41 expression in Gag transgenic N. 
benthamiana: (A) TMV, (B) Gemini, and (C) Gemini +p19. A fourth dual replicon Gemini vector 
+p19 transiently expresses Gag, dgp41, and p19 simultaneously in WT plants (D). Coomassie-
stained gels show equal TSP across lanes (left) and specific immunoblot for Gag (middle) and 
dgp41 (right) proteins was used to determine expression levels and identify peak expression day. 
Images shown are representative of triplicate leaf samples processed for each vector. dpi - days 
post infiltration; TSP – total soluble protein; WT – wild-type 
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Figure 7 - Optimization of Purification Technique to Minimize Rubisco in VLP Extractions 
Two strategies were tested for efficiency in extracting VLPs with minimal remaining rubisco in 
each sample. The first strategy utilized sequential ammonium sulfate precipitations at 20% (20% 
SN and P) and 40% (40% SN and P), where rubisco is expected to pellet around 25%. The 
second strategy employed pH changes to pH 5.5 (5.5 P) followed by pH 5.0 (5.0 SN and P) 
where rubisco is expected to pellet at pH 5.5. An additional 40% ammonium sulfate precipitation 
was performed on the pH 5.0 SN to pellet any remaining VLPs (5.0 – 40% SN and P). Lanes 
were loaded with equivalent TSP as shown by Coomassie staining (A). Expression of Gag (B) 
and dgp41 (C) in each fraction was analyzed by immunoblot. SN – supernatant; P – pellet; TSP – 
total soluble protein 
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Figure 8 - Purification of HIV-1 VLPs Produced by TMV and Geminivirus-based Vectors 
Six-week old N. benthamiana Gag transgenic plants were infiltrated to transiently express dgp41 
with TMV (A), Gemini (B), or Gemini +p19 (C). (D) WT plants were infiltrated with a dual-replicon 
Gemini +p19 to transiently express Gag and dgp41. Leaf tissue was harvested on peak 
expression day and VLPs were extracted in 20 g batches (T – total extract) through 20% 
ammonium sulfate precipitation (SN – 20% ammonium sulfate supernatant; P – pellet) and 
density gradient centrifugation with step-wise 10-20-50% iodixanol layers (Top – sample after 
centrifugation; 10% iodixanol; 20% iodixanol; 50% iodixanol). 5 μg total soluble protein (TSP), as 
determined by Bradford assay, was loaded into each lane and analyzed by Coomassie staining 
(left), and for Gag (middle) and dgp41 (right) expression. VLPs are almost completely pelleted 
with 20% ammonium sulfate with little to no detectable protein remaining in the SN and isolate to 
the 20/50% barrier of the density gradient. Purifications representative of three independent 
extractions for each vector are shown. 
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Figure 9 - VLP-induced Gag and Dgp41-specific Serum IgG 
C57BL/6 mice (n = 3) were injected i.p. at Days 0 and 45 with VLPs, indicated by arrows. Anti-
p24 (Gag) and anti-MPER (dgp41) serum IgG are shown over time as the ELISA OD 490 nm for 
the 1:50 dilution (lowest tested). At the Day 52 endpoint, all animals have detectable levels of 
both Gag and dgp41 specific antibodies. Data are the mean of two measurements for each 
sample for all time points. 
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 Table 4 - Total Gag and Dgp41 Expression from Ammonium Sulfate Precipitation 
 
 
 
 
 
 
 
 
 
 
 
a Protein expression is expressed as mg of p24 or MPER per kg fresh leaf weight for Gag and 
dgp41, respectively. Triplicate samples were processed for each vector and reported here as 
mean with standard error. 
  
Vector Infiltrated 
Plant Line 
Transient 
Expression 
Gag Yield 
(mg p24/kg)a 
dgp41 Yield 
(mg MPER/kg)a 
TMV Gag 
 
dgp41 1.04 ± 0.59 3.45 ± 2.29 
Gemini 0.62 ± 0.16 0.82 ± 0.52 
Gemini (+p19) 0.85 ± 0.34 4.62 ± 1.52 
Dual Gem. (+p19) WT Gag & dgp41 1.09 ± 0.38 5.46 ± 1.49 
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Table 5 - HIV-1 VLP Yield with Transient Expression in N. benthamiana 
a Levels of protein are expressed as μg p24 or MPER for Gag and dgp41, respectively, per kg 
fresh leaf weight. Gag and dgp41 yield were determined in triplicate by quantitative immunoblot 
from density gradient VLP-enriched fractions and reported here as mean with standard error. 
b Molar ratio is calculated as amount of dgp41 MPER to p24 Gag based on a molecular weight 
ratio of 1.6 (p24 = 24 kDa/MPER = 15 kDa) and the lowest and highest ratios are shown as a 
range. 
  
Vector Infiltrated 
Plant Line 
Transient 
Expression 
Gag Yield 
(μg p24/kg)a 
dgp41 Yield 
(μg MPER/kg)a 
Molar Ratio 
(MPER:p24)b 
TMV Gag 
 
dgp41 343 ± 131 33 ± 16 0.74 – 5.2 
Gemini 175 ± 68 11 ± 3 0.47 – 1.34 
Gemini 
(+p19) 
130 ± 30 57 ± 37 0.61 – 9.8 
Dual Gem. 
(+p19) 
WT Gag & dgp41 322 ± 92 84 ± 38 1.7 – 11.8 
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Chapter 3 
PLANT-PRODUCED HIV-1 VLPS STIMULATE A TH2 RESPONSE THROUGH TOLL-LIKE 
RECEPTOR DEPENDENT ACTIVATION OF INNATE IMMUNE CELLS 
 
Abstract 
The innate immune system provides the pathway to activation of adaptive responses, 
and the Toll-like receptors (TLRs) represent one of the primary sensor groups that detect 
components of bacteria cell walls and endosomal nucleic acids. Plant-based production of virus-
like particles (VLPs) inherently involves plant proteins, the gram-negative bacteria Agrobacterium 
tumefaciens, and viral-based expression vectors. Each of these offers a unique pathogen 
associated molecular pattern (PAMP), which could potentially lead to induction of the TLRs if 
present in the final VLP-enriched product. In this study, it was demonstrated that plant-produced 
HIV-1 Gag/dgp41 VLPs are capable of stimulating each TLR and do contain nucleic acids that 
could be delivered to the endosome. Furthermore, it was shown that VLPs induce a preferential 
up-regulation of the CD11b integrin and CD40 co-stimulatory factor in THP-1 cells and mouse 
splenocytes. Furthermore, the up-regulation of CD11b and cytokine production is dependent 
upon signaling through MyD88 and TICAM, but not IFN-α/β receptors, indicating a TLR-specific 
activation. It was further shown that the CD11b population represents alternatively activated M2b 
macrophages secreting primarily IL-10, thus resulting in Th2-biased responses characterized by 
IgG1 isotype switching and minimal IgG2a. Finally, the immunogenicity of the plant-produced 
VLPs was demonstrated to be dependent upon TICAM signaling. Results suggest that TLR4 is 
likely the primary receptor for VLP-induced activation, due the resemblance of responses to LPS 
exposure and the dependence on both TLR adaptor proteins. Based on these results, it is 
proposed that plant-based production of VLPs and other antigens represents a unique platform 
that introduces inherent adjuvancy, which could be complemented by specifically choosing a 
vaccine formulation to enhance the innate immune stimulatory effects described here. 
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Introduction 
The innate immune system is the first defense against invading pathogens, and therefore 
provides key non-specific responses to pathogen associated molecular patterns (PAMPs) to 
initiate the adaptive response (Hoebe et al., 2004; Iwasaki and Medzhitov, 2015). These PAMP 
responses are often regulated through the Toll-like receptors (TLRs), which can sense both 
extracellular PAMPs primarily involving bacterial cell wall components [i.e. lipopolysaccharide 
(LPS), lipotechoic acids, flagellin] and intracellular nucleic acids in the endosomal compartment 
(Akira et al., 2006; Kawai and Akira, 2007; Kawai and Akira, 2010; O'Neill et al., 2013; Takeda et 
al., 2003). All TLRs, with the exception of TLR3, signal through the adaptor protein MyD88, to 
induce expression of cytokines primarily through the transcription factor NFκB (Janeway and 
Medzhitov, 2002; Takeda et al., 2003). TLR3 utilizes an alternative pathway through TICAM [Toll-
IL-1 receptor homology domain (TIR)-containing adaptor molecule, also known as TRIF], while 
TLR4 is the only known TLR capable of signaling through both adaptor proteins, resulting in 
activation of NFκB and IRF3 transcription factors (Kawai and Akira, 2010). 
Many antigen presenting cells (APCs), including dendritic cells (DCs) and macrophages, 
express TLRs, and stimulation through these pathways leads to up-regulation of co-stimulatory 
molecules, including CD40, CD80, and CD86 (Banchereau and Steinman, 1998; Hoebe et al., 
2003; Kaisho et al., 2001; Schnare et al., 2001). These co-stimulatory molecules are involved in 
the immunological synapse between APCs and T cells, and are required for T cell activation 
(Friedl et al., 2005; Huppa and Davis, 2003; McHeyzer-Williams et al., 2000). TLR signaling is 
also required for efficient antibody (Ab) production through activation of B cell and CD4 T cell 
responses (Nemazee et al., 2006; Pasare and Medzhitov, 2004; Pasare and Medzhitov, 2005; 
Schnare et al., 2001), demonstrating the necessity of TLRs and other pattern recognition 
receptors (PRRs) in the initial responses which lead to mobilization of the adaptive response. 
Activation of B cells not only requires stimulation by innate cells but also requires TLR 
expression and signaling within the B cells themselves (Pasare and Medzhitov, 2005). TLR2 and 
TLR4 signaling through MyD88 is required for the development of long-lived Ab responses 
(Komegae et al., 2013) while TLR4 and 9 induce memory B cells to differentiate into plasma cells 
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for Ab secretion (Richard et al., 2008). Furthermore, when TLR ligands are detected by antigen-
stimulated B cells, a non-canonical NFκB pathway is triggered resulting in activation-induced 
cytidine deaminase (AID) up-regulation, which controls Ab class-switching (Pone et al., 2012). 
This leads to a T-independent class-switch towards IgG3 and IgG2a, which can occur in the 
absence of TLR signaling (Nemazee et al., 2006; Pasare and Medzhitov, 2005). However, TLR 
signaling is required for T-dependent antigens to produce IgM and IgG1, but not IgG3 (Pasare 
and Medzhitov, 2005). Such differences in class-switching can also be induced by differential 
stimulation of cytokines, such as IL-12 and IL-4, which respectively result in a bias toward either 
Th1 or Th2 CD4 responses (Snapper and Paul, 1987; Szabo et al., 2003), and TLRs have been 
implicated in at least partially regulating this outcome (Akira et al., 2001; Jankovic et al., 2002; 
Kaisho et al., 2002; Pasare and Medzhitov, 2005; Re and Strominger, 2001; Schnare et al., 
2001). Therefore, the presence of antigen with or without TLR signaling can result in differential 
class-switching, ultimately resulting in two distinct types of immune responses. Understanding 
which pathways are activated by vaccine antigens is important when deciding vaccine 
formulations, including adjuvant choice, because alum, Freund’s complete and incomplete 
adjuvant, and Ribi adjuvant, do not act through TLR pathways (Gavin et al., 2006; Nemazee et 
al., 2006). 
Virus-like particles (VLPs) are immunogenic subunit vaccines which more accurately 
represent the structure of a native virion (Kushnir et al., 2012; Yildiz et al., 2011). VLPs are known 
stimulators of innate immunity (Raghunandan, 2011) and the role of TLRs in VLP immunogenicity 
is of great interest to determine their mode of activation. The interaction of VLPs, but not soluble, 
monomeric antigens, with naïve B cells and follicular DCs induces transport of antigen to draining 
lymph nodes where it initiates adaptive responses (Bessa et al., 2012; Link et al., 2012), making 
them an attractive vaccine component compared to other subunit vaccines. VLPs for several 
viruses, including HIV-1, human papillomavirus (HPV), and hepatitis C virus (HCV) have been 
shown to directly activate DCs (Barth et al., 2005; Buonaguro et al., 2006; Lacasse et al., 2008; 
Lenz et al., 2001; Tsunetsugu-Yokota et al., 2003; Yang et al., 2004). Baculovirus-produced HPV 
VLPs are known to stimulate through TLR4, and vaccination in mice or humans can induce a 
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mixed Th1/Th2 cytokine profile (Lenz et al., 2001; Pinto et al., 2005; Yan et al., 2005; Yang et al., 
2004). Alternatively, baculovirus-produced HIV-1 Gag VLPs were shown to activate human 
PBMC monocytes resulting in a Th2-biased response (Buonaguro et al., 2008; Buonaguro et al., 
2006; Speth et al., 2008), though this was shown to be independent of TLR2 and 4 (Buonaguro et 
al., 2006). Furthermore, HIV-1 Gag VLPs produced in a yeast system were shown to induce a 
Th1 response which requires TLR2 (Tsunetsugu-Yokota et al., 2003), suggesting that the VLPs 
are not only responsible for stimulating TLRs, but the host production system may also play a role 
in directing the specific cytokine activation due to differential PAMPs. To our knowledge, there is 
no data available on the interaction of TLRs with plant-produced antigens, despite the high safety 
profile and immunogenicity of plant-derived VLPs (Chen and Lai, 2013; Rybicki, 2009; Rybicki, 
2010; Rybicki, 2014; Scotti and Rybicki, 2013; Yusibov et al., 2014). 
HIV-1 Gag VLPs have been successfully produced in plants by several groups, and are 
known to be immunogenic in mice, inducing both B cell and CD8 T cell responses (Kessans et 
al., 2013; Kessans et al., 2016; Meyers et al., 2008; Pillay et al., 2010; Scotti et al., 2009). VLPs 
used in this study also contain the deconstructed-gp41 (dgp41) transmembrane protein (Kessans 
et al., 2013), which contains the highly conserved membrane proximal external region (MPER) 
targeted by several broadly neutralizing antibodies [bnAbs, (Huang et al., 2012; Purtscher et al., 
1994; Zwick et al., 2001)]. Producing proteins in plants inherently involves the use of the gram-
negative bacteria, Agrobacterium tumefaciens, and the widely used deconstructed viral 
expression vector based on tobacco mosaic virus (TMV), a positive-sense ssRNA virus (Gleba et 
al., 2005; Marillonnet et al., 2004; Marillonnet et al., 2005). A. tumefaciens contains potential TLR 
PAMPs, including LPS and flagellin (Chesnokova et al., 1997; Silipo et al., 2004). The TMV 
vector includes the viral RNA-dependent RNA polymerase, thus amplifying the recombinant 
gene’s mRNA in the cytoplasm, resulting in abundant ssRNA which could be incorporated into 
VLPs (Marillonnet et al., 2004). Indeed, HIV-1 VLPs are known to incorporate cellular mRNAs 
and are capable of delivering them to other cells (Valley-Omar et al., 2011). Similar “RNA-
loading” of bacteriophage Qβ VLPs can induce both systemic and mucosal IgA antibody 
responses through a TLR7-dependent mechanism (Bessa et al., 2009). Based on these 
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observations, it was hypothesized that plant-produced HIV-1 VLPs may incorporate some 
components which are known to be stimulators of the TLR pathways (Kawai and Akira, 2010; 
Takeda and Akira, 2004). This is proposed as an advantage of producing VLPs in plants, as 
many of the TLR ligands that could be artificially introduced during plant-based production have 
been explored as vaccine adjuvants (Hjelm et al., 2014; Mata-Haro et al., 2007; Nagpal et al., 
2015; Steinhagen et al., 2011). 
In this study, VLPs were specifically tested for their capacity to interact with the innate 
immune system through TLRs. HIV-1 VLPs can efficiently be produced in plants and have been 
shown to be immunogenic in mice (Kessans et al., 2013; Kessans et al., 2016; Meyers et al., 
2008; Pillay et al., 2010; Scotti et al., 2009). It was shown here that plant-produced VLPs induce 
proliferation of CD11b+ cell populations, up-regulating both CD11b itself and the co-stimulatory 
molecule CD40 in an ex vivo assay. This activation results in biased production of Th2 cytokines 
from alternatively activated macrophages, resulting in IgG1 Ab switching. The interaction with 
CD11b+ innate cells is dependent upon both MyD88 and TICAM, and TLR signaling through 
TICAM is required for immunogenicity of the VLPs, indicating a potential TLR4-dominant 
adjuvant-like effect. 
 
Materials and Methods 
Plant Expression and Sample Purification 
Wild-type (WT) or Gag transgenic six-week-old Nicotiana benthamiana plants were either 
left uninfiltrated (WT or Gag/uninfil), mock infiltrated with A. tumefaciens (OD600 = 0.1) harboring 
an empty vector (WT or Gag/mock) or a vector for expression of dgp41 (WT or Gag/dgp41; 
described previously Kessans et al., 2013). Leaf tissue was harvested at peak dgp41 expression 
(4 days post-infiltration, dpi) by flash freezing in liquid nitrogen. Expression vectors used here are 
based on the TMV magnICON® transient expression system (Gleba et al., 2005; Marillonnet et 
al., 2004; Marillonnet et al., 2005). 
Sample purification was performed as previously described for plant-produced VLPs 
(Kessans et al., 2013). Briefly, leaf tissue was crushed in liquid nitrogen, solubilized in extraction 
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buffer (25 mM sodium phosphate, 100 mM NaCl, 1 mM EDTA, 50 mM sodium ascorbate, 1 mM 
PMSF, pH 7.8) for 1 hr, and protein precipitated with 40% ammonium sulfate. The 40% 
ammonium sulfate pellets were resuspended in 1X PBS and further purified by iodixanol density 
gradient. The 20% iodixanol fraction was collected for use in this study because this is the 
fraction in which VLPs are isolated (Kessans et al., 2013). Total soluble protein (TSP) was 
quantified by Bradford assay for the 20% gradient fraction to standardize amount of protein used 
in subsequent experiments. Equivalent TSP for each 20% gradient fraction was loaded in 12% 
polyacrylamide gels and assessed for expression of Gag and dgp41 as previously described 
(Kessans et al., 2013). 
 
Toll-like Receptor Reporter Assay 
HEK293T cells individually expressing TLR2/6, 3, 4, 5, 7, or 9 (Invivogen) were grown in 
DMEM (Corning Cellgro) with 10% heat-inactivated FBS and 10 μg/mL blasticidin (Invivogen). 
Null 293T cells lacking expression of any TLR were grown in the same manner, only without 
blasticidin. Cells were seeded in 6-well plates and transfected in a 3:1 ratio with Lipofectamine 
Reagent and 500 ng/well of the pNiFty2-SEAP reporter plasmid (Invivogen), which contains the 
SEAP gene under control of an NFκB promoter. After 24 hrs, wells were treated with 1 μg TSP of 
20% gradient-purified plant samples: WT uninfiltrated (WT/uninfil), WT mock infiltrated 
(WT/mock), WT dgp41 infiltrated (WT/dgp41), Gag uninfiltrated (Gag/uninfil), Gag mock infiltrated 
(Gag/mock), or Gag/dgp41 (VLPs). Cells were allowed to incubate with plant samples for another 
24 hrs, then growth medium was collected and 20 μL added to QUANTI-Blue™ (Invivogen) per 
manufacturer’s protocol. Color change was monitored for up to 4 hrs, and upon reaching 
saturation (defined as no additional color change for 1 hr), samples were read at OD 630 nm. 
Positive controls for each TLR were included: TLR3 – 1 μg/mL poly(I:C) (Invivogen), TLR4 – 
0.01-1 ng/mL LPS, TLR5 - Escherichia coli whole cell lysate (1 μg TSP), TLR7 – 1μg/mL 
imiquimod (Invivogen), and TLR9 – 10 μg/mL ODN2006 (Invivogen). A TLR2/6 positive control 
was not available. 
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Nuclease Digestion 
WT or VLP 20% gradient fractions were treated with either DNase I (Fermentas) or 
RNase A/T1 mix (Thermo Scientific) per manufacturer’s protocol. Samples were diluted to the 
same volume in PBS. Upon addition of the nuclease, samples were digested for 15 min at 37° C 
followed by addition of EDTA for enzyme inactivation at 65° C for 10 min. A control treatment was 
included in which all buffers and heating steps, including inactivation of the enzyme, were carried 
out in the absence of any nuclease. Another sample that was untreated was included in assays 
as a control for any alterations in signaling induced by buffer changes or heating cycles. Controls 
for proper digestion were included as plasmid DNA for DNase I and cellular mRNA extractions for 
RNase A/T1. These samples were either digested with their respective nucleases or subjected to 
all buffers and heat cycles in the absence of nucleases. After treatments were completed, all WT 
and VLP samples were incubated with TLR7 (RNase) or TLR9 (DNase) reporter cells as 
described above. All digested samples, control treatments, and TLR reporter samples were done 
in triplicate. 
To assess the role of the VLP envelope in protecting nucleic acids from digestion, an 
additional assay was performed in which the above RNase treatments were done with or without 
1% Triton X-100 detergent in order to disturb the VLP membranes. Samples were diluted into 
equal volumes of PBS, either with or without 1% Triton X-100, followed by addition of RNase 
A/T1 mix buffers and enzyme for the same incubations listed above. A control with all buffers and 
heat cycles in the absence of RNase was included. After nuclease treatment, RNA was extracted 
separately from DNA using TRIzol® reagent (Thermo Fisher) per manufacturer’s protocol. Final 
RNA pellets were resuspended in 10 μL water and concentrations measured by OD 260 nm 
readings. RNA yield was calculated by setting the control (no RNase) samples to 100% yield and 
the samples containing RNase were then calculated as a percent of the control. All digests and 
controls were done in triplicate. 
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THP-1 Activation and Differentiation 
THP-1 cells were grown in RPMI 1640 medium (Corning Cellgro) supplemented with 10% 
heat-inactivated FBS, 25 mM HEPES, 2 mM L-glutamine, penicillin (100 units/mL), and 
streptomycin (100 μg/mL). 4 x 105 cells were incubated with 5 μg TSP of WT or VLP 20% 
gradient fractions for 72 hrs. Cells were then stained with CD11b-PE (macrophage; BD 
Biosciences) or CD11c-V450 (DC; BD Biosciences) and activation marker antibodies CD40-APC, 
CD80-FITC, and CD86-PE (BD Biosciences). Surface expression was measured via flow 
cytometry on an LSR Fortessa. For analysis of up-regulation of activation markers on dendritic 
cells (CD11c+), THP-1 cells were first differentiated into DCs by plating 2 x 105 cells/well and 
treating with 100 ng/mL of human IL-4 and GM-CSF (Gold Biotechnology, Inc.) for 5 days, 
refreshing cytokines and medium every 2 days and selecting for adhered cells only. After full 
differentiation, DCs were incubated with WT or VLP 20% gradient fractions for 72 hrs and 
analyzed via flow cytometry for expression of surface activation markers, as above. 
 
Dendritic Cell VLP Attachment Assay 
THP-1 cells were differentiated into DCs as described above, then incubated with 5 μg 
VLPs or Gag/uninfiltrated 20% gradient fractions for 2 hrs. After incubation was complete, cells 
were stained with CD11c-V450 (BD Biosciences) and human anti-gp41 antibody 2F5 (AIDS 
Reagents Program). Cells were fixed with Cytofix/Cytoperm™ Kit (BD Biosciences), then stained 
with anti-human Ig κ light chain-PE (BD Biosciences) for detection of 2F5. Cells were analyzed 
via flow cytometry. 
 
Ex vivo VLP Stimulation of Mouse Splenocytes 
Spleens were harvested from eight to ten-week-old C57BL/6 (n = 3), TICAM -/- (n = 5), 
MyD88 -/- (n = 3), or IFNAR -/- (n = 3) mice (Jackson Laboratories) in Hank’s medium (Corning 
Cellgro), and cells strained through a 0.7 μm filter for resuspension in complete RPMI [cRPMI: 
10% FBS, penicillin (100 units/mL), streptomycin (100 μg/mL), 2 mM L-glutamine]. Red blood 
cells were lysed with ACK Lysing Buffer (Gibco) and splenocytes resuspended in cRPMI at a 
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concentration of 2 x 107 cells/mL. Cells were plated at 1 x 106 cells/well and incubated with 
cRPMI (negative) or 5 μg TSP of WT or VLP 20% gradient fractions for 12 hrs and then a further 
8 hrs after addition of GolgiPlug™ (BD Biosciences). After incubation, cells were stained with the 
indicated anti-mouse antibodies in each assay [including: CD11c-FITC (BD Biosciences), CD11b-
APC (BD Biosciences) or CD11b-PerCP-Cy5.5 (BD Biosciences), F4/80-PE-Texas Red® (BD 
Biosciences)], fixed and permeabilized with Cytofix/Cytoperm™ Kit (BD Biosciences), and 
intracellularly stained with indicated antibodies for cytokines [including: TNFα-PE (BD 
Biosciences), IFNγ-eFluor® 450 (eBioscience), IL10-FITC (eBioscience), and IL12-PE (BD 
Biosciences)]. Cells were analyzed via flow cytometry. 
 
Cell Proliferation Assay 
Spleens were harvested and prepared from C57BL/6 mice (n = 3) as described above. 
After red blood cell lysis, cells were washed twice with 1X PBS (Corning Cellgro), labeled with 1 
μM CFSE per manufacturer’s protocol, and washed an additional three times in 1X PBS after 
labeling to remove excess dye. Cells were resuspended in cRPMI and plated 1 x 106 cells/well 
then incubated for 48 hrs with cRPMI (negative) or 5 μg WT or VLP 20% gradient fractions. 
Splenocytes were stained with CD11b and fluorescence intensity of CFSE was measured via flow 
cytometry. 
 
Mouse Immunizations 
All animal studies were done in accordance with the Arizona State University Institutional 
Care and Use Committee. 
Six-week-old C57BL/6 (wild-type) or TICAM -/- mice (Jackson laboratories) were injected 
intraperitoneally (i.p.) with 2 μg p24 and 0.76 μg MPER, as quantified by immunoblot (described 
previously Kessans et al., 2016). Serum was collected after 14 days to analyze antigen-specific 
IgG Ab production. 
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ELISA and Antibody Isotyping 
Serum samples were analyzed for antigen-specific IgG using either p24 (Gag) or MPER 
(dgp41) peptides, as previously described (Kessans et al., 2016). Total antigen-specific IgG was 
identified with rabbit anti-mouse IgG-HRP (Calbiochem). For Ab isotyping, isotype-specific 
antibodies were used: goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP (Santa Cruz 
Biotechnology). Purified mouse IgG1 kappa chain or mouse IgG2a kappa chain primary 
antibodies (Sigma) were use as controls. ELISAs were developed using SIGMAFAST™ OPD 
(Sigma) per manufacturer’s protocol with samples read at OD 450 nm. 
 
Data Analysis 
All flow cytometry was performed using an LSR Fortessa, and data analyzed using 
FlowJo Software (TreeStar Inc., San Carlos, CA). All statistical analyses were performed using 
ANOVA multiple comparisons one-way or two-way, depending on comparisons, in GraphPad 
Prism Software (GraphPad Prism Software Inc., La Jolla, CA). Significance cut-off was set as p < 
0.05. 
 
Results 
VLP and Control Preparations for TLR Stimulation 
HIV-1 Gag/dgp41 VLPs are of interest as an HIV-1 vaccine candidate (Kessans et al., 
2016), and have potential for TLR stimulation due to their production mechanism. To assess 
these interactions, six control groups were devised: WT/uninfiltrated (plant protein only), 
WT/mock (plant + bacteria), WT/dgp41 (plant + dgp41 + bacteria), Gag/uninfiltrated (plant + Gag 
VLPs), Gag/mock (plant + Gag VLPs + bacteria), and Gag/dgp41 (plant + Gag/dgp41 VLPs + 
bacteria). Comparison of these controls will allow delineation of which VLP components are 
primarily responsible for any stimulation of innate pathways. 
To generate these controls, six-week-old wild-type (WT) or Gag transgenic (Kessans et 
al., 2013) N. benthamiana plants were either left uninfiltrated, infiltrated with A. tumefaciens 
harboring an empty vector (mock infiltration), or with a TMV-based expression vector for dgp41 
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(Kessans et al., 2013). In an effort to fully mimic the VLP purification steps, whether or not Gag 
VLPs are present, all samples were passed through iodixanol density gradients. HIV-1 VLPs 
isolate to the 20% fraction (Kessans et al., 2013), therefore this is the only fraction used in 
immunological assays. The 20% fraction from each control was assessed for expression of Gag 
or dgp41, shown at 55 kDa and 23 kDa, respectively (Figure 10). All Gag transgenic extractions 
contain Gag VLPs, and infiltration appears to increase the yield of Gag in the 20% fraction when 
protein is loaded equally (Figure 10A). Furthermore, dgp41 was detectable in the Gag/dgp41 
sample as expected, and interestingly, was also shown to be present in the WT/dgp41 sample in 
the absence of Gag VLPs (Figure 10B). 
 
Plant-produced VLPs Stimulate TLRs 
In order to determine which TLRs were activated by gradient-purified VLPs, HEK293T 
cell lines expressing each TLR independently were utilized for individual assessment. Upon 
transfection with a SEAP NFκB reporter plasmid, cells were treated with each of our six controls 
to identify which components (e.g. A. tumefaciens components, plant or recombinant HIV-1 
proteins, or VLPs) are required for TLR stimulation. 
Extracellular receptors, TLR2/6, 4 and 5 (Figure 11A), were all activated by the Gag 
transgenic plants that were mock infiltrated with an empty vector or with a dgp41-expressing 
vector. However, the matched WT plant controls did not show similar activation. For TLR4, a 
titration curve of purified LPS was used to quantify the endotoxin levels in the VLP sample, 
calculated at approximately 300 ng LPS/mL (data not shown). The TLR reporter cell treatment 
used 1 μg TSP of each sample which corresponds to a treatment of 0.27 ng of LPS, assuming a 
direct comparison between E. coli and A. tumefaciens LPS potency. Interestingly, a similar 
activation pattern was seen with the endosomal nucleic acid receptors, TLR3, 7 and 9 (Figure 
11B), in which the Gag/mock and Gag/dgp41 VLP fractions activate NFκB reporter gene 
expression, but WT/mock and WT/dgp41 samples do not. Notably, the only exception to this was 
TLR2/6 stimulation by the WT/dgp41 sample, suggesting a non-canonical stimulator of TLR2/6 in 
this fraction (Figure 11A). These data indicate that VLPs are necessary for TLR-stimulating A. 
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tumefaciens components to co-purify to the 20% gradient fraction, because matching WT controls 
lacking VLPs do not induce a similar pattern of TLR activation. 
 
VLP Stimulation of TLRs is Resistant to Nuclease Digestion 
Activation of the nucleic acid sensors TLR3, 7 and 9 was surprising because they are 
endosomal, suggesting the VLPs must deliver nucleic acids to these compartments because the 
WT matched controls for these fractions do not mimic this interaction (Figure 11B). In order to first 
determine whether nucleic acids are detectable and encapsulated by the VLPs, we performed 
nuclease digestions on the WT/uninfiltrated and Gag/dgp41 VLP 20% gradient samples with and 
without membrane-disrupting detergent Triton X-100 (Figure 12A). The WT uninfiltrated sample 
showed clear loss of RNA when digested with RNase without Triton X-100, and this was not 
disrupted in the presence of 1% detergent. In sharp contrast to this, the VLP fraction had 
complete recovery of RNA when exposed to RNase in the absence of detergent. However, 
addition of 1% Triton X-100 allowed for the RNA to be digested in a similar manner to the WT 
sample. Therefore, the data suggest that VLPs protect nucleic acids from nuclease digestion and 
therefore, nuclease treatment should not affect their ability to stimulate the endosomal TLRs. To 
test this hypothesis, VLPs were left untreated, treated with nucleases, or exposed to nuclease 
buffer and heating cycles in the absence of any nuclease. Buffer and heating cycles alone did not 
alter signaling of VLP or WT samples (Figure 12B-C). While DNase treatment had no effect on 
TLR9 signaling (Figure 12C), RNase treatment of VLPs only slightly reduced TLR7 stimulation, 
though this is still significantly higher than WT samples (Figure 12B). Together, these data 
suggest that VLPs acquire nucleic acids from the plant cells during production, offer protection 
from nucleases through the membrane envelope to survive the purification process, and can 
successfully deliver them to the endosomal TLRs. 
 
VLPs Induce THP-1 Differentiation 
Many innate immune cells express TLRs, and undergo observable changes in expression 
of cell surface markers upon stimulation. Therefore, it was hypothesized that VLP interaction with 
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TLRs on human THP-1 monocytes could induce activation and/or differentiation. To this end, 
non-differentiated THP-1 cells were incubated with Gag uninfiltrated particles, VLPs, or medium 
alone (negative control), then stained for expression of CD11c (DC marker), CD11b (macrophage 
marker), and CD40 (activation marker). Unstimulated cells have a bias toward expression of 
CD11c, whereas VLPs shift the cell population to be primarily CD11b+ (Figure 13A). Expression 
of the activation marker, CD40, is also up-regulated in VLP-treated wells for both the macrophage 
(Figure 13B) and DC (Figure 13C) populations. The Gag uninfiltrated VLPs display an 
intermediate phenotype in which the cell populations are more evenly split between DC and 
macrophage markers (Figure 13A); however, there is little up-regulation of CD40 by these 
particles (Figure 13B-C). This indicates the A. tumefaciens components are required for more 
potent activation of undifferentiated monocytes. 
 
VLPs Directly Interact with and Activate DCs 
If VLPs are capable of stimulating differentiation of THP-1 cells, it was reasoned that they 
could also activate fully differentiated cells derived from this cell line. THP-1 cells were 
differentiated into DCs and were then treated with Gag uninfiltrated particles or Gag/dgp41 VLPs 
for 2 hours to allow VLP attachment and then stained for flow cytometry (Figure 13D). Results 
clearly indicate VLPs are in association with DCs while Gag uninfiltrated particles, which lack 
expression of gp41, do not have significant detection of 2F5 similar to the negative control (Figure 
13D), thus confirming the detection of 2F5 in this assay is specific to gp41. 
In order to assess whether VLPs or WT plant material can induce activation of DCs, the 
THP-1-derived DCs were also incubated with WT uninfiltrated plant material or VLPs for 24 hrs 
and then analyzed by flow cytometry for expression of activation markers (Figure 13E-F). CD40 
had the most significant up-regulation by VLPs (Figure 13E) and CD86 also displayed some 
minor up-regulation (Figure 13F). CD80 was also analyzed but did not display significant up-
regulation by VLPs or WT gradient fractions (data not shown). Therefore, these data indicate that 
plant-produced VLPs are capable of inducing differentiation and activation of monocytes and 
DCs, likely through direct interaction by attachment to these cell types. 
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VLPs Activate CD11b+ Cells in a TLR-dependent Manner 
In order to test whether TLR stimulation has any significance in the activation of 
monocytes seen in cell culture, whole splenocytes were isolated from C57BL/6 mice strains: wild-
type (B6), TICAM (TRIF) -/-, MyD88 -/-, and IFNAR -/- (Jackson laboratories). TICAM and MyD88 
are the primary adaptor proteins for TLR signaling, where TLR3 is the only receptor solely 
dependent upon TICAM, and TLR4 is the only receptor which can signal through both TICAM and 
MyD88 (Kawai and Akira, 2010; Takeda and Akira, 2004). IFNAR knockout mice are deficient in 
their ability to respond to type I interferons (i.e. IFN-α/β), but TLR signaling is unaffected, and 
therefore they are included as a control. 
Total splenocytes were incubated ex vivo for a total of 20 hrs in the presence of WT or 
VLP gradient fractions (5 μg TSP) then assessed for CD11b/c expression and production of IFN-γ 
and TNF-α cytokines (Figure 14). The negative control baseline expression was subtracted from 
all data unless it is shown in the graph. Down-regulation of CD11c was detected for both WT and 
VLP-treated samples in B6 mice, but only for VLP samples in all knockout mice (Figure 14A). The 
CD11c+ population also showed up-regulation of CD80 when exposed to both WT and VLP 
gradient fractions, though this is not detectable in MyD88 -/- or IFNAR -/- mice, suggesting a non-
specific, TLR-independent activation of the DC population (Figure 14B). WT plant material 
induces minor up-regulation of CD11b, which is significantly increased by VLPs in B6 mice 
(Figure 14C). Interestingly, both TICAM -/- and MyD88 -/- mice showed a similar loss of CD11b 
up-regulation induced by VLPs, while IFNAR -/- mice are unaffected (Figure 14C). Representative 
plots of CD11b and CD11c gates are shown in Figure 14E, noting the strong shift induced by 
VLPs towards a predominantly CD11b+ population in B6 and IFNAR -/- mice. This up-regulation is 
reduced by approximately 50% in the TLR knockout mice. Interestingly, the CD11b+ population in 
B6 and IFNAR -/- mice has increased IFN-γ single-positive and TNF-α/IFN-γ double positive cells 
when exposed to VLPs compared to WT plant material, and this activation is lost in both the 
TICAM -/- and MyD88 -/- mice (Figure 14D). No significant results were detected for TNF-α 
single-positive cells.  
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Furthermore, nuclease treatment of VLPs did not largely effect up-regulation of CD11b or 
cytokine expression in B6 mice (Figure 15A-B). Only a slight reduction in the CD11b up-
regulation was seen with DNase treatment of VLPs, though this did not alter cytokine expression 
(Figure 15A). WT plant material actually showed an increase in cytokine expression when 
exposed to DNase treatment (Figure 15B), potentially indicating some off-target effect by the 
presence of the enzyme during the assay, even though it was inactivated prior to incubation. 
Overall, this data suggests that VLPs uniquely induce a shift toward a CD11b+ population that 
expresses IFN-γ and TNF-α cytokines in a TLR-dependent manner, matching the biased 
activation seen in THP-1 monocytes (Figure 13A-C). 
 
VLPs Induce Macrophage Proliferation 
It was noted during the ex vivo splenocyte stimulation (described above) that there was a 
vast expansion of the CD11b+ population in VLP-treated samples (Figure 13A). A likely 
explanation for this would be proliferation and expansion of this population upon VLP treatment, 
which could also be dependent upon the presence of A. tumefaciens components from the 
infiltration process. To address this question, splenocytes from B6 mice were stained with CFSE, 
then incubated with medium alone or 5 μg TSP of WT, Gag uninfiltrated (Gag), or VLP gradient 
fractions for a total of 20 hrs. The CD11b+ population is clearly up-regulated in the VLP-treated 
samples, with somewhat intermediate phenotypes for Gag and WT samples (representative plots 
shown in Figure 16A). Proliferation was measured for the CD11b+ population by analyzing 
reduction in CFSE fluorescence, represented by the gate in Figure 16A. The negative control and 
WT samples show no detectable proliferation of the CD11b+ population (Figure 16A), which is 
also expressed as a percentage of total live cells in Figure 16B. However, Gag uninfiltrated and 
VLP samples both induced a significant reduction in CFSE fluorescence intensity in the CD11b+ 
population that is much more profound in the VLP sample (Figure 16B). The significant difference 
between the Gag and VLP samples indicate that infiltration with A. tumefaciens contributes 
toward the VLP-induced proliferation, though Gag particles are capable of some stimulation on 
their own. 
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VLPs Stimulate a TLR-dependent, Th2 Immune Response 
CD11b can be expressed by multiple cell types, and due to the non-specific interaction 
between VLPs and CD11c+ DCs, further analysis of the specific macrophage population was 
pursued. Therefore, to better characterize the macrophage cytokine profile of this population, a 
secondary marker for splenic macrophages (F4/80) was included in assays below. 
Macrophages can differentiate into a multitude of classes, each activated by different 
signals and each possessing unique immunological functions (Gordon, 2003; Martinez and 
Gordon, 2014; Mosser and Edwards, 2008). Based on the characteristics of plant-produced 
VLPs, two potential macrophage subsets were candidate targets: M1 and M2b (Martinez and 
Gordon, 2014; Mosser and Edwards, 2008). M1, or classically activated macrophages, are 
triggered by a combination of LPS and IFN-γ, while M2b macrophages are stimulated by immune 
complexes and TLR ligands, thus making either subset a potential target of the VLPs. These 
subsets can be distinguished by their cytokine profiles: M1 macrophages produce more IL-12 
than IL-10, while M2b macrophage cytokine profile is precisely the opposite. Therefore, VLP and 
WT-stimulated B6 mouse splenocytes were analyzed for IL-10 and IL-12 expression. WT plant 
material elicited no detectable levels of either cytokine while VLPs stimulated primarily IL-10, 
though IL-12 expression was still significantly higher than in the WT sample (Figure 17A). This is 
indicative of M2b macrophage activation. 
Macrophage cytokine production is known to skew CD4 responses toward either Th1 or 
Th2, which ultimately results in differential Ab isotype switching by B cells. Production of IL-10 by 
M2b macrophages is associated with a Th2 immune response, which predominantly elicits IgG1 
Ab isotype switching, while IL-12 and M1 macrophages induce a Th1-dominanted response 
characterized by production of IgG2a (Martinez and Gordon, 2014; Snapper and Paul, 1987). To 
assess whether the M2b cytokine profile induces the expected IgG1 isotype switching, four to six-
week-old wild-type C57BL/6 mice (n = 5) were immunized i.p. with VLPs and serum collected 14 
dpi for analysis of serum IgG isotypes. Antigen-specific ELISA for the p24 subunit of Gag (Figure 
17B) and the MPER peptide of dgp41 (Figure 17C) detected primarily IgG1 isotypes with minimal 
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IgG2a production. Therefore, the Ab isotype switching directly correlates with the M2b 
macrophage activation indicative of a Th2 biased immune response through production of IL-10. 
 
TLR Signaling is Required for VLP Immunogenicity 
In order to assess whether the TLR-dependent stimulation of M2b macrophages ex vivo 
translates to enhanced immunogenicity in vivo, wild-type C57BL/6 (B6) and TICAM -/- mice were 
immunized with VLPs or a mock injection of PBS via the i.p. route, and analyzed for antigen-
specific serum IgG 14 dpi. Gag-specific responses to the p24 subunit are detectable in B6 mice 
but not TICAM -/- mice, resulting in a significant difference in Ab production (Figure 18A). 
Responses to the MPER peptide of dgp41 indicate a similar trend, though the Ab levels did not 
reach significance in any group after a single injection (Figure 18B). Therefore, it is clear that 
plant-produced HIV-1 VLPs induce antigen-specific Ab responses that are dependent upon TLR 
signaling through TICAM. 
 
Discussion 
VLPs are an attractive alternative to subunit vaccines and are considered to be a safer 
choice than live or attenuated viral vectors (Kushnir et al., 2012; Noad and Roy, 2003). In addition 
to a high safety profile, VLPs are highly immunogenic and plant-based production has 
successfully produced VLPs from a variety of human and veterinary infectious diseases [for 
extensive reviews see (Chen and Lai, 2013; Rybicki, 2009; Rybicki, 2010; Rybicki, 2014; Scotti 
and Rybicki, 2013; Yusibov et al., 2014)]. Plants offer some unique advantages over other 
production systems, including: speed to production, versatility of expression vectors, ease of 
scale, and most importantly, a lack for potential contaminating human pathogens (Egelkrout et al., 
2012; Rybicki, 2009). A variety of HIV-1 antigens have been produced in plants (Horn et al., 
2003; Matoba et al., 2009; Meyers et al., 2008; Rosales-Mendoza et al., 2012; Rosales-Mendoza 
et al., 2013; Scotti et al., 2009), including Gag/dgp41 VLPs used here (Kessans et al., 2013), 
which were shown to be immunogenic in mice (Kessans et al., 2016). The nature of plant-based 
protein expression involves the gram-negative A. tumefaciens, which delivers T-DNA to the plant 
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nuclei where a deconstructed TMV viral expression vector is utilized to amplify mRNA in the 
cytoplasm (Gleba et al., 2005; Marillonnet et al., 2004; Marillonnet et al., 2005). Therefore, this 
system offers a range of potential TLR ligands for activating the innate immune system (Kawai 
and Akira, 2007; Kawai and Akira, 2010; Takeda et al., 2003). While there is data collected on 
VLPs produced in baculovirus (Buonaguro et al., 2008; Buonaguro et al., 2006; Petrizzo et al., 
2012; Pinto et al., 2005; Yan et al., 2005; Yang et al., 2004) and yeast (Tsunetsugu-Yokota et al., 
2003) for innate immune activation, there was no available information on plant-produced VLPs 
or other antigens. Here it was demonstrated that plant-produced HIV-1 VLPs stimulate the innate 
immune system to activate a Th2 response in a TLR-dependent manner, and this signaling is 
necessary for immunogenicity. Thus, this finding promotes the use of plants for vaccine antigen 
production due to their natural adjuvancy through the TLR sensors. 
Surprisingly, plant-produced VLPs infiltrated with mock or dgp41 expression vectors both 
stimulated all extracellular and endosomal TLRs while the Gag and WT/uninfiltrated, WT/mock, 
and WT/dgp41 samples did not induce a similar pattern (Figure 11). This suggests that both Gag 
VLPs and A. tumefaciens/TMV must be present in order for the PAMPs to localize to the 20% 
gradient fraction. Additionally, TLR2/6 was stimulated by WT/dgp41 in the absence of Gag VLPs 
(Figure 11A), and dgp41 is detectable in the gradient fraction (Figure 10). It is likely that dgp41 
formed large aggregates or was incorporated into liposomes during the extraction process due to 
its hydrophobicity, thus allowing the protein to pass through the density gradient. Though the 
presence of flagellin (TLR5) and LPS (TLR4) was anticipated in the VLP preparations due to A. 
tumefaciens, and dsRNA (TLR3) and ssRNA (TLR7) due to the replication of the TMV vector, the 
stimulation of the remaining TLRs was unexpected. Nonetheless, it is possible for each of the 
remaining PAMPs to be present in the plant tissue. For instance, TLR2 and TLR4 ligands have 
been found in minimally processed vegetables (Erridge, 2011a; Erridge, 2011b), suggesting N. 
benthamiana may also have similar contaminating byproducts. Additionally, after infiltration, the 
plants undergo varying stages of necrosis until the tissue dies. During this process, it is possible 
that some damaged plant DNA may end up in the cytoplasm, thus also allowing incorporation into 
budding Gag virions leading to activation of TLR9. Thus, it can be concluded that due to the lack 
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of stimulation by Gag VLPs in the absence of A. tumefaciens infiltration, this stimulation pattern is 
not an inherent property of HIV-1 VLPs. This is consistent with the TLR2/TLR4-independent 
innate response by baculovirus-produced HIV-1 Gag VLPs (Buonaguro et al., 2006) and the 
TLR2-dependent response from yeast-produced Gag VLPs, indicating a strong influence by the 
production method in determining the immune activation pathways. 
Furthermore, data revealed that the enveloped VLPs are harboring RNA and 
inadvertently protecting it from nuclease digestion (Figure 12). This characteristic is unique to the 
VLPs because a WT extract lacking Gag contains RNA which is not resistant to nuclease 
digestion (Figure 12A). One of the functions of the Gag protein is to incorporate HIV-1 genomic 
ssRNA (Parent and Gudleski, 2011), and Gag VLPs are not only capable of incorporating cellular 
RNA species, but can also deliver functional mRNA to cells (Valley-Omar et al., 2011). However, 
future studies should address the functionality, if any, of the mRNA found in these VLPs. 
Stimulation of TLR3, 7 and 9 suggests that Gag/dgp41 VLPs can successfully deliver nucleic 
acids to the endosomal compartment (Figure 11B), despite the lack of a functional gp120, 
potentially implicating the VLPs are endocytosed non-specifically. The absence of activation by 
any of the WT samples, further supports the premise that VLPs must be present in order to 
encapsulate and deliver nucleic acids to the endosome, and infiltration with A. tumefaciens 
carrying a TMV vector can greatly enhance the level of mRNA incorporated, because 
Gag/uninfiltrated VLPs did not activate the nucleic acid sensors. 
Stimulation of multiple TLR pathways indicates that the VLPs could be potent activators 
of innate immune cells, and many types of VLPs are known to induce innate responses through 
TLR-dependent mechanisms (Buonaguro et al., 2006; Deml et al., 2005; Lacasse et al., 2008; 
Lenz et al., 2001; Yan et al., 2005; Yang et al., 2004). Therefore, VLP were first tested for 
induction of differentiation of the human THP-1 monocytic cell line. THP-1 cells can be induced to 
differentiate into macrophages (Daigneault et al., 2010; Tsuchiya et al., 1982) and DCs (Berges 
et al., 2005), which are capable of antigen presentation (Sallusto and Lanzavecchia, 1994). Such 
differentiation can be assessed by expression of surface markers CD11b (macrophage) and 
CD11c [DC, (Rosmarin et al., 1989)]. Incubation of THP-1 cells with Gag/dgp41 VLPs induced a 
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preferential up-regulation of macrophage marker CD11b (Figure 13A), which is also accompanied 
by increased expression of the co-stimulatory factor CD40 (Figure 13B-C). Even though 
Gag/uninfiltrated VLPs do not activate any of the TLRs based on reporter assays, they do induce 
an intermediate phenotype for maturation of CD11b monocytes. Therefore, the Gag VLPs can 
induce an activation state in the absence of detectable TLR NFκB activity, though infiltration with 
A. tumefaciens greatly enhances this functionality. Additionally, THP-1 derived DCs can be 
detected in direct association with VLPs (Figure 13D) in addition to up-regulation of CD40 (Figure 
13E) and CD86 (Figure 13F), but not CD80 (data not shown). Thus, VLPs can also induce DC 
maturation despite the biased induction of CD11b macrophages from immature monocytes. 
Additionally, VLP-treated THP-1 cells show increased phosphorylation of p38 MAP kinase within 
24-48 hours (data not shown), which is known to be triggered by TLR pathways (Feng et al., 
1999; Park et al., 2004). The CD11b bias resembles other stimulatory molecules, including all-
trans retinoic acid [ATRA, (Cho et al., 2011)] and similar flavonoids from Morus alba (Kollar et al., 
2015), both of which trigger a similar CD11b differentiation, which has also been at least partially 
attributed to stimulation of p38 kinase pathways (Kollar et al., 2015). The resemblance in 
differentiation of THP-1 towards CD11b monocytes by our plant-produced VLPs could indicate 
incorporation of a similarly acting compound(s) from N. benthamiana. 
Interestingly, ex vivo stimulation of B6 splenocytes mirrors the activation phenotype seen 
with THP-1 cells (Figure 14C) with a shift towards a CD11b-dominant population and this stark 
increase in numbers was shown to be attributable to VLP-induced proliferation of these cells 
(Figure 16). The CD11c+ DC population showed down-regulation of CD11c (Figure 14A), which is 
an indicator of DC activation (Winzler et al., 1997), in addition to the up-regulation of CD80 
(Figure 14B). However, the activation of DCs was not specific to the VLPs, as WT/uninfiltrated 
samples induced a similar activation state, which is no dependent upon TLR signaling. Thus, 
potentially suggesting an alternative pathway is responsible for this phenotype. Others have 
shown that endotoxin-induced down-regulation of CD11c does not require MyD88, but is 
dependent upon TLR4 (Winzler et al., 1997), however, MyD88 -/- mice still have an impaired 
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ability to respond to endotoxin (Kawai et al., 1999). Therefore, future studies should address the 
role specifically of TLR4 in the DC activation shown in this study. 
The up-regulation of CD11b is significant to note due to its stimulatory role in the 
response to sensing endotoxin (Ling et al., 2014; Perera et al., 2001), it is even implicated in 
direct binding to bacterial LPS (Wright et al., 1989). CD11b has been shown to be a key regulator 
in TLR responses (Han et al., 2010), and often displays distinct roles depending upon cell type. 
For instance, in DCs CD11b enhances TLR4-induced innate stimulation (Ling et al., 2014), but 
negatively regulates TLR9 (Bai et al., 2012). In contrast, CD11b is secreted by macrophages 
which sense a TLR9 PAMP (Kim et al., 2016), can act as a co-stimulatory molecule to enhance 
certain macrophage functions in response to LPS stimulation (Fan and Edgington, 1991), and is 
an important marker for phagocytosis (Aderem, 2003). Peritoneal CD11b+ macrophages infiltrate 
the peritoneum in response to multiple exposures to LPS (Kim et al., 2009), and are capable of 
facilitating more rapid antigen clearance (Kataru et al., 2009). Therefore, CD11b could play a role 
in regulating the innate response to the VLPs, potentially enhancing phagocytosis and antigen 
presentation. 
In this study, data showed that VLP-triggered activation of CD11b+ cells is dependent 
upon both of the TLR adaptor proteins, TICAM and MyD88, but independent of the IFN-α/β 
receptor (Figure 14). The loss of CD11b up-regulation and cytokine expression when either TLR 
signaling adaptor protein is lost suggests that the VLPs are likely primarily stimulating TLR4 due 
to its ability to signal through both adaptors. It would be interesting to test whether TLR4 knockout 
mice have a similar loss in signaling comparable to the MyD88 and TICAM knockouts to further 
validate this hypothesis. Additionally, no loss in activation by the IFNAR -/- mice correlates well 
with unpublished data in which VLP treatment of THP-1 cells did not lead to production of 
detectable IFN-β mRNA when analyzed via quantitative RT-PCR (data not shown). Based on 
these findings, the VLP-induced CD11b up-regulation (Figure 13A & Figure 14C) and proliferation 
(Figure 16) is characteristic of described responses due to LPS exposure, and future studies 
would benefit from LPS removal assays to determine the significance of this correlation. 
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When taken together, the bias towards CD11b and CD40 up-regulation in the THP-1 cells 
and splenocytes should induce Th2 responses which result in B cell isotype switching to IgG1, 3, 
or 4 but not IgG2 (Fujieda et al., 1995; Hasbold et al., 1999; Pasare and Medzhitov, 2005). In the 
absence of CD40 signaling, Th2 responses are specifically impaired (Gardby et al., 2000). 
Additionally, CD40 is required to induce class switching (Jabara et al., 2009), and TLR signaling 
can up-regulate AID to initiate class switching in B cells (Pone et al., 2012). In support of this 
hypothesis, the CD11b+ F4/80+ macrophage population displayed a cytokine profile characterized 
by VLP-induced IL-10 Th2 cytokine production with lower, though detectable amounts of the Th1 
cytokine IL-12 (Figure 17A). Thus, this data matches an alternative activation phenotype for M2b 
macrophages, which primarily recognize TLR ligands and immune complexes (Gordon, 2003; 
Martinez and Gordon, 2014; Mosser, 2003; Mosser and Edwards, 2008). Other types immune 
complexes have also been shown to elicit IL-10 through alternative activation of macrophages 
(Ronnelid et al., 2003; Tripp et al., 1995). The Th2 cytokine bias should result in class switching 
towards IgG1 and not IgG2 (Fujieda et al., 1995). Indeed, isotyping of VLP-injected mice showed 
a strong bias towards IgG1 with minimal, though detectable, antigen-specific IgG2a (Figure 17B-
C), thus suggesting that the CD40-induced isotype switching may be relevant to VLP immune 
activation. LPS is known to be a potent inducer of CD40 expression in splenic DCs (Kaisho et al., 
2002; Kaisho et al., 2001) and peritoneal macrophages (Hoebe et al., 2003). Therefore, it is 
possible that incorporation of LPS into the VLP envelope during plant infiltration is primarily 
responsible for the activation of innate immunity. The lack of Ab production in TICAM -/- mice 
further indicates TLR signaling through TLR3 or TLR4 is likely the primary target of VLP innate 
activation (Figure 18). Endotoxin induction of a Th2 response can occur through both MyD88 and 
TICAM pathways (Hoebe et al., 2003; Kaisho et al., 2002; Kaisho et al., 2001; Kawai et al., 1999). 
Indeed, it would be interesting in future work to address the requirement for CD40 and TLR4 in 
VLP-induced innate immune activation and Ab responses. Additionally, it is interesting to note 
that Th2 responses are not regulated by IFN (Mosmann and Coffman, 1989; Snapper and Paul, 
1987), thus the data showing no loss of activation in the IFNAR -/- mice further substantiates the 
Th2-bias. 
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Furthermore, it is known that T-independent antigens activate B cells directly and do not 
require TLR signaling (Nemazee et al., 2006), while T-dependent antigens do require TLRs for Ab 
production (Pasare and Medzhitov, 2005). Long-lived Ab responses require TLR4 and TLR2 
signaling and memory cell differentiation (Nemazee et al., 2006). Furthermore, T-dependent 
antigens not only require TLR signaling in DCs to induce maturation and activate T helper cell 
responses, primarily controlled through CD40/CD40L interactions (Fujieda et al., 1995; Gardby et 
al., 2000; Grewal and Flavell, 1998; Hasbold et al., 1999; Schonbeck and Libby, 2001), but B 
cells must also have functional TLR signaling to initiate Ab production (Pasare and Medzhitov, 
2005). Therefore, the lack of Ab production in the TICAM -/- mice may not only be due to the 
reduced innate immune activation seen in Figure 14, but may also be a result of dysfunctional B 
cell TLR signals. It is important to determine if plant-produced VLPs are T-independent or T-
dependent antigens, because many immune complexes are T-independent, meaning they can 
stimulate B cell receptors (BCRs) and TLRs simultaneously, thus bypassing the need for CD4 T 
cell help (Medzhitov, 2007). However, the up-regulation of CD40 and the Th2 cytokine profile of 
the macrophage population indicates that CD4 T cell help may be critical for these particular 
VLPs (Figure 17A). 
In this study, a TLR-dependent activation of macrophages was shown to result in a Th2 
cytokine response which affects B cell isotype switching in response to plant-produced HIV-1 
VLPs. This proposes that plants offer a unique platform for protein production due to the inherent 
adjuvancy provided by plant proteins, A. tumefaciens, and viral-based expression vectors. 
Overall, the TLR-dependent immune activation here could be supplemented by choosing specific 
adjuvants for vaccine formulation to either enhance the VLP effects using TLR4-dependent 
adjuvants such as monophosphoryl lipid A (Mata-Haro et al., 2007), or complement the VLP 
responses by using TLR-independent adjuvants such as Freund’s, alum, or Ribi (Gavin et al., 
2006; Nemazee et al., 2006). The results shown in this study, combined with the known ability of 
plant-produced VLPs to induce systemic and mucosal Ab responses (Kessans et al., 2016; 
Meyers et al., 2008) and their ability to boost T cell responses (Pillay et al., 2010), make plant-
based vaccine production of HIV-1 VLPs an attractive platform. 
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Figure 10 - Expression of Gag and Dgp41 in Gradient-purified Plant Extractions 
N. benthamiana wild-type (WT) or Gag transgenics (Gag) were either left uninfiltrated or infiltrated 
with A. tumefaciens harboring an empty plasmid vector (mock) or a dgp41 expression vector 
(dgp41). The 20% Optiprep gradient fractions were analyzed for presence of Gag (A) or dgp41 
(B) via immunoblot. 
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Figure 11 - 293T TLR Reporter Cell Stimulation with VLPs 
Gag transgenic or wild-type (WT) N. benthamiana plants were either left uninfiltrated (uninfil), 
mock infiltrated (mock), or infiltrated with A. tumefaciens harboring an expression vector for the 
dgp41 protein (dgp41). Both cell surface (A) and endosomal (B) TLRs were treated for 24 hrs with 
1 μg total soluble protein (TSP) from density gradient-purified VLPs or controls. SEAP reporter 
expression, under control of an NFκB promoter, was read as a colormetric output at OD 630 nm 
until saturation. Background levels from untreated negative controls was subtracted from reported 
values for each TLR cell line. 293T null cells lacking expression of any TLR were used as a 
negative control for non-specific activation. The average OD for null cells is represented by a 
dotted line in each graph. Data are means of three replicates shown with standard error. 
Statistical significance when compared to the WT uninfiltrated sample is indicated with an 
asterisk. (** p < 0.01; *** p < 0.001; **** p < 0.0001) 
  
71 
 
Figure 12 - Nuclease Treatment of VLP and WT Gradient Fractions 
(A) VLP and WT 20% gradient fractions were treated with RNase A/T1 mix, with or without 1% 
Triton X-100, followed by TRIzol® extraction. The OD 260 nm was measured for RNA-containing 
TRIzol® fractions. Untreated controls were set to have 100% yield and the percent of RNA in the 
nuclease treated sample was calculated as percent of untreated samples. Data shown is from 
three independent replicates and asterisks indicate significant differences between control and 
RNase samples. (B-C) VLP or WT 20% gradient fractions were left untreated, treated with 
digestion buffers and heating cycles (Buffer group), or complete treatment with buffers and 
nuclease (RNase or DNase). RNase samples were incubated with TLR7 (B) and DNase samples 
with TLR9 (C) in a 293T cell SEAP reporter assay for NFκB activation. The dotted line represents 
background OD 630 nm of null 293T cells, which do not express any TLR. Asterisks over VLP 
samples indicate significance compared to WT uninfiltrated sample. The asterisk over VLP 
+RNase indicates significant difference from VLP untreated. Data are means of three replicates 
shown with standard error. (* p < 0.05; *** p < 0.001; **** p < 0.0001) 
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Figure 13 - Interaction Between THP-1 Cells and Plant-produced VLPs 
(A) Expression of CD11c and CD11b surface markers on THP-1 cells exposed to gradient-
purified Gag uninfiltrated (Gag) or Gag/dgp41 VLPs (VLP). Statistically significant differences 
between negative and treated samples are indicated by asterisks, which are color-coded to their 
respective cell surface marker. CD40 up-regulation on CD11b+ (B) and CD11c+ (C) cells is shown 
as mean fluorescence intensity (MFI) of CD40. (D) VLP attachment to THP-1-derived DCs was 
determined by flow cytometry after 2 hrs of exposure to splenocyte medium (Negative), Gag 
uninfiltrated (Gag), or Gag/dgp41 (VLP) 20% gradient fractions. 2F5 and a fluorescent anti-
human IgG secondary were used to detect Gag/dgp41 VLPs on CD11c+ cells and the Gag 
sample (i.e. no dgp41) is included as a negative control for 2F5 and anti-human IgG staining. (E-
F) THP-1 cells were differentiated into DCs and exposed to either wild-type (WT) or VLP gradient 
fractions or an LPS control. Surface expression of CD40 (E) and CD86 (F), as measured by flow 
cytometry, is shown as percent of the CD11c+ population. Data show the means for three 
independent measurements with standard error. Statistical significance from the negative control 
is indicated by an asterisk. (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001) 
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Figure 14 - DC and Macrophage Activation in Knockout Mice 
Mouse splenocytes from wild-type C57BL/6 (B6, n = 4), TICAM -/- (n = 5), MyD88 -/- (n = 3), or 
IFNAR -/- (n = 3) were treated with either cell growth medium (negative), gradient-purified wild-
type (WT) or VLP plant samples and analyzed by flow cytometry for expression of CD11c (A) and 
CD80 (B) to measure DC activation. Macrophage activation was measured by up-regulation of 
CD11b (C) and expression of TNF-α and IFN-γ cytokines (D). Representative flow cytometry plots 
for CD11b and CD11c populations are shown. Percent of total live splenocytes population is 
indicated for both CD11b and CD11c (E). (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001) 
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Figure 15 - Effect of Nuclease Treatment on VLP Stimulation of Macrophages 
Gradient-purified wild-type (WT) or VLP plant material was either left untreated or exposed to 
DNase I or RNase A/T1 mix. Samples were then used to stimulate splenocytes from wild-type 
C57BL/6 mice (n = 3). Cells were analyzed by flow cytometry for up-regulation of CD11b (A). The 
CD11b+ population was assessed for expression of TNF-α and IFN-γ (B). Statistical significance 
is indicated by asterisks. (* p < 0.05; ** p < 0.01) 
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Figure 16 - Macrophage Proliferation Induced by VLP Stimulation 
Mouse splenocytes from wild-type C57BL/6 mice (n = 3) were labeled with CFSE and exposed to 
medium (Negative/Neg), gradient-purified wild-type (WT), Gag uninfiltrated (Gag), or Gag/dgp41 
VLP (VLP) plant material for 48 hrs. Surface expression of CD11b and fluorescence intensity of 
CFSE was analyzed by flow cytometry (A). A reduction in CFSE intensity was interpreted as 
cellular proliferation. The mean percentage of live cells which are CFSElow CD11b+ (population 
indicated by the gate in A) is shown with statistical significance indicated by asterisks (B). (* p < 
0.05; **** p < 0.0001) 
  
76 
 
Figure 17 - Characterization of Macrophage Cytokine Profile and Antibody Isotypes 
 
(A) Splenocytes from wild-type C57BL/6 mice (n = 3) were stimulated with gradient-purified wild-
type (WT) or VLP samples and analyzed by flow cytometry. F4/80+ CD11b+ cells were selected 
by gating and assessed for expression of IL-10 or IL-12. (B-C) Mice immunized with VLP samples 
were tested by isotype-specific ELISA for presence of p24- (B) or MPER-specific (C) IgG1 or 
IgG2a. OD 450 nm values are shown for the lowest dilution (1:50) tested, and statistical 
significance is indicated by asterisks. (** p < 0.01; *** p < 0.001; *** p < 0.0001) 
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Figure 18 - TLR Signaling is Required for VLP Immunogenicity 
Wild-type C57BL/6 (B6) or TICAM -/- mice were injected with 2 μg p24 and 0.75 μg MPER 
intraperitoneally without adjuvant (B6, n = 5; TICAM -/-, n = 3). Mock injections consisted of PBS 
for wild-type B6 (n = 2) and TICAM -/- mice (n = 5). Serum samples were collected 14 dpi and 
analyzed by ELISA to determine Ab responses specific for Gag (p24, A) or dgp41 (MPER, B). 
Raw OD 490 nm values are shown for the 1:50 dilution (lowest tested), and statistical significance 
is indicated by asterisks. (* p < 0.05) 
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Chapter 4 
ACTIVATION OF ANTIVIRAL AND ER STRESS PATHWAYS BY NYVAC-KC VACCINIA 
VIRUS VECTORS EXPRESSING HIV-1 ANTIGENS GAG AND DGP41 
 
Abstract 
Due to the most successful HIV-1 clinical trial (RV144) utilizing a non-replicating 
canarypox vector (ALVAC) and a protein boosting system, much interest has been generated in 
the use of poxviral vectors to improve the modest 30% efficacy obtained in the RV144 trial. One 
such vector was generated by re-inserting two host-range genes, K1L and C7L, into the highly 
attenuated NYVAC vector to create NYVAC-KC, thus maintaining attenuation while restoring 
replication in human tissues. Here, we describe expression of HIV-1 Gag and deconstructed-
gp41 (dgp41) in NYVAC-KC vectors resulting in cytotoxic effects and reduced growth of the viral 
vector. This phenotype is linked to activation of IRF3 and IFN-β through a TBK1-dependent 
pathway and the stimulation of the unfolded protein response (UPR) through PERK/eIF2α 
phosphorylation. Though the TBK1 inhibitor MRT67307 could abrogate IRF3 signaling and PERK 
phosphorylation, it could not prevent eIF2α activation or rescue viral growth. The activation of 
eIF2α is PKR-independent, suggesting an alternative upstream kinase is stimulated. Furthermore, 
re-insertion of 12 immune modulators in NYVAC+12-ZM96 and Cop-Gag vectors neither 
prevented IRF3 signaling nor rescued growth. However, when immunogenicity was compared in 
C57BL/6 mice, wild-type Cop-Gag induced higher Gag-specific CD8 T cell responses at lower 
doses than NYVAC-KC-Gag, suggesting that while the in vitro system indicates similar toxicity 
and IRF3 activation, there is an unidentified factor in the Cop genome which is compensating in 
vivo. Future studies will focus on identifying the gene(s) responsible for the enhanced 
immunogenicity and further characterize the IRF3/TBK1 signaling pathway. Such characterization 
would allow for the strategic development of poxvirus HIV-1 vaccine vectors and could be applied 
for use in other vaccines. 
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Introduction 
Poxviruses have been of interest as vaccine vectors since their use in the eradication of 
smallpox (Wehrle, 1980). Many strains of VACV have been engineered primarily for enhanced 
immunogenicity while maintaining high safety profiles (Jacobs et al., 2009; Tartaglia et al., 1992a; 
Verardi et al., 2012). The canarypox vector, ALVAC, has been a major focus of HIV-1 vaccine 
research due to the modest success of the RV144 phase III clinical trial [Thai Trial, (Rerks-Ngarm 
et al., 2009)]. Avipoxviruses are naturally attenuated in human hosts, due to their evolution in 
avian systems, thus accounting for the high safety of this vector (Taylor and Paoletti, 1988; Taylor 
et al., 1988). In an effort to improve immunogenicity of the ALVAC vector, many variations of 
other VACV vaccine strains, namely modified vaccinia Ankara (MVA) and NYVAC, were tested 
for efficacy as HIV-1 vaccines (Esteban, 2014; Gomez et al., 2012a; Pantaleo et al., 2010). MVA 
is a non-replicating strain derived by passaging in chick embryo fibroblasts (CEFs) which resulted 
in a highly restricted host-range (McCurdy et al., 2004). NYVAC was derived from Copenhagen 
(Cop) by specifically deleting 18 ORFs and, similarly to MVA, lacks the ability to replicate in 
human cells (Tartaglia et al., 1992b). However, a now more widely accepted regime is the design 
replication-competent, highly attenuated HIV-1 viral vectors that cause little to no adverse side 
effects (Parks et al., 2013). It was recently shown that a replicating cytomegalovirus (CMV) vector 
was capable of clearing SIV infection through a mechanism involving non-canonical CD8 T cell 
responses recognizing antigen presented on MHC II (Hansen et al., 2013a; Hansen et al., 
2013b). Replication competence was achieved for NYVAC by reintroducing two host-range 
genes, K1L and C7L, thereby generating NYVAC-KC which permits replication in humans while 
maintaining a high safety profile (Kibler et al., 2011; Quakkelaar et al., 2011). Therefore, this 
study proposes the use of NYVAC-KC as a replicating, yet attenuated, HIV-1 vaccine candidate. 
To this end, NYVAC-KC-Gag and NYVAC-KC-dgp41 were generated. 
Gag contains many important CD8 T cell epitopes which are correlated with reduced viral 
load in HIV-infected patients (Jiao et al., 2006; Kiepiela et al., 2007; Ogg et al., 1998; Stephenson 
et al., 2012). The HIV-1 membrane protein gp41 contains the highly conserved membrane 
proximal external region (MPER), which is the target of the difficult-to-elicit broadly neutralizing 
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antibodies (bnAbs) such as 2F5, 4E10, and 10E8 (Huang et al., 2012; Purtscher et al., 1994; 
Zwick et al., 2001). Therefore, the use of these two vectors for an HIV-1 vaccine would effectively 
target both critical T cell epitopes and potentially protective Ab responses. However, during 
generation of the recombinant NYVAC-KC vectors, it was observed that the viruses grew to 
reduced titers, and in the case of NYVAC-KC-dgp41, had greatly reduced plaque sizes, 
suggesting toxicity to the VACV vector. Analysis of NYVAC-KC-Gag or NYVAC-KC-dgp41 
infected cells using transmission electron microscopy (TEM) revealed large protein aggregates in 
the cytoplasm amongst visible signs of apoptosis. Therefore, it was hypothesized that the UPR 
may be triggered when VACV is expressing recombinant proteins. 
The UPR is a critical regulator of protein expression and cell stress response 
mechanisms in a variety of eukaryotic organisms (Chakrabarti et al., 2011; Hetz, 2012; Schroder, 
2006; Schroder and Kaufman, 2005). Recombinant protein expression is known to trigger the 
UPR in multiple expression systems, including mammalian cells (Du et al., 2013; Pybus et al., 
2014), yeast (Čiplys et al., 2011; Mattanovich et al., 2004), and fungi (Ohno et al., 2011). 
Furthermore, the UPR has an increasingly understood role in immunity due to induction by viral 
infection in both mammalian (Bettigole and Glimcher, 2015; Janssens et al., 2014; Smith, 2014) 
and plant systems (Zhang et al., 2015; Zhang and Wang, 2012). In the event of non-recovery by 
the cell, integration of UPR signals results in apoptosis, generally through mitochondria-regulated 
pathways (Boyce and Yuan, 2006; Hetz, 2012; Holcik and Sonenberg, 2005; Li and Dewson, 
2015; Marchi et al., 2014; Rainbolt et al., 2014) and will activate autophagy to clear the effected 
organelles or protein aggregates (Marchi et al., 2014; Ogata et al., 2006; Ron and Walter, 2007). 
There are two predominant branches of the UPR, one regulated through ATF6 and IRE-1, which 
are ER-stress specific, and the other controlled by PERK, which converges with multiple 
pathways at the phosphorylation of eIF2α for an integrated stress response (ISR), resulting in 
shutdown of translation (Donnelly et al., 2013; Harding et al., 2000; Okada et al., 2002). PERK 
serves multiple roles, including increasing ER/mitochondria connections to facilitate cross-talk 
and calcium transfer, and directly links eIF2α phosphorylation to stimulation of other transcription 
factors and induction of autophagy (Kouroku et al., 2007; Rainbolt et al., 2014). VACV encodes 
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an eIF2α homolog, K3L, which interferes with the activation of eIF2α (Carroll et al., 1993). Though 
K3L is present in NYVAC, the vector is known to induce apoptosis when expressing HIV-1 
antigens Gag-Pol-Nef (GPN), a phenotype not characteristic of MVA expressing GPN (Gomez et 
al., 2007; Guerra et al., 2006; Najera et al., 2006). Many of the genes which were deleted from 
NYVAC are known immune modulators (Tartaglia et al., 1992b), including several inhibitors of 
apoptosis (Taylor and Barry, 2006). However, NYVAC-induced apoptosis was shown to be 
inhibited by re-insertion of C7L (Najera et al., 2006), suggesting an important, non-redundant 
function for inhibiting apoptosis by one or more of the other missing genes in NYVAC-KC 
expressing HIV-1 antigens.  
Furthermore, multiple inhibitors of IFN signaling are absent in the NYVAC-KC genome 
(Smith et al., 2013), and signaling by vectors described here persists despite the antagonism 
provided by K1L and C7L (Meng et al., 2009), suggesting non-redundant mechanisms by one or 
more of the other deleted genes. Notably, a TBK1 inhibitor C6L is among the deleted genes in 
NYVAC-KC (Unterholzner et al., 2011), and is expressed by MVA (McCurdy et al., 2004). TBK1 is 
a downstream kinase of multiple antiviral signaling pathways (Zhao, 2013), but of significance 
here is its role in the downstream regulation of the stimulator of interferon genes (STING, also 
known as MPYS, MITA, and ERIS), whereby the activation of STING/TBK1 results in 
phosphorylation of the transcription factor IRF3 (Tanaka and Chen, 2012; Zhong et al., 2008). 
STING is an ER-resident transmembrane protein primarily known for its role in cytoplasmic DNA 
sensing, resulting in upregulation of type I interferons (IFNs) due to the ultimate activation of IRF3 
(Abe et al., 2013; Burdette and Vance, 2013; Ishikawa and Barber, 2008; Ishikawa et al., 2009; 
Sun et al., 2009). Interestingly, MVA was shown to signal through cyclic GMP/AMP synthase 
(cGAS) production of cyclic di-nucleotides (diNTs) that interact with STING (Dai et al., 2014). 
STING also has a less well characterized role in the UPR that was recently shown to activate 
IRF3 through calcium signaling, and trigger autophagy as a negative regulation for STING 
activation (Liu et al., 2012; Mitzel et al., 2014; Petrasek et al., 2013; Rasmussen et al., 2011; 
Saitoh et al., 2009). The lack of C6L and the known induction of apoptosis by NYVAC-based HIV-
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1 vectors thereby presents a potential mechanism for the toxicity and reduced titers seen with 
recombinant NYVAC-KC vectors, and is the subject of this study. 
NYVAC-KC-dgp41 notably also had reduced plaque sizes, and the protein aggregates 
visualized with TEM are subjectively more predominant than infection with NYVAC-KC-Gag. The 
cytoplasmic tail (CTT) of gp41 contains lentiviral lytic peptides (LLPs), which are amphipathic 
helices that can disrupt membrane integrity, and are implicated in virally-induced apoptosis 
(Postler and Desrosiers, 2013). During HIV-1 infection, the CTT interacts with many host proteins, 
such as calmodulin (CaM), to enhance replication efficiency and minimize Env exposure at the 
cell surface to avoid immune detection (Santos da Silva et al., 2013). HIV-1 induced apoptosis is 
CaM-dependent and can be disrupted by specific mutations or deletions in the C-terminus of the 
cytoplasmic tail (Micoli et al., 2006; Newman et al., 2007; Sasaki et al., 1996). Calcium release 
from the ER during times of ER stress can result in the uptake of calcium by the mitochondria and 
activate pro-apoptotic proteins such as Bak and Bax resulting in cytochrome c release and 
inflammasome formation for caspase-dependent cell death (Marchi et al., 2014). STING also 
interacts with RIG-I and MAVS (mitochondria antiviral signaling protein), the primary site of 
NLRP3 (NOD-like receptor protein) inflammasome formation, and is also involved in the ER 
translocon for protein secretion through the Golgi (Ishikawa and Barber, 2008; Marchi et al., 
2014). Activation of the NLRP3 inflammasome results in proteolytic cleavage of proIL-1β and 
proIL-18 for secretion and antiviral signaling (Marchi et al., 2014), and VACV encodes respective 
soluble receptors B15R (Spriggs et al., 1992) and C12L (Smith et al., 2000) to disrupt this 
signaling, both of which are present in NYVAC-KC and MVA. However, MVA was recently shown 
to activate the NLRP3 inflammasome through TLR2/6 and MDA-5 (Delaloye et al., 2009), 
implicating other poxvirus genes in the upstream prevention of inflammasome formation by MVA 
and NYVAC vectors. Thus, the induction of calcium signaling by expression of full-length CTT of 
gp41 in NYVAC-KC vectors could activate the STING-dependent ER stress pathway resulting in 
caspase-dependent cell death and inflammasome formation mediated by the mitochondria. 
Truncation of the gp41 CTT is not a viable option to rescue cytotoxicity because such 
alterations change the conformation of the gp120 spike and induce differing neutralizing antibody 
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(nAb) profiles (Durham et al., 2012; Kalia et al., 2005; Kuwata et al., 2013; Vzorov et al., 2016), in 
addition to the requirement for full-length CTT for efficient virion incorporation (Murakami and 
Freed, 2000). Thus, full-length CTT is essential for the production of structurally accurate HIV-1 
VLPs and understanding its interaction with the host system in viral vectors is an important 
avenue of study. This chapter describes the induction of toxic effects to both the cell and viral 
vector by NYVAC-KC-Gag and dgp41 vectors resulting in activation of the UPR and IRF3 through 
a TBK1-dependent mechanism. The activation of the UPR results in reduced immunogenicity in 
vivo compared to Cop vectors which contain all 18 deleted ORFs from NYVAC. However, 
expression of the TBK1 inhibitor C6L was not sufficient to rescue IRF3 activation. Therefore, it is 
likely there are redundant mechanisms by which the host senses NYVAC-KC vectors and further 
identification of the genes involved in abrogating this signaling should be pursued to enhance 
immunogenicity. 
 
Materials and Methods 
Plasmid Cloning 
Gag and deconstructed-gp41 genes were derived from pTM 813 and pTM 816, 
respectively (described in Chapter 5), for insertion into the pTK-MCS plasmid under the synthetic 
early/late promoter. The Gag gene was amplified using primers oTM 864 (5’- 
TATACTCGAGATGGGAGCTAGAGC-3’) and 865 (5’- TACACCCGGGTTATTGAGAGGAAG-3’) 
with AccuStart Taq DNA polymerase HiFi PCR kit (Quanta Biosciences) and ligated into TOPO 
pCR-2.1 vector (Invitrogen) and screened in DH5α Escherichia coli. Sequence was confirmed 
with M13F and M13R primers and the plasmid was denoted pTM 936. The added XhoI and XmaI 
sites (shown in italics) were then used to ligate Gag into pTK-MCS under the synthetic early/late 
promoter already present in the backbone. For addition of the dgp41 gene, primers oTM 866 (5’- 
TATAGTCGACGGATCCGGTCGACC-3’) and 867 (5’- TATAGCGGCCGCTTATTGCAAAGCAG-
3’) were used to amplify the gene plus the synthetic early/late promoter from pTM 816 for ligation 
into the TOPO vector, subsequently named pTM 926, and screened using DH5α E. coli. The 
added NotI and SalI sites (shown in italics) were used to ligate the synthetic early/late promoter 
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and dgp41 into the pTK-Gag plasmid with the promoters facing opposite directions. This plasmid 
was named pTK-Gag/dgp41 and further used for generating recombinant viruses. 
 
In vivo Recombination 
BSC-40 cells were maintained in DMEM (Corning Cellgro) with 5% FBS, gentamycin, and 
2 mM L-glutamine. Simultaneous transfection/infection [in vivo recombination, IVR (Brandt and 
Jacobs, 2001; Kibler et al., 1997)] was performed with pTM 815 (Gag) and pTK-Gag/dgp41 and 
Cop-PGNR (Gyrase-PKR, GFP, neomycin resistance) to insert Gag and dgp41 into the vaccinia 
virus TK locus for negative selection using coumermycin (Cmr) sensitivity (White et al., 2011). 
500 ng of plasmid DNA was transfected using Lipofectamine and PlusTM Reagent (Invitrogen) per 
manufacturer’s protocol. This was immediately followed by infection with Cop-PGNR at an MOI = 
0.01 in 35 mm2 dishes of BSC-40 cells. Recombination was allowed to proceed for 24 hrs 
followed by addition of Cmr antibiotic (100 ng/mL). Cells were harvested and lysed at 48 hours 
post infection (hpi). The IVR was used to infect 100 mm2 dishes of BSC-40 cells for selection of 
individual antibiotic-resistant plaques for subsequent expression screening. This process was 
repeated for multiple rounds of antibiotic selection before a >98% pure virus was isolated as 
measured by immunoplaque assay. 
Generation of NYVAC-KC-Gag and NYVAC-KC-dgp41 is described in Chapter 5. 
NYVAC-C-KC (referred to as ZM96 in all figures and text) was previously described (Kibler et al., 
2011) as a vector that expresses HIV-1 Gag-Pol-Nef (GPN) and gp120. NYVAC+12-C (referred 
to as +12-ZM96 throughout) also expresses GPN/gp120 in addition to containing the re-insertion 
of 12 genes between K1L and C7L and was a kind gift of Karen Kibler (Arizona State University). 
ZM96 refers to the HIV-1 isolate that matches the Gag gene present in the viral vectors. 
 
Expression Screening 
Individual antibiotic-resistant plaques were grown in 60 mm2 dishes of BSC-40 cells to 
CPE and lysed with RIPA lysis buffer [1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 1X 
protease inhibitor cocktail III (Research Products International Corp., Prospect, IL), in 1X PBS 
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without calcium or magnesium (Corning)]. RIPA lysates were mixed with an equal volume of 2X 
SDS sample buffer (1X concentrations: 50 mM Tris-Cl pH 6.8, 2% SDS, 0.1% bromophenol blue, 
10% glycerol, 100 mM β-mercaptoethanol). Cell lysates were screened using SDS-PAGE as 
previously described (Kessans et al., 2013). Briefly, boiled samples were run on 12% 
polyacrylamide gels under denaturing conditions, transferred to nitrocellulose membranes (Bio-
Rad) and probed with either Gag or dgp41 antibodies and anti-rabbit or anti-human IgG-HRP 
secondaries, respectively. Proteins were detected via chemiluminescence (ImmunoCruz Luminol 
Reagent, Santa Cruz). 
 
Immunoplaque Assays 
Immunoplaque assays were performed in 6-well dishes by infecting BSC-40s with 50 pfu 
of individual plaques. Once plaques were visible the cells were fixed with 1:1 acetone:methanol 
for 30 min at -20° C, washed with PBS, then incubated with anti-p24 Gag polyclonal rabbit serum 
or 2F5 (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: from Dr. 
Hermann Katinger) at 1:1000 in 3% FBS-PBS. Secondary biotinylated antibodies for anti-rabbit 
IgG or anti-human IgG from Vectastain ABC Kits (Vector Laboratories, Inc.) were used for 
detection with DAB peroxidase substrate (Vector Laboratories, Inc.) per manufacturer’s protocol. 
After counting positive plaques, cells were stained with Coomassie blue dye to count the number 
of negative plaques. Percentages were calculated by dividing positive plaques by total plaques 
per well. The plaque with the highest percentage of positives was used for further purification until 
a plaque with >98% purity was identified and used to grow stocks. 
 
Virus Stocks 
BHK-21 cells were maintained in MEM (Corning Cellgro) with 5% FBS, gentamycin, and 
2 mM L-glutamine. The final Cop-Gag and Cop-VLP (Gag/dgp41) plaques with >98% purity 
determined by immunoplaque assay were grown to CPE in BHK-21 cells in a 60 mm2 dish for the 
first passage (P1) stock. The P1 stock was titered in BSC-40s and used to infect five T150 flasks 
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of BHK-21 cells at an MOI = 0.01 for the P2 stock. Cells were harvested at CPE, subjected to 
freeze-thaw and sonication, then cell lysates were placed on a 36% sucrose pad and centrifuged 
at 22,000 rpm for 80 min at 4° C with an SW28 rotor to pellet virions. Purified virions were 
resuspended in 10 mM Tris-HCl pH 9.0, their titer determined in BSC-40s, and were stored in 
aliquots at -80° C until further use. 
 
Antibodies 
The following antibodies were used for protein detection where indicated: anti-p24 Gag 
polyclonal rabbit serum (Kessans et al., 2013); human anti-MPER 2F5 (AIDS Reagent Program 
and the kind gift of Morgane Bomsel); goat anti-human IgG-HRP (Sigma) for immunoblot; goat 
anti-rabbit IgG-HRP (Santa Cruz Biotechnology) for immunoblot; rabbit anti-IRF3-P S386 
(Abcam); rabbit anti-eIF2α-P S51 (Abcam); rabbit anti-PKR-P T446 (Abcam); rabbit anti-PERK-P 
Y980 (Cell Signaling Technology); rabbit anti-TBK1/NAK-P S172 (Cell Signaling Technology); 
anti-E3L polyclonal rabbit serum (#1675, generated in the laboratory of Bertram Jacobs, Arizona 
State University); mouse anti-GAPDH (Santa Cruz Technology). 
 
Transmission Electron Microscopy (TEM) 
BSC-40 cells grown in T75 flasks were infected at an MOI = 5 and harvested by 
trypsinization 24 hpi. Cells were pelleted between all wash steps at 700 xg for 5 min at 4° C until 
embedded in agarose prior to secondary fixation. Pelleted cells were washed twice in 1X PBS 
(140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). For primary fixation, cells 
were placed in 2% glutaraldehyde in PBS for 15 min at room temperature followed by a second 
incubation with fresh fixative for 1 hour at 4° C. Fixed cells were resuspended in 1% agarose and 
washed three times in PBS for 30 min each at room temperature. Cells were then fixed with 1% 
osmium tetroxide in PBS for 1 hour at room temperature followed by four 15-minute washes in 
water. A 0.2% uranyl acetate solution in water was used to stain en bloc overnight at 4° C 
followed by three 15-minute washes in water. An ethanol series from 20% to 100% (anhydrous) 
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was used for dehydration, increasing the ethanol concentration by 20% every 10 min with three 
incubations in anhydrous ethanol. Spurr’s resin was gradually introduced through 4- to 8-hour 
incubations with 1:3, 1:1, and 3:1 ratios of resin:100% ethanol followed by three incubations in 
100% resin. Cells were divided into several blocks of Spurr’s resin and polymerized at 60° C for 
36 hours. 70 nm sections were placed on formvar-coated copper slot grids and post-stained with 
2% uranyl acetate and 3% Sato’s lead citrate before imaging. 
 
Viral Growth Curves 
Single-step growth curves were performed in 35 mm2 dishes of BSC-40 cells infected at 
an MOI = 5 and rocked for 1 hour at 37° C to allow viral entry. Cells were then washed three 
times with 1X PBS prior to adding growth medium. The 0 hpi well was harvested immediately and 
24 hpi wells harvested in duplicate. Cells were scraped into medium and subjected to three 
rounds of freezing and thawing. For those analyses where intracellular and extracellular virions 
are titered separately, cells were pelleted at 1000 xg for 3 min and medium removed. Fresh 
medium was added to resuspend cells prior to freeze/thaw cycles to release virions. Virus was 
titered in BSC-40s for all growth curves. Multi-step growth curves were performed in the same 
manner as single-step curves, except that the beginning MOI = 0.01. 
Chemical inhibitors were added directly to growth medium (where indicated) immediately 
after PBS washes at the following final concentrations: 2 μM MRT67307 (Sigma) or 10 μM W-7 
(Santa Cruz Biotechnology). For experiments involving Vpu, 500 ng of the expression vector pTM 
808 [obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pcDNA-
Vphu from Dr. Stephan Bour and Dr. Klaus Strebel; (Nguyen et al., 2004)] was transfected into 
BSC-40 cells using X-tremeGENE 9 DNA Transfection Reagent (Roche Diagnostics) per 
manufacturer’s protocol. Expression was allowed to proceed for 24 hrs before infection with 
VACV vectors and addition of fresh media, with inhibitors where indicated. 
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Detection of Phosphorylated Proteins via SDS-PAGE 
THP-1 cells (4 x 105) were infected at the indicated MOIs by pelleting cells at 500 xg for 3 
min at 4° C and resuspended in 100 μL cell growth medium with the indicated virus(es). Cells 
were incubated for 30 min at 37° C prior to addition to 1 mL of growth medium either with 
inhibitors where indicated at the following concentrations: 2 μM MRT67307 (Sigma), 10 μM W-7 
(Santa Cruz Biotechnology), or 100 μg/mL rifampicin (Gold Biotechnology). AraC was added at 
200 μg/mL 30 min prior to addition of virus for infection, then added fresh to growth medium after 
30 min of incubation with virus. Experiments involving Vpu were transfected and infected as 
described above for growth curves. 
Cells were harvested 18 hpi in RIPA lysis buffer with HALT™ Protease and Phosphatase 
Inhibitor Cocktail with 5 mM EDTA (Thermo Fisher Scientific) and mixed with equal volume of 2X 
SDS sample buffer as described above. Fresh BSC-40 cells were seeded in 35 mm2 dishes upon 
first split and infected at the indicated MOIs for each experiment and harvested the same as THP-
1 cells at 18 hpi. For THP-1 time courses, infection proceeded as above only in the presence of 
rifampicin, and samples were harvested as described at each indicated time point. 
Cell lysates were analyzed via SDS-PAGE on 10% polyacrylamide gels transferred to 
nitrocellulose membranes and probed with antibodies in 3% BSA-TBST overnight at 4° C for 
phosphorylated IRF3, TBK1, and PKR or 1 hour at room temperature for phosphorylated PERK 
and eIF2α. E3L expression was used to ensure equal viral infectivity and also monitor viral 
replication stages in time courses. GAPDH expression is used as a total cell loading control for all 
experiments. Phosphorylated proteins were developed with SuperSignal™ West Dura Extended 
Duration Substrate (Thermo Fisher Scientific) and E3L and GAPDH were detected with Pierce™ 
ECL Western Blotting Substrate (Thermo Fisher Scientific). 
 
Quantitative RT-PCR 
THP-1 cells (4 x 105) were infected at an MOI = 5 with or without inhibitors as described 
above and harvested 18 hpi in NP-40 lysis buffer (20 mM HEPES pH 7.5, 120 mM KCl, 5 mM 
magnesium acetate, 1 mM DTT, 10% glycerol, 0.5% Nonidet P-40). RNA was extracted from cell 
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lysates using the RNeasy® Mini Kit (Qiagen). The cDNA conversion was performed using 
PrimeScript™ RT reagent Kit (TaKaRa Bio, Inc.) per manufacturer’s protocol. The cDNA was 
analyzed for IFN-β and GAPDH mRNA levels using the PerfeCTa® SYBR® Green FastMix® for 
iQ™ (Quanta Biosciences) per manufacturer’s protocol on a Bio-Rad CFX Connect™ Real-Time 
PCR Detection System. Human IFN-β primers: forward 5’- AAACTCATGAGCAGTCTGCA-3’ and 
reverse 5’-AGGAGATCTTCAGTTTCGGAGG-3’. Human GAPDH primers: forward 5’-
GCCTTCCGTGTCCCCACTG-3’ and reverse 5’- CGCCTGCTTCACCACCTTC-3’. Results were 
normalized to GAPDH. 
 
Mouse Immunization 
All experiments were done with approval from the Arizona State University Institutional 
Care and Use Committee. 
Four- to six-week-old C57BL/6 mice (bred at Arizona State University), were injected 
intraperitoneally (i.p.) or scarified at the base of the tail with indicated doses of NYVAC-KC-Gag 
(n = 3/dose), Cop-Gag (n = 4/dose), or Cop-VLP (n = 4/dose) diluted in 1X PBS, pH 7.4 (Corning 
Cellgro). Mock mice (n = 3 for scarification; n = 5 for i.p.) received equivalent volumes of 1X PBS 
via the same route. Mice were monitored for weight loss and other signs of illness to ensure 
vector safety. Spleens were collected 7-10 dpi for analysis of antigen-specific CD8 T cell 
responses. 
 
Intracellular Cytokine Staining and Flow Cytometry 
Spleens were harvested in Hank’s medium (Corning Cellgro) and cells strained through a 
0.7 μm filter for resuspension in complete RPMI [cRPMI: 10% FBS, penicillin (100 units/mL), 
streptomycin (100 μg/mL), 2 mM L-glutamine]. Red blood cells were lysed with ACK Lysing Buffer 
(Gibco) and splenocytes resuspended in cRPMI at a concentration of 2 x 107 cells/mL. Cells were 
plated at 1 x 106 cells/well and incubated for 5 hours in the presence of GolgiPlug™ (BD 
Biosciences) and 1 μg/mL of each of five different immunodominant ZM96 Gag CD8 epitopes (5 
μg/mL total): LRSLYNTV (LRS8), VIPMFTAL (VIP8), AMQMLKDT (AMQ8), YSPVSILDI (YSP9), 
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EVKNWMTDTL (EVK10) (synthesized by GenScript and resuspended according to 
manufacturer’s protocol). Cells were stained with fluorescently conjugated antibodies: CD3-APC 
(BD Biosciences), CD8-APC-Cy7 (BD Biosciences), TNFα-PE (BD Biosciences), and IFNγ-eFlour 
450 (eBioscience). Fixation and permeabilization was performed with a Cytofix/Cytoperm™ Kit 
(BD Biosciences) with final resuspension in FACS Buffer (1% FBS in 1X PBS). Samples were 
analyzed by flow cytometry on an LSR Fortessa. Data was analyzed using FlowJo Data Analysis 
Software (FlowJo, LLC; Ashland, OR). 
 
Statistics 
All statistical analyses were performed in GraphPad Prism Software (GraphPad Prism 
Software Inc.; La Jolla, CA). All data were analyzed using a one-way or two-way ANOVA with 
correction for multiple comparisons. Significance cut-off was defined as p < 0.05. 
 
Results 
NYVAC-KC HIV-1 Vectors Display Cytotoxic Effects that Deter Viral Growth 
During the generation of recombinant NYVAC-KC vectors, it was noted that NYVAC-KC-
dgp41 plaques displayed reduced plaque size and grew to lower titers during virus stock 
preparations. Visualization with a transmission electron microscope (TEM) revealed what appear 
to be large protein aggregates or precipitates in the cytoplasm of NYVAC-KC-Gag or NYVAC-KC-
dgp41 single and co-infected BSC-40 cells (Figure 19). In contrast, NYVAC-KC (Figure 19A), 
showed organized viral factories with characteristic intracellular mature virions (IVs, white 
arrows), immature virions with (white triangles) and without (black triangles) genome 
incorporated. However, upon infection with NYVAC-KC-Gag or dgp41-expressing vectors or co-
infected cells (Figure 19B-D), few mature virions were visible, and factories are dominated by 
presumably “empty” shell virions (“E”) and early crescent formations (black arrows). Overall the 
viral factories appear disorganized and are surrounded by large, dense areas of protein denoted 
here as cytoplasmic “junk” (“J”) and malformed mitochondria (“M”). Mitochondria are a key 
regulator of apoptotic cell death (Li and Dewson, 2015), and their malformation visualized with 
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TEM potentially indicates that infection with the NYVAC-KC-Gag and dgp41 vectors trigger 
mitochondrial stress leading to apoptosis. Intense vacuolization of the cytoplasm is also apparent 
in the micrographs, which could be indicative of autophagy. Autophagy can be induced in an 
effort to recover from ER stress, but can also be associated with cell death (Marchi et al., 2014; 
Ogata et al., 2006). Furthermore, NYVAC-KC-dgp41 infected cells display other hallmarks of 
apoptosis, notably nuclear condensation (see Chapter 5). 
Upon discovery of the severe toxicity seen with TEM in NYVAC-KC vectors expressing 
Gag and dgp41, it was questioned whether this had a direct impact on viral growth in cell culture. 
To this end, BSC-40 cells were infected with NYVAC-KC-wild-type (WT, i.e. empty TK locus), -
Gag, -dgp41, or co-infected with Gag/dgp41 vectors at an MOI = 5 per virus for a 24-hour single-
step growth curve. Cells and growth medium were harvested separately to titer intracellular 
mature virions (IVs) and extracellular enveloped virions (EVs) separately. After a single round of 
growth, the Gag and dgp41 single or co-infections grew to significantly reduced titers for both IVs 
(Figure 20A) and EVs (Figure 20B). NYVAC-KC-Gag growth was reduced by approximately 1 log 
compared to WT while expression of dgp41 reduced growth by 2-3 logs. The extreme reduction in 
EVs suggests that viral spread may also be affected as this is the primary virion form responsible 
for spread in animals, though it accounts for less than 1% of the total virus production (Payne, 
1980; Smith and Law, 2004). To assess any effect on viral spread, BSC-40 cells were infected 
with NYVAC-KC-WT, Gag, or dgp41 at an MOI = 0.01 and harvested 72 hpi. For this assay, 
medium and cells were harvested and titered together for total virion yield. Both NYVAC-KC-Gag 
and dgp41 vectors displayed significantly reduced viral spread by 1 log and 2 logs, respectively 
(Figure 2C). As these vectors are candidates for HIV-1 vaccine development, a reduction in viral 
spread, while enhancing safety, may also reduce vector immunogenicity. In order to prevent this 
phenotype in vivo, the signaling pathways involved in the observed toxicity must be identified. 
 
NYVAC-KC HIV-1 Vectors Activate IRF3 and IFN-β Production 
NYVAC-KC was specifically developed to replicate in human cells (Kibler et al., 2011), 
therefore, the human monocytic cell line, THP-1, was chosen for signaling assays. THP-1 cells 
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were infected at an MOI = 10 with NYVAC-KC-WT, Gag, dgp41, or an MOI = 5 of each of the 
Gag and dgp41 vectors in co-infections. Cell lysates were harvested at a late time post-infection 
(18 hours) due to the TEM images being taken at 24 hpi. All HIV-1 protein-expression vectors 
induced IRF3 phosphorylation (IRF3-P) while the WT vector did not (Figure 21A). E3L expression 
shows equal infectivity of each viral vector, suggesting the lack of IRF3 in the WT vector is not 
due to reduced growth. IRF3 is a primary transcription factor for type I interferons (IFNs), 
therefore the levels of mRNA for IFN-β in THP-1 virally-infected cells was assessed, and WR-
∆E3L served as a positive control for the assay. Infection with both the Gag and dgp41 vectors 
induced significantly higher IFN-β mRNA than the WT vector (Figure 21B). Interestingly, infection 
in the human HeLa cell line does not induce IRF3 activation (data not shown), suggesting an 
inherent difference in pathway components between these two cell lines. 
 
IRF3 Activation Initiates Early and Persists Throughout Viral Infection 
The phenotype visualized in the TEM closely resembled a known issue in VACV 
morphogenesis associated with palmitate deficiency for de novo fatty acid synthesis in the 
mitochondria (Greseth and Traktman, 2014), and the general malformation of the mitochondria 
suggested stress induced on this particular organelle may play a role. Therefore, in order to better 
characterize the stage of replication during which activation of IRF3 occurs, two inhibitors were 
utilized, to target different stages. AraC is a nucleotide analog inhibitor of DNA replication (Furth 
and Cohen, 1968), and the antibiotic rifampicin (Rif) is an inhibitor of VACV morphogenesis 
(Moss et al., 1969). By comparing results between these two extremes it is possible to delineate 
whether the stress occurs during entry, morphogenesis, or between these stages. Inhibition by 
AraC effectively prevented IRF3 phosphorylation and activation of a known up-stream kinase 
TBK1 (Figure 22A), however, Rif did not completely eliminate IRF3 activation (Figure 22B). Thus, 
DNA replication must occur, but the toxicity is not necessarily due to a hindrance of 
morphogenesis induced by Gag or dgp41 expression. In agreement with these results, 
supplementing fatty acid free BSA conjugated to palmitate in the cell growth medium did not 
inhibit IRF3 or increase viral growth (data not shown). This implicates a unique phenotype 
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associated with cytotoxic effects induced by expression of Gag and dgp41 during VACV growth, 
which is unrelated to fatty acid synthesis in the mitochondria. 
The inhibition by AraC suggests that the activator of IRF3 does not inherently enter the 
cell with the virion, but must be produced de novo. To narrow down the stage of replication, THP-
1 cells were harvested at multiple times post infection to individually assess each transition in 
replication: entry, uncoating, early/middle/late gene expression, morphogenesis/assembly, and 
viral release (0, 1, 3, 6, 9, 12, and 24 hpi, respectively). Infections were done in the presence of 
Rif to prevent virion spread to other cells, which would induce another round of gene expression 
and antiviral pathway stimulation. NYVAC-KC-dgp41 shows early TBK1 phosphorylation followed 
immediately by IRF3 phosphorylation which persists until the last time point (Figure 22C). 
Interestingly, expression kinetics for an early gene (E3L) is delayed in both NYVAC-KC-dgp41 
(Figure 22C) and NYVAC-KC (Figure 22D), suggesting a natural attenuation for both viruses in 
this cell type, which may not be related to dgp41 expression, but perhaps to one or several of the 
16 ORFs deleted during the generation of NYVAC. 
 
Signaling Occurs Through PERK and TBK1 
Due to the large protein aggregates/precipitates seen with TEM during NYVAC-KC-Gag 
and dgp41 infections, it was hypothesized that these could be due to ER stress. One canonical 
ER stress occurs through membrane proteins such as PERK, which results in phosphorylation of 
eIF2α and the shut-down of translation as an antiviral defense mechanism (Boyce and Yuan, 
2006; Donnelly et al., 2013; Ron and Walter, 2007). Protein kinase R (PKR) can also act to 
phosphorylate eIF2α during sensing of dsRNA (Donnelly et al., 2013) and this is known to occur 
during VACV infection (Kibler et al., 1997), and is inhibited by the VACV E3L gene (Langland and 
Jacobs, 2004; Langland et al., 2006). VACV also encodes a homolog of eIF2α known as K3L, 
which re-directs phosphorylation away from eIF2α to prevent translational shutdown (Beattie et 
al., 1991; Carroll et al., 1993). Both K3L and E3L are present in NYVAC-KC. Therefore, BSC-40 
cell lysates were analyzed for phosphorylation of PERK, PKR, and eIF2α at 18 hpi to assess 
activation of antiviral signaling and ER stress pathways. Infection with NYVAC-KC-Gag, dgp41, or 
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co-infection with Gag/dgp41 displayed increased eIF2α phosphorylation, which was not evident in 
WT infection (Figure 23A). Analysis of up-stream kinases PKR and PERK revealed that PKR was 
not activated in the NYVAC-KC vectors but was detectable in our positive control (Cmr-treated 
WR-GyrPKR). However, PERK was constitutively phosphorylated in BSC-40s, and was down-
regulated by NYVAC-KC but not the Gag or dgp41-expressing vectors. This suggests that during 
recombinant gene expression, K3L is not sufficient to prevent activation of ER stress while E3L 
remains fully capable of preventing dsRNA-stimulated antiviral pathways. 
Interestingly, ER stress can lead to IRF3 activation in cases involving calcium flux 
through a STING/TBK1-dependent pathway (Liu et al., 2012; Mitzel et al., 2014; Petrasek et al., 
2013). Additionally, HeLa cells do not express STING while THP-1 cells do (Sun et al., 2009), 
thus we hypothesized that this difference may account for the lack of IRF3 signaling in HeLa cells 
by the NYVAC-KC-Gag and dgp41 vectors. Therefore, to determine whether the IRF3 activation 
was TBK1-dependent, a specific inhibitor of TBK1, MRT67307 (MRT), was used (Clark et al., 
2011). THP-1 cells were infected with NYVAC-KC vectors with or without 2 μM MRT, then 
assessed 18 hpi for activation of IRF3, TBK1, and PERK (Figure 23B). MRT did not prevent 
TBK1 phosphorylation, but was capable of preventing downstream activation of IRF3 in both Gag 
and dgp41-infected cells. It also effectively prevented the activation of PERK in all infections. This 
suggests that in NYVAC-KC-Gag or dgp41 infections, ER stress and IRF3 activation are linked 
through the phosphorylation of TBK1. 
 
Inhibition of TBK1, but not Calmodulin, can Prevent IRF3 Activation 
As mentioned above, there is a known ER stress pathway which is dependent upon 
STING/TBK1 and is known to be activated during stressors involving calcium flux (Liu et al., 
2012). HIV-1 infection is known to induce calcium flux through a CaM-dependent pathway 
(Sasaki et al., 1996), and this has, at least in part, been linked to the CTT of gp41 (Newman et 
al., 2007). Therefore, this led to the hypothesis that this pathway may be triggered by infection 
with a dgp41-expressing virus, which contains the full-length CTT. In order to determine if 
inhibition of either TBK1 or CaM can prevent IRF3 signaling and IFN-β production, THP-1 cells 
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were infected with NYVAC-KC-dgp41 with or without the TBK1 inhibitor, MRT, and the CaM 
antagonist, W-7, or the two in combination. Interestingly, MRT but not W-7 was capable of 
inhibiting IRF3 phosphorylation (Figure 24A) and significantly reducing IFN-β production (Figure 
24B). The combination of MRT and W-7 resembled MRT alone. Furthermore, it is interesting to 
note that in the presence of W-7, IRF3-P and IFN-β appear to be up-regulated, suggesting an 
additional stress on the cells in the absence of CaM signaling. 
 
HIV-1 Vpu cannot Inhibit ER Stress Pathways, but Increases VACV Protein Expression 
To assess whether inhibition of IRF3 in THP-1 cells correlates with reduced ER stress 
signs, the same inhibitors were tested in BSC-40 cells for their ability to prevent activation of 
eIF2α and PERK. Surprisingly, neither MRT nor W-7 were able to inhibit eIF2α-P and may have 
even caused an increase in phosphorylation (Figure 25A). However, in the presence of MRT, with 
or without W-7, PERK phosphorylation was undetectable and the kinase source for eIF2α 
activation was not a result of PKR stimulation. HIV-1 Vpu protein is a potential inhibitor of IRF3, 
though there are conflicting reports of the true functionality of this role (Doehle et al., 2012a; 
Doehle et al., 2012b; Hotter et al., 2013; Manganaro et al., 2015; Park et al., 2014). Despite the 
few negative reports, the ability of Vpu to abrogate ER stress signaling by our VACV vectors was 
analyzed in BSC-40s. 24 hours prior to infection with NYVAC-KC-dgp41, Vpu was transfected 
into BSC-40s. Chemical inhibitors MRT, W-7, or both MRT/W-7 were added to growth medium 
upon infection, and cell lysates were analyzed 18 hpi for signs of ER stress activation. Vpu 
expression was not able to inhibit eIF2α or PERK phosphorylation. Additionally, the presence of 
MRT, with or without W-7, induced a noticeable increase in activation of eIF2α, while the PERK-P 
seemed to be a result of Vpu expression (Figure 25B). Despite the increased PERK activation, 
the presence of Vpu substantially increased VACV E3L expression from the untreated sample, 
potentially indicating that enhanced viral replication may be a side effect of Vpu co-expression. 
Viral vectors expressing Vpu are being pursued for co-expression with HIV-1 proteins for 
inhibition of IRF3. 
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TBK1 Inhibition can Partially Rescue Replication Kinetics, but not Growth 
Due to the inhibition of IRF3-P and IFN-β production seen with the TBK1 inhibitor MRT, it 
was hypothesized that MRT might rescue viral kinetics and growth. THP-1 cells were infected 
with NYVAC-KC-dgp41 at an MOI = 5 and lysates harvested at the indicated time points to 
determine the stage at which E3L, an early VACV gene, is expressed. In the absence of MRT, 
E3L expression is not substantial until 12-24 hpi for either NYVAC-KC or NYVAC-KC-dgp41 
(Figure 22C-D). However, in the presence of MRT, detectable E3L expression begins around 6 
hpi (Figure 26A), indicating a marginal rescue of kinetics more closely resembling what would be 
expected of a wild-type VACV. In contrast, inhibition of TBK1 by MRT did not rescue growth to 
WT NYVAC-KC levels (Figure 26B). Quite surprisingly, W-7 was the only inhibitor to display a 
marginal enhancement of growth for NYVAC-KC-dgp41, though this is not statistically significant 
(Figure 26B). The results for W-7 contradict its inability to inhibit IRF3, eIF2α, or PERK 
phosphorylation or IFN-β production (Figure 24 & Figure 25). These contrasting results indicate 
there may be a more complex pathway involved in the cytotoxicity of HIV-1 Gag and dgp41 
proteins. 
 
Inhibition of IRF3 by VACV Immune Modulators 
The NYVAC strain was originally derived from Cop by specifically deleting 18 open 
reading frames (ORFs), many of which are known immune modulators (Tartaglia et al., 1992b). 
NYVAC was subsequently engineered to replicate in human cells by re-introducing two host-
range genes, K1L and C7L (Kibler et al., 2011). Thus, NYVAC-KC is still missing 16 ORFs, 
including C6L, a known TBK1 inhibitor (Unterholzner et al., 2011) and multiple genes responsible 
for inhibition of NFκB (Smith et al., 2013), another transcription factor involved in ER stress signal 
transduction. To broadly assess the ability of these genes to prevent IRF3 activation, two viruses 
were utilized, NYVAC-KC-ZM96-Gag and NYVAC+12-ZM96-Gag (kind gift of Karen Kibler), 
which has a re-insertion of a large genome fragment with the 12 genes between K1L and C7L 
that includes C6L and other inhibitors of NFκB activation (N1L, N2L, M2L, and C4L). Expression 
of these genes in NYVAC+12 was not sufficient to prevent IRF3 activation (Figure 27A), and did 
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not rescue growth to WT NYVAC-KC levels (Figure 27C). However, IRF3 activation can still be 
prevented by TBK1 inhibitor MRT with the NYVAC+12 vector, suggesting that C6L’s interference 
with TBK1 does not preclude activation of this particular antiviral signaling pathway (Figure 27B). 
Furthermore, Cop-Gag infection results in IRF3 signaling (Figure 27A), despite the inclusion of all 
gene products deleted from NYVAC. Additionally, both Cop-Gag and Cop-VLP (Gag/dgp41 co-
expressing vector) show reduced replication compared to WT Cop (Figure 27C). These results 
suggest that no Cop gene product is fully capable of interfering with the pathway in vitro. 
However, when Gag is co-expressed with dgp41 in the same vector, no IRF3 activation is evident 
but the virus still grows to reduced titers (Figure 27A & C). This implies co-expression of Gag and 
dgp41 can prevent the stimulation of the IRF3 antiviral pathway but may still result in ER stress, 
thus reducing growth. Additionally, NYVAC-KC-PGNR (Gyrase-PKR, neomycin resistance) does 
not result IRF3 activation, indicating that the stimulation of the pathway is not a result of merely 
any gene expression from the TK locus, but is specific to the HIV-1 antigen-expressing constructs 
(Figure 27A). 
 
Toxicity by NYVAC-KC Vectors Reduces Immunogenicity in Mice 
Due to IRF3 activation and reduced replication seen with Cop and NYVAC-KC vectors, 
immunogenicity was assessed in C57BL/6 mice in dose curves with Cop-Gag (n = 4/dose), Cop-
VLP (n = 4/dose), and NYVAC-KC-Gag (n = 3/dose) vectors. Peak CD8 T cell response were 
analyzed 7-10 dpi for specificity to 5 immunodominant ZM96 Gag epitopes. Mice receiving 
NYVAC-KC-Gag displayed low CD8 responses, which did not reach significance even amongst 
the highest dose when administered intraperitoneally (Figure 28A). However, Cop-Gag and Cop-
VLP were able to elicit an average Gag-specific response of 2.9% and 3.3% IFN-γ expressing 
CD8 T cells, respectively, after a single dose of 105 pfu. Increasing the dose to 107 pfu induced a 
higher peak CD8 T cell response to 5.0% (Cop-Gag) and 4.8% (Cop-VLP) IFN-γ+ CD8+ T cells in 
the spleen (Figure 28A). Despite the activation of IRF3 by Cop-Gag but not Cop-VLP, no large 
differences were detectable in their CD8 T cell responses, suggesting that this difference is not 
significant in vivo.  
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NYVAC-KC-Gag was also tested via scarification immunization route, as it is the primary 
method used in practice for VACV, and mice can tolerate higher doses of VACV via this route. 
C57BL/6 mice (n = 3/dose) were scarified at the base of the tail after hair removal with increasing 
doses of NYVAC-KC-Gag, and peak CD8 T cell responses in the spleen were analyzed 7-10 dpi. 
Responses were much higher using this route of immunization, with both 108 and 109 pfu eliciting 
8.0% IFN-γ secreting, Gag-specific CD8+ T cells (Figure 28B). Though these results are higher 
than Cop vectors administered i.p., NYVAC-KC-Gag required several log higher doses to achieve 
significant responses. However, despite the similarities with IRF3 activation and reduced growth 
in vitro between NYVAC-KC-Gag and Cop-Gag, the lower responses in NYVAC-KC-Gag infected 
mice indicates that one or more of the additional gene products in Cop, including C6L, may have 
a significant impact in vivo. 
 
Discussion 
The modest success of the RV144 clinical trial utilizing a non-replicating canarypox 
vector (ALVAC) generated interest in improving immunogenicity of the vaccine strategy by 
exploring different strains and modifications of poxvirus vectors. Many variations to the vaccine 
strains MVA and NYVAC have been tested for efficacy in animal models and a few human safety 
trials (Esteban, 2014; Garcia et al., 2011; Goepfert et al., 2011; Gomez et al., 2012a; Greenough 
et al., 2008). Though MVA and NYVAC are both non-replicating in human cells (McCurdy et al., 
2004; Tartaglia et al., 1992b), they can induce robust T cell responses (Gomez et al., 2007; Mooij 
et al., 2008) which are polyfunctional (Harari et al., 2008; Harari et al., 2012; Precopio et al., 
2007) and even detectable at mucosal sites (Perreau et al., 2011). However, the only known case 
of a viral vector capable of clearing an established SIV infection utilized a replicating 
cytomegalovirus (CMV) vector (Hansen et al., 2013a), thus emphasizing the important role that 
safe, yet replicating vectors could play in the pursuit of a more immunogenic and protective HIV-1 
vaccine. Re-insertion of the K1L and C7L genes to NYVAC restored the ability to replicate in 
human cells while remaining heavily attenuated (Kibler et al., 2011), yet displaying improved 
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immunogenicity (Quakkelaar et al., 2011). Therefore, NYVAC-KC is of interest as a safe, 
immunogenic, and replicating HIV-1 vaccine candidate. 
The generation of NYVAC-KC-Gag and NYVAC-KC-dgp41 revealed severe toxicity to the 
cells (Figure 19) and the viral vector itself (Figure 20). Signs of apoptosis and autophagy were 
apparent, especially in NYVAC-KC-dgp41 infected cells (Figure 20C). While NYVAC is known to 
induce apoptosis when expressing GPN (Gomez et al., 2007), inclusion of K1L and C7L was 
shown to reduce this by 2-fold (Kibler et al., 2011). Further direct measures of apoptosis are 
necessary in order to assess whether expression of dgp41 significantly increases cell death 
induced by NYVAC-KC. Not only does this affect vector growth in vitro, but the 1-2 log reduction 
in EV formation and lesser ability to spread could have a substantial impact on animal 
immunogenicity (Figure 20B-C). Indeed, NYVAC-KC-ZM96 (C-KC) is known to have limited 
spread compared to the mouse adapted VACV strain, WR (Kibler et al., 2011). Furthermore, the 
inclusion of GPN/gp120 in Cop, the parental strain of NYVAC, attenuates the virus by 1 log in a 
mouse model of pathogenicity (Kibler et al., 2011). This suggests one or more of the HIV-1 
proteins expressed in those vectors is contributing to the attenuation, potentially through vector or 
cellular toxicity as seen with the vectors described in this study. 
It was shown here that expression of Gag or dgp41 results in IRF3-P in THP-1 cells 
(Figure 21A), which led to significant up-regulation of IFN-β (Figure 21B). IRF3 activation 
corresponds exactly with the phenotype visualized under TEM (Figure 19), thus cellular stress 
pathways related to protein expression were assessed, as the additional HIV-1 antigen gene is 
the only difference between NYVAC-KC and the vaccine vectors. 
ER stress can be triggered by PERK, ATF6, or IRE-1 activation as part of the UPR, which 
can ultimately lead to apoptosis (Boyce and Yuan, 2006; Chakrabarti et al., 2011; Hetz, 2012; 
Hussain et al., 2014; Ron and Walter, 2007). It is known that VACV-encoded K3L is an eIF2α 
homolog which is the downstream target of PERK (Carroll et al., 1993). However, another 
upstream sensor known as PKR can sense VACV-produced dsRNA, which is abrogated by 
expression of E3L (Kibler et al., 1997; Langland and Jacobs, 2004; Langland et al., 2006). 
Therefore, the phosphorylation of all three signaling components was assessed, and it was clear 
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that even though NYVAC-KC contains K3L, this is insufficient to prevent activation of PERK when 
recombinant HIV-1 proteins Gag and dgp41 are being expressed, though E3L expression is 
sufficient to preclude PKR activation (Figure 23A). Intriguingly, an ALVAC HIV-1 vaccine vector 
engineered to express VACV K3L and E3L displayed increased VLP production and reduced 
apoptosis in HeLa cells, though the vector was shown to signal through PKR (Fang et al., 2001). 
Thus, stimulation of an IRF3 pathway correlates exactly with the inability to prevent 
phosphorylation of the ER/cell stress regulator PERK and eIF2α (Figure 23A), and thereby offers 
an explanation for the large protein aggregates in the electron micrographs being indicative of 
UPR activation (Figure 19). 
Another interesting point is that the TBK1 inhibitor could rescue PERK-P but did not 
prevent eIF2α-P, however, the activation was PKR-independent (Figure 25A). There are other 
upstream kinases for eIF2α which could be analyzed (de Haro et al., 1996; Donnelly et al., 2013), 
and it would be key to show that in PKR -/- cell lines or mice that antiviral signaling and growth 
cannot be rescued. Furthermore, inhibition of PERK-P did not rescue growth when using the 
TBK1 inhibitor, suggesting that multiple ER stress pathways are likely triggered. Namely, IRE-1 
activation is known to trigger multiple signaling pathways, including mitogen-activated protein 
kinases (MAPK), caspases, and its primary target XBP1 can even act as an enhancer for IRF3 
(Bettigole and Glimcher, 2015; Ron and Walter, 2007). It would be interesting to assess IRE-1 
and its downstream effectors in the presence of the different inhibitors used in this study. Overall, 
this data implicates an ER stress pathway in the attenuation, reduced growth, and IFN sensitivity 
of NYVAC-KC vectors expressing GPN, Gag, or dgp41 antigens. 
ER stress has also been linked to STING/IRF3 activation in several systems (Liu et al., 
2012; Mitzel et al., 2014; Petrasek et al., 2013), including a calcium flux-dependent pathway (Liu 
et al., 2012). STING is an ER-resident cytoplasmic DNA sensor which signals through TBK1 to 
stimulate IRF3 resulting in IFN-stimulated gene (ISG) expression, including IFN-β (Burdette and 
Vance, 2013; Ishikawa and Barber, 2008; Ishikawa et al., 2009; Sun et al., 2009; Tanaka and 
Chen, 2012; Zhong et al., 2008). Interestingly, the CTT of dgp41 contains LLPs which have been 
linked to CaM-dependent calcium flux during HIV-1 infection, and can be prevented by specific 
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point mutations in the LLPs or the CaM antagonist W-7 (Micoli et al., 2006; Sasaki et al., 1996). 
HIV-1 also evolved to inhibit the activity of IRF3 with the Vpu, which is known to interfere with 
IRF3, potentially through targeting it for degradation (Doehle et al., 2012a; Doehle et al., 2012b; 
Park et al., 2014), thus suggesting that in vivo this pathway can have adverse antiviral effects for 
HIV-1 replication. 
Activation of IRF3 by NYVAC-KC-Gag and -dgp41 was inhibited by a TBK1-specific 
inhibitor, MRT67307 (Figure 23B & Figure 24A), which effectively prevented IFN-β production 
(Figure 24B). However, this could not be linked to CaM signaling because the CaM antagonist W-
7 did not prevent IRF3 or PERK activation (Figure 24A). This suggests that while the pathway 
utilizes the TBK1 adaptor protein for IRF3 activation and could still be linked to STING and 
calcium flux, the CaM-dependent apoptosis known to be induced by the CTT of gp41 may not be 
responsible for the phenotype of these vectors. Consistent with this hypothesis, co-expression of 
Vpu in NYVAC-KC-dgp41 infected cells did not substantially impact eIF2α-P and actually 
increased PERK-P (Figure 25B), likely due to the added protein production stress on the ER from 
transfection of an expression vector. However, expression of Vpu seemingly increases VACV 
E3L expression, implying that this protein has beneficial effects to the viral vector, despite the 
PERK phosphorylation (Figure 25B). It would be interesting to express Vpu in a viral vector with 
Gag or dgp41 to assess the ability to preclude IRF3 activity in THP-1 cells and the effect on 
immunogenicity in vivo. Furthermore, none of the inhibitors were capable of rescuing growth 
(Figure 26B) regardless of their interaction with IRF3 and PERK, suggesting alternative pathways 
are also activated. Future studies would benefit from genetic knockouts for TBK1, IRF3, and 
STING to more stringently identify the reliance of IRF3 activation on this pathway. 
Intriguingly, none of the 12 genes inserted to generate NYVAC+12-ZM96 were capable 
of abrogating signaling (Figure 27A). This implies that inhibition of TBK1 by C6L and N1L, NFκB 
by K1L, IRF3 by N2L, MAPK/ERK by M2L, and apoptosis by C7L and N1L was insufficient to 
rescue the phenotype, implying non-redundant mechanisms of inhibition by other proteins outside 
this region (see Figure 29 for an overview of the proteins and pathway interactions). Of interest 
are two genes which are deleted from both MVA and NYVAC, B13R and B14R. B13R is a viral 
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serine protease inhibitor (serpin) that serves as a pan-caspase inhibitor (Dobbelstein and Shenk, 
1996; Kettle et al., 1997; Macen et al., 1996), and has been suggested as the most potent of the 
poxvirus anti-apoptotic proteins (Veyer et al., 2014). Caspase cascades can be a result of both 
intrinsic and extrinsinc death receptor stimuli and are critical executors for inflammasomes and 
the mitochondria-regulated cell death pathway (Duprez et al., 2009). MVA was shown to stimulate 
the inflammasome through a TLR2/6-dependent pathway (Delaloye et al., 2009), however, the 
induction of apoptosis by MVA is cell-specific. MVA and NYVAC both induce apoptosis in 
monocyte-derived dendritic cells (MDDCs), similar to the THP-1 cell line, but only NYVAC results 
in apoptosis in HeLa cells (Guerra et al., 2006), a phenotype prevented by expression of C7L 
(Najera et al., 2006). However, C7L is present in NYVAC-KC, and N1L was introduced in 
NYVAC+12, and thus neither can account for the results shown here. In support of this, analysis 
of MDDCs revealed differential up-regulation of genes when compared to HeLa cells (Guerra et 
al., 2007), suggesting cell-specific pathways are involved. Many of the up-regulated genes 
implicate inflammasome formation and TNF/Fas-mediated apoptosis, which relies on caspases 
(Duprez et al., 2009), and is the primary apoptotic pathway induced by HIV-1 (Micoli et al., 2006; 
Sasaki et al., 1996). The soluble IL-1 receptors B15R and C12L act downstream of the 
inflammasome, thus would not rescue an infected cell from apoptosis, but merely prevent 
signaling to surrounding cells, thus accounting for their inability to rescue signaling in these 
assays. Taken together, this data suggests a role for B13R in the inhibition of apoptosis and 
inflammasome production of IL-1β and IL-18 in caspase-dependent cell death (Figure 29). If the 
cell death is indeed caspase-dependent, then this implies an alternative apoptotic pathway than 
the CaM-dependent apoptosis induced by gp41, and thus explains why W-7 could not rescue 
growth (Figure 27B). To confirm this hypothesis, re-insertion of B13R to NYVAC-KC vectors 
and/or the use of a pan-caspase inhibitor should be pursued to determine the importance of this 
pathway in the phenotype presented here. 
The absence of IRF3 signaling in HeLa cells contrasted by potent stimulation in MDDCs 
described above and in agreement with data presented here, is best explained by the difference 
in STING expression (Sun et al., 2009). Indeed, MVA infection results in activation of a 
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cGAS/STING-dependent pathway (Dai et al., 2014), thus analysis of NYVAC-KC vectors in 
STING knockout cell lines is being pursued in an effort to confirm a similar pathway. The 
activation of STING is known to activate both NFκB and IRF3 pathways (Ishikawa and Barber, 
2008), and in cases of ER stress involving calcium flux, STING was shown to regulate the 
activation of IRF3 in response to these stressors (Liu et al., 2012). STING is also implicated in 
regulation of the exocytosis pathway from the ER due to its association with the translocon 
(Ishikawa and Barber, 2008), thus providing a potential physical link in regulation of ER stress 
pathways, though this has not yet been fully delineated. STING’s activation of NFκB is prudent to 
data shown here because abrogating TBK1/IRF3 signaling does not rescue growth (Figure 26B), 
and NYVAC+12-ZM96 still induced IRF3 signaling (Figure 27A), despite the inclusion of C6L and 
N1L, which inhibit TBK1 (DiPerna et al., 2004; Unterholzner et al., 2011), and N2L, a nuclear 
inhibitor of IRF3 (Ferguson et al., 2013). This is further substantiated by MVA’s activation of 
STING/cGAS (Dai et al., 2014), because MVA also expresses C6L and N2L, suggesting neither 
of these proteins are sufficient to inhibit this pathway. B14R is the most likely protein outside of 
the region re-inserted into NYVAC+12 to be necessary to inhibit STING downstream effector 
functions (Figure 29). 
B14R is a specific inhibitor of the IKKα/β complex responsible for degradation of IκBα to 
activate NFκB (Chen et al., 2008; Graham et al., 2008), and this complex has also been shown to 
stimulate TBK1 through TLR and TNF receptor signal cascades (Clark et al., 2011). Thus, in the 
presence of MRT, TBK1 phosphorylation can still occur through the IKK complex, but 
downstream activation of IRF3 would be inhibited, in agreement with Figure 24. Furthermore, 
MRT and C6L/N1L/N2L expression would have no effect on NFκB activation, thus potentially 
explaining the inability to rescue growth. Interestingly, MRT can still prevent activation of IRF3 in 
NYVAC+12-ZM96 (Figure 27B), suggesting that the pathway is still reliant on TBK1 and perhaps 
the VACV-encoded inhibitors are insufficient to prevent it, or there is a novel role for B14R in the 
cross-talk with the IKK complex and IRF3. 
Furthermore, STING induces autophagy as a negative regulation mechanism to prevent 
prolonged signaling (Mitzel et al., 2014; Saitoh et al., 2009). When considered along with the 
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ability for PERK/eIF2α to induce autophagy (Kouroku et al., 2007), and the inhibition of PERK 
phosphorylation by MRT treatment (Figure 24A), this provides a mechanism linking STING and 
PERK activation to the visible signs of autophagy and apoptosis seen with TEM (Figure 19). 
Additionally, STING is known to interact with RIG-I at the ER-mitochondria interface (Ishikawa 
and Barber, 2008), where assembly with MAVS provides a plausible platform for inflammasome 
formation (Marchi et al., 2014). It would be interesting to assess inflammasome activation by 
NYVAC-KC HIV-1 vectors and determine whether they show a similar reliance on TLR2/6 as 
shown for MVA (Delaloye et al., 2009), because both viruses have deleted B13R and B14R 
genes. Therefore, B14R should be assessed alongside B13R for independent or cooperative 
inhibition of STING and caspase-dependent apoptosis/inflammasome formation. 
Surprisingly, even expression of all NYVAC-deleted genes in Cop-Gag did not preclude 
IRF3 signaling (Figure 27A). There is a little characterized pathway involving cyclophilin A 
(CYPA) in which newly synthesized p55 capsid protein engages CYPA to activate IRF3 in 
dendritic cells (Manel et al., 2010), though this pathway has been suggested to be an evasion 
mechanism to avoid detection by cGAS during HIV-1 entry and replication and the subsequent 
activation of STING (Lahaye et al., 2013; Rasaiyaah et al., 2013). Interestingly, co-expression of 
Gag and dgp41 in Cop-VLP does not display the same IRF3 activation though it has limited 
growth compared to WT (Figure 27), thereby implicating that interaction between gp41 and the 
newly synthesized Gag protein may abrogate its interaction with CYPA and prevent activation of 
IRF3. Thus, it is possible that even in the presence of VACV-encoded inhibitors, these vectors 
could trigger an alternative antiviral pathway through CYPA, thus activating IRF3 independently of 
TBK1 resulting in antiviral signaling and reduced growth. Therefore, it is necessary to generate 
knockout cell lines of STING, cGAS, and CYPA to assess the individual contributions to IRF3 
activation in the NYVAC-KC HIV-1 vectors. 
Interestingly, Cop-Gag and Cop-VLP induced higher Gag-specific CD8 T cell responses 
at lower doses than NYVAC-KC-Gag (Figure 28A). This suggests that while Cop-Gag, Cop-VLP, 
and NYVAC-KC-Gag all display reduced growth in BSC-40s (Figure 27C), Cop vectors have an 
advantage in vivo which allows them to compensate and generate higher responses, despite the 
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similar activation of IRF3 seen in vitro. Furthermore, this offers a unique opportunity to analyze 
the effect of these pathways on immunogenicity of the viral vectors by directly comparing CD8 T 
cell responses to Gag in knockout mouse strains for STING, cGAS, and CYPA. It would be 
hypothesized that if this pathway is responsible for vector toxicity, then removal of this signaling 
would increase replication and antigen load for enhanced immunogenicity. Such studies will 
directly compare in vivo pathogenicity and immunogenicity of NYVAC-KC-Gag, NYVAC+12-
ZM96, NYVAC-KC-B13/B14R-Gag, and Cop-Gag. Additionally, due to the IFN-β production by 
these vectors, similar experiments in IFN-α/β receptor (IFNAR) -/- mice would also determine 
whether or not the in vivo attenuation and reduced immunogenicity/spread is IFN-dependent. 
A balance between immunogenicity and safety can be difficult to strike, therefore it would 
be beneficial to identify for NYVAC-KC which of the deleted genes from Cop or NYVAC+12 are 
necessary to improve immunogenicity (i.e. higher responses at lower doses) by inhibiting the 
IRF3 activation pathway described here. Many vectors have been studied by individually deleting 
genes in an effort to enhance immunogenicity. For instance, deletion of C6L from MVA results in 
an enhancement of immunogenicity for HIV-1 antigens, which is likely due to the activation of 
IRF3 and other signaling pathways regulated by TBK1 (Garcia-Arriaza et al., 2013; Garcia-
Arriaza et al., 2011). In addition to C6L, other immune modulators have been deleted in NYVAC 
and MVA vectors, such as the soluble IFN receptors B19R and B8R (Kibler et al., 2011; 
Quakkelaar et al., 2011), a TLR inhibitor A46R (Perdiguero et al., 2013), and an NFκB/IRF3 
inhibitor K7R (Garcia-Arriaza et al., 2013). In each case, immunogenicity of the viral vector was 
enhanced, allowing the presumption that these genes are not essential for in vivo efficacy of 
VACV vaccine vectors. It is plausible that in the case of NYVAC-KC, re-insertion of B14R could 
abrogate IRF3 signaling, and B13R could serve to prevent caspase activation and apoptosis, thus 
making a strategically engineered HIV-1 vaccine vector for enhanced immunogenicity, specifically 
for these antigens. Similar strategies could be employed for other viral vectors which may 
express proteins that result in toxicity to both the host cells and viral vector itself. 
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Figure 19 - TEM with NYVAC-KC HIV-1 Vectors Show Signs of Cytotoxicity 
 
BSC-40 cells were infected at an MOI = 5 with NYVAC-KC (A), NYVAC-KC-Gag (B), NYVAC-KC-
dgp41 (C), or co-infected with NYVAC-KC-Gag and dgp41 (D). Representative images of viral 
factories are shown, revealing disorganization in the HIV-1 vectors with few, if any, mature virions 
and accumulation of protein precipitates. Mitochondria also appear to be malformed. Scale bars: 
500 nm. Mature virions, white arrows; white triangles, immature virions with genome 
incorporated; crescents, black arrows; immature virions, black triangles; cytoplasmic junk, “J”; 
empty virions, “E”; mitochondria, “M”. 
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Figure 20 - NYVAC-KC Vectors have Impaired Growth in BSC-40s 
(A-B) BSC-40 cells were infected for single-step growth curves at an MOI = 5 with each of the 
indicated viruses (co-infection total MOI = 10), then medium and cells were harvested at 0 or 24 
hpi. Cell lysates were titered in BSC-40s for intracellular mature virions (IVs) for input at 0 hpi and 
growth at 24 hpi (A). Infection medium was titered in BSC-40s at 24 hpi for release of 
extracellular mature virions (EVs, B). A multi-step growth curve was also performed in BSC-40s 
harvesting medium and cells together at 72 hpi for titering total virion production (C). Statistical 
significance from wild-type (WT) NYVAC-KC titer is indicated by asterisks. (* p < 0.05; ** p < 0.01; 
*** p < 0.001) 
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Figure 21 - NYVAC-KC Vectors Activate Antiviral Signaling Pathway Through IRF3 
THP-1 cells were infected at an MOI = 10 [MOI = 5 of each virus in the Gag/dgp41 (G/d) co-
infection]. Cells were harvested 18 hpi and tested for IRF3 phosphorylation by western blot (A) 
and IFN-β production via quantitative RT-PCR (B). GAPDH serves as a total cell loading control 
while E3L expression determines equivalent infectivity of viruses. RT-PCR results are normalized 
to GAPDH expression. Statistical significance from the mock infected cells is indicated with 
asterisks and WR-∆E3L serves as a positive control for the assay. (*** p < 0.001; **** p < 0.0001) 
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Figure 22 - IRF3 Activation Requires DNA Replication and Persists Through the Viral Life 
Cycle 
 
THP-1 cells were infected with the indicated viruses at an MOI = 10 to match the NYVAC-KC-
Gag/dgp41 (G/d) co-infection (MOI = 5 of each virus) and analyzed 18 hpi for phosphorylated 
IRF3 and TBK1, or GAPDH loading control. Cells were treated with 200 μg/mL AraC to inhibit 
DNA replication (A) or 100 μg/mL of rifampicin to inhibit viral morphogenesis (B). (C-D) THP-1 
cells were infected in the presence of rifampicin and harvested at multiple time points to monitor 
viral replication using E3L for NYVAC-KC-dgp41 (C) and NYVAC-KC (D). The timeline for 
phosphorylation of IRF3 and TBK1 was also analyzed for NYVAC-KC-dgp41. 
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Figure 23 - NYVAC-KC Vectors Signal Through PERK and TBK1 
(A) BSC-40 cells were infected with an MOI = 10 of the indicated viruses [MOI = 5 for each virus 
in NYVAC-KC-Gag/dgp41 (G/d) co-infection] and analyzed 18 hpi with the indicated antibodies. 
Two pathways for activation of eIF2α were analyzed: the ER stress PERK pathway and the 
dsRNA-sensing PKR pathway. WR expressing the coumermycin sensitivity gene, Gyrase-PKR, 
was used as a positive control for PKR activation. (B) THP-1 cells were infected as in (A) for 18 
hours in the presence of 2 μM of a TBK1 inhibitor, MRT67307. IRF3, TBK1, and PERK 
phosphorylation was assessed. GAPDH expression is shown in both images as a loading control. 
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Figure 24 - Rescue of IRF3 Activation by Chemical Inhibitors 
THP-1 cells were infected at an MOI = 5 with NYVAC-KC-dgp41 and either left untreated (UT) or 
were treated with the indicated inhibitor: 2 μM MRT67307 (MRT, TBK1 inhibitor), 10 μM W-7 
(calmodulin antagonist), or both inhibitors (MRT/W-7). Cell lysates were analyzed 18 hpi for 
activation of IRF3, TBK1, and PERK (A) and IFN-β production via qRT-PCR (B). E3L is included 
as a control for equal viral infection and GAPDH is shown as a total loading control for western 
blots. RT-PCR data is normalized to GAPDH mRNA levels. Statistical significance from the 
untreated sample in (B) is indicated with an asterisk. (* p < 0.01) 
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Figure 25 - Inhibition of ER Stress by Chemical Inhibitors and HIV-1 Vpu Expression 
BSC-40 cells were infected at an MOI = 5 with NYVAC-KC-dgp41 or coumermycin treated WR 
expressing Gyrase-PKR (WR lane) as a PKR positive control. Cells were analyzed for activation 
of the indicated proteins, and E3L and GAPDH loading controls at 18 hpi. (A) Virally infected cells 
were left untreated (UT) or were treated with 2 μM MRT67307 (MRT), 10 μM W-7, or both 
inhibitors combined (MRT/W-7). (B) BSC-40 dishes were transfected with 500 ng/well of a Vpu 
expression vector then infected with viral vectors 24 hours later and treated with the indicated 
inhibitors at the same concentrations as in (A). Lysates were harvested 18 hours after viral 
infection. 
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Figure 26 - Rescue of Viral Growth and Replication Kinetics 
(A) BSC-40 cells were infected at an MOI = 5 with NYVAC-KC-dgp41 in the presence of 100 
μg/mL rifampicin. Lysates were harvested at the indicated time points and assessed for E3L 
expression for viral replication kinetics using GAPDH as a loading control. (B) BSC-40 cells were 
infected for single-step growth curves at an MOI = 5 with NYVAC-KC wild-type (WT) or NYVAC-
KC-dgp41 with or without inhibitors: untreated (UT), 2 μM MRT67307 (MRT), 10 μM W-7, both 
MRT67307 and W-7 (MRT/W-7), or transfected with a Vpu expression vector (Vpu). Cells were 
harvested at 0 and 24 hpi and titered in BSC-40s in duplicate. Fold change is calculated as the 24 
hour titer divided by the input (0 hpi) titer. Statistical significance from the UT sample is indicated 
with an asterisk. (* p < 0.05) 
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Figure 27 - Inhibition of IRF3 Activation by VACV Immune Modulators 
(A) THP-1 cells were infected with the indicated viruses at an MOI = 5 for 18 hours. Cell lysates 
were analyzed for IRF3 phosphorylation. (B) THP-1 cells were infected at an MOI = 5 with 
NYVAC-KC-ZM96 or NYVAC+12-ZM96 for 18 hours with (MRT) or without (untreated, UT) the 
TBK1 inhibitor MRT67307. (C) Single-step growth curves in BSC-40 cells were harvested at 0 
and 24 hpi in duplicate. The indicated viruses were used to infect cells at an MOI = 5. Cells were 
lysed and virus titer determined in BSC-40s. Fold change was calculated as the 24 hpi titer 
divided by the 0 hpi titer. Statistical significance from the respective wild-type (WT, i.e. no HIV-1 
recombinant genes) is shown with asterisks. (* p < 0.05; ** p < 0.01) 
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Figure 28 - Effect of Cytotoxicity Phenotype on Immunogenicity of Viral Vectors 
Four- to six-week-old C57BL/6 mice were infected with increasing doses (pfu) of the NYVAC-KC-
Gag (n = 3/dose), Cop-Gag (n = 4/dose), Cop-VLP (n = 4/dose) or mock infected (n = 3 for 
scarification, n = 5 for i.p.) either intraperitoneally (A) or via scarification (B). Peak Gag-specific 
CD8 T cell responses in the spleen were analyzed 7-10 dpi. Percent IFN-γ expressing CD8+ T 
cells are shown with statistical significance from the mock infected group indicated by asterisks. (* 
p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001) 
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Figure 29 - NYVAC-KC Vector Inhibition of Signaling Pathways 
The prominent signaling pathways are shown for stimulation of TLRs (navy blue), the TNF death 
receptor (navy blue), and ER stress activators (tan, shown on ER membrane), through their 
adaptor proteins (tan) culminating in the activation of one or more transcription factors (yellow). 
Encoded NYVAC-KC viral inhibitors are depicted as blue circles, additional genes in NYVAC+12 
are shown in pink, and untested genes are shown in red. All viral proteins are shown at their point 
of inhibition. For reviews of the viral proteins and their effector functions, please see (Gonzalez 
and Esteban, 2010; Smith et al., 2013; Taylor and Barry, 2006). HIV-1 proteins are shown in 
burgundy at their points of interaction.  
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Chapter 5 
A HETEROLOGOUS PRIME-BOOSTING STRATEGY WITH REPLICATING VACCINICA 
VIRUS VECTORS AND PLANT-PRODUCED HIV-1 GAG/DGP41 VIRUS-LIKE PARTICLES 
 
Abstract 
The past several decades have seen many HIV-1 vaccine clinical trials, testing various 
strategies, immunization regimens, and antigens. Still, more than 30 years after the discovery of 
HIV-1, only one such clinical trial has shown any, albeit modest, efficacy. The Phase III RV144 
“Thai Trial” utilized a non-replicating canarypox viral vector and a gp120 protein boost to achieve 
approximately 30% efficacy, which waned over time. Despite the short-lived immune responses, 
this trial revived hope that a prophylactic HIV-1 vaccine was achievable. Here we built upon the 
Thai Trial strategy by developing a novel combination of a replicating, but highly attenuated 
Vaccinia virus vector, NYVAC-KC (Kibler et al., 2011), and plant-produced HIV-1 virus-like 
particles (VLPs). Both components contain the full-length Gag matrix and a truncated version of 
the transmembrane portion of the Envelope protein, denoted deconstructed-gp41 (dgp41). Gag is 
a desirable target for CD8 T cell responses while the membrane-anchored dgp41 presents the 
membrane proximal external region (MPER) with its conserved epitopes for broadly neutralizing 
antibodies such as 2F5, 4E10, and 10E8 in a conformation resembling the pre-fusion state. We 
tested different combinations of these components in C57BL/6 mice and showed that the group 
primed with NYVAC-KC vectors and boosted with both the viral vectors and plant-produced VLPs 
have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing 
IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited 
the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1. 
 
Introduction 
Despite the success of antiretroviral treatment, human immunodeficiency virus (HIV-1) 
still causes millions of new infections every year, primarily in regions of the world with limited 
access to healthcare, making the need for a vaccine more apparent every year. To date, even the 
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most successful HIV-1 vaccine clinical trial, the phase III Thai Trial (RV144) had only modest and 
short-lived efficacy, thus leaving room for improvement (Rerks-Ngarm et al., 2009). The Thai Trial 
used a non-replicating canarypox viral vector (ALVAC) carrying recombinant genes for Gag, Pol 
and the surface subunit of the envelope (Env) protein (gp120) followed by an AIDSVAX protein 
boost consisting of recombinant gp120 B/E produced in Chinese hamster ovary (CHO) cells. 
While ALVAC and AIDSVAX showed no protection when tested individually, their combination in 
RV144 was modestly protective and provided some valuable information on immune correlates of 
protection. The most direct immune correlates of protection pertained to antibody (Ab) responses 
against the V1-V2 loop of gp120 and revealed the importance of polyfunctional, non-neutralizing 
Abs (Chung et al., 2014; Haynes et al., 2012; Liao et al., 2013a; Yates et al., 2014). This short-
lived humoral response faded over time and did not provide long-lasting protective advantage 
over the placebo arm (Yates et al., 2014). The results of the RV144 trial indicated the strength of 
a prime-boost approach integrating on a live vector with a subunit protein vaccine. However, the 
modest efficacy of the trial also suggests that the particular combination of the specific antigens 
chosen can be further optimized (Corey et al., 2015; Haynes et al., 2012; McMichael and Koff, 
2014; Prentice et al., 2015; Yates et al., 2014). 
Because of its surface exposure, its immunogenicity, and the critical roles it plays during 
target-cell infection, gp120 has been a natural target for vaccine development since the early 
days of HIV-1 research (Burton and Mascola, 2015; Mascola and Haynes, 2013). This, however, 
has proven to be far from straightforward, because gp120 also functions as a highly mutable 
decoy with most of its functionally important immunogenic sites conformationally occluded or 
shielded by glycans. In fact, monomeric preparations of gp120, as well as various preparations 
aimed at presentation of gp120 trimers, have repeatedly failed to induce protective immune 
responses in animal models or humans, with the sole and modest exception of the Thai Trial 
(Haynes et al., 2016; Jacob et al., 2015; McGuire et al., 2014; Moore et al., 2015). 
In contrast, far fewer studies have examined gp41. It contains highly immunogenic 
determinants that induce production of Abs that are among the first to arise during acute HIV-1 
infection but are of very limited protective value, showing little or no antiviral activities (Bonsignori 
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et al., 2012; Burton and Mascola, 2015; Liao et al., 2011). These immunodominant epitopes are 
located in a region of the protein spanning the two heptad repeat domains and in particular within 
the loop that connects them (Zolla-Pazner, 2004) and are exposed on the gp41 “stump” in its six-
helical bundle conformation upon removal of the gp120 subunit (Burton and Mascola, 2015). Still, 
gp41 was found to be the target of a number of broadly neutralizing Abs (bnAbs) directed against 
conformational [35O22 binding at the gp41-gp120 interface, (Huang et al., 2014)] and linear 
epitopes [2F5, 4E10, Z13 and 10E8 that recognize closely situated sites within the membrane 
proximal external region, MPER, (Cardoso et al., 2005; Huang et al., 2012; Nelson et al., 2007; 
Parker et al., 2001)].  
Beyond neutralization, anti-MPER Abs, including the above-mentioned bnAbs, were 
found to exhibit other potent anti-HIV-1 activities including transcytosis blockade (Matoba et al., 
2008; Matoba et al., 2009; Matoba et al., 2004; Shen et al., 2010; Tudor et al., 2012), Ab-
dependent cell-mediated cytotoxicity [ADCC, (Hessell et al., 2007; Tudor and Bomsel, 2011)], 
and curbing of dendritic cell-mediated trans-infection (Magerus-Chatinet et al., 2007; Sagar et al., 
2012; Tudor et al., 2012). Moreover, passive immunization with these bnAbs provided impressive 
protection against mucosal transmission of a simian-HIV hybrid (SHIV) in the macaque model 
(Baba et al., 2000; Hessell et al., 2010; Klein et al., 2013b). Anti-MPER Abs with anti-viral 
activities were also described in mucosal secretions of highly-exposed but seronegative 
individuals (Devito et al., 2000a; Devito et al., 2000b; Kaul et al., 2001; Kaul et al., 1999; Pastori 
et al., 2000; Tudor et al., 2009). Lastly, anti-MPER Abs that were passively passed through 
breast milk from infected mothers to their uninfected babies were correlated with protection 
(Diomede et al., 2012; Pollara et al., 2015).  
Despite their long-standing promise, anti-MPER bnAbs are naturally rare and are 
notoriously difficult to elicit. For example, less than 25% of HIV-1-infected patients develop broad 
and potent nAbs, which even if present require ~2-4 years to produce (Burton and Mascola, 
2015; Haynes et al., 2016; Mascola and Haynes, 2013; Mascola and Montefiori, 2010). Several 
explanations have been suggested, including a lengthy maturation process involving many 
somatic mutations and extensive affinity maturation (Kepler et al., 2014; Klein et al., 2013a), and 
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clonal deletion of the B-cell lines secreting such bnAbs that were shown to be partially 
autoreactive (Verkoczy et al., 2011; Verkoczy et al., 2013; Verkoczy et al., 2010). Interestingly, 
many of the autoreactivity targets are lipids that can be found in both the plasma membrane of 
the host cell and in the viral envelope (Alam et al., 2007; Alam et al., 2009; Haynes et al., 2005; 
Irimia et al., 2016).  
It is widely accepted that the membrane milieu of the MPER region plays a major role in 
the functional immunogenicity of gp41 (Alam et al., 2009; Chen et al., 2014). Both the metastable 
native conformation of the gp120-gp41 trimer and the highly stable post-fusion conformations do 
not expose the neutralizing epitopes (Buzon et al., 2010; Frey et al., 2010; Frey et al., 2008; 
Pancera et al., 2014), and fail to efficiently elicit bnAbs (Crooks et al., 2015; Davis et al., 2009; 
Decker et al., 2005; Labrijn et al., 2003; Sanders et al., 2015; Williams et al., 2015) or engage the 
germline B cell precursors for specific bnAbs (Hoot et al., 2013; Jardine et al., 2013; McGuire et 
al., 2014). 
An effective MPER-based antigen therefore requires presentation of the MPER within a 
context of a membrane, and exposure of the region in a conformation mimicking the putative pre-
fusion intermediate. For example, Bomsel and co-workers used a gp41 peptide (residues 649-
684) spanning the MPER and part of the C-terminal heptad repeat to decorate liposomes 
(“virosome”) and demonstrated the ability of the immunogen to elicit systemic and mucosal 
antibodies with transcytosis-blocking activity in humans (Leroux-Roels et al., 2013), and 
nonhuman primates that were thereafter protected against a mucosal SHIV challenge (Bomsel et 
al., 2011). Together, these results indicate a strong potential for this antigenic region to be used 
as a vaccine component when presented correctly on a membrane. 
The laboratory of Tsafrir Mor previously developed an efficient production method for 
enveloped VLPs in the tobacco-relative Nicotiana benthamiana, consisting of Gag and 
deconstructed-gp41 (dgp41: MPER, transmembrane domain, and full-length cytoplasmic tail) 
(Kessans et al., 2013). Such VLPs display the MPER of gp41 without steric hindrance from 
gp120, without the immunodominant epitopes on both Env subunits, and with a higher antigen 
load per VLP than what exists in an HIV-1 virion (Kessans et al., 2016). A similar construct has 
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been shown to be a likely trimer with its bnAb epitopes exposed (Gong et al., 2015). When 
administered to mice, these VLPs elicit both serum IgG and mucosal IgA to Gag and dgp41 
antigens (Kessans et al., 2016). 
Live viral vectors are appealing as vaccine vehicles for the expression of HIV-1 antigens 
due to their proficiency for eliciting T cell responses. For example, a cytomegalovirus (CMV) 
vector was recently shown in nonhuman primates to clear an established SIV infection with 
dependency on CD8 T cells recognizing non-canonical epitopes on major histocompatibility 
complex (MHC) II instead of MHC I (Hansen et al., 2013a; Hansen et al., 2013b). Poxviruses also 
stand out amongst other viral vectors [see reviews (Gomez et al., 2012a; Jacobs et al., 2009; 
Pantaleo et al., 2010)], as attested by the Thai Trial that employed a canarypox-based vector and 
was the first and only HIV-1 vaccine clinical trial to show efficacy (Haynes et al., 2012; Rerks-
Ngarm et al., 2009). The canarypox-based viral vector used in the trial, ALVAC, is not capable of 
replication in mammalian cells (Taylor and Paoletti, 1988; Taylor et al., 1988). Inability to replicate 
in vivo in humans makes the virus safer to use as a vaccine or a vaccine vector. However, it was 
hypothesized that replication could enhance immunogenicity by increasing antigen load as the 
virus replicates in vivo.  
To test this hypothesis, a strategy was employed using a replicating vaccinia virus strain, 
NYVAC-KC. The virus was developed from the NYVAC strain, previously rendered replication 
incompetent in human cells by deletion of 18 open reading frames (ORFs) from the genome of 
Copenhagen (Cop), its parental strain (Tartaglia et al., 1992b). NYVAC-KC contains a re-insertion 
of two host-range genes, K1L and C7L, which allows the virus to replicate in human tissue, thus 
improving immunogenicity while remaining highly attenuated (Kibler et al., 2011; Quakkelaar et 
al., 2011). 
In this study, we describe the development of replicating vaccinia virus vectors based on 
NYVAC-KC which express Gag and dgp41 as matching antigens to the plant-produced VLPs for 
prime/boosting purposes. It is shown that the viral vectors produce VLPs in vitro, and the viral 
vectors were tested in different combinations with plant-produced VLPs in mice. The animal study 
revealed that these two vaccine components work in concert to elicit Gag-specific CD8 T cell 
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responses and both systemic and mucosal antibodies to Gag and dgp41 peptides in the 
immunization group which most closely mimics the Thai Trial. 
 
Materials and Methods 
Cloning pGNR Plasmids for Virus Recombination 
The Gag and dgp41 genes were cloned into the pGNR plasmid, which harbors a neoGFP 
selection cassette (neomycin resistance gene fused to GFP, known as pGNR) between 
homologous recombination arms for the vaccinia TK locus. Gag and dgp41 genes were amplified 
from pTM 488 (Gag) and pTM 602 (dgp41) [described in (Kessans et al., 2013)] into TOPO pCR-
2.1 vectors (Invitrogen). Cloning was achieved using AccuStart Taq DNA polymerase HiFi PCR 
kit (Quanta Biosciences) with primers oTM 664 (5’- ACTAGTATGGGAGCTAGAGCCTCT-3”) and 
665 (5’- CCCGGGTTATTGAGAGGAAG-3’) for Gag and oTM 666 (5’- 
ACTAGTATGGGATCTCAAACTCAACAA-3’) and 667 (5’- CCCGGGTTATTGCAAAGCAG-3’) for 
dgp41 for the addition of 5’ flanking SpeI and 3’ flanking XmaI sites, denoted in italics. Ligation 
reactions were electroporated into DH5α Escherichia coli and plated onto LB +ampicillin plates. 
Gene insertion was confirmed by colony PCR using GoTaq Green Master Mix (Promega). 
Plasmids were extracted using the E.Z.N.A. mini-prep kit (Omega) and sequences verified using 
backbone-specific primers M13-forward and M13-reverse. The TOPO plasmids were designated 
pTM 813 (Gag) and pTM 814 (dgp41). Both pTM 813, 814, and pGNR were digested with SpeI 
and XmaI (NEB) and fragments separated via gel electrophoresis and extracted using QIAquick 
Gel Extraction Kit (Qiagen), then ligated into the pGNR backbone using T4 DNA ligase 
(Promega). Ampicillin resistant DH5α E. coli colonies were screened by colony PCR and 
plasmids extracted as above. Sequences were confirmed with pGNR backbone-specific primers 
oTM 686 (5’- CCCACCCGCTTTTTATAGTAA-3’) and 687 (5’- CGGTTTATCTAACGACACAACA-
3’). Sequence-verified pGNR plasmids were named pTM 815 (Gag) and pTM 816 (dgp41). 
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Cell Lines and Viruses 
BSC-40 cells were grown in DMEM (Corning Cellgro) with 5% FBS plus gentamycin and 
2 mM L-glutamine. BHK-21 cells were grown in MEM (Corning Cellgro) with 5% FBS plus 
gentamycin. Generation of the parental vaccinia virus (VACV) strain NYVAC-KC was described 
previously (Kibler et al., 2011). 
 
In vivo Recombination (IVR) 
Simultaneous transfection/infection [in vivo recombination, IVR (Brandt and Jacobs, 
2001; Kibler et al., 1997)] was performed with pTM 815 (Gag) and pTM 816 (dgp41) and NYVAC-
KC to insert Gag and dgp41 into the vaccinia virus TK locus. 500 ng of plasmid DNA was 
transfected using Lipofectamine and PlusTM Reagent (Invitrogen) per manufacturer’s protocol. 
This was immediately followed by infection with NYVAC-KC at an MOI = 0.01 in 35 mm2 dishes of 
BSC-40 cells. Recombination was allowed to proceed for 24 hrs followed by addition of G418 
antibiotic (500 μg/mL). Cells were harvested and lysed at 48 hours post infection (hpi). The IVR 
was used to infect 100 mm2 dishes of BSC-40 cells for selection of individual antibiotic-resistant 
plaques for subsequent expression screening (note: a mutation in the GFP gene prevented use of 
fluorescent screening). This process was repeated for multiple rounds of antibiotic selection 
before a >98% pure virus was isolated as measured by immunoplaque assay. 
 
Expression Screening 
Individual antibiotic-resistant plaques were grown in 60 mm2 dishes of BSC-40 cells to 
CPE and harvested in 1X SDS sample buffer [50 mM Tris-Cl pH 6.8, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol, 100 mM β-mercaptoethanol, 1X protease inhibitor cocktail III 
(Research Products International Corp., Prospect, IL)], and then centrifuged through a 
QiaShredder (Qiagen) for NYVAC-KC-Gag plaques. For NYVAC-KC-dgp41, cells were lysed with 
RIPA lysis buffer [1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 1X protease inhibitor cocktail 
III, in 1X PBS without calcium or magnesium (Corning)]. RIPA lysates were mixed with an equal 
volume of 2X SDS sample buffer. Cell lysates were screened using SDS-PAGE as previously 
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described (Kessans et al., 2013). Briefly, boiled samples were run on 12% polyacrylamide gels 
under denaturing conditions, transferred to nitrocellulose membranes (Bio-Rad), and probed with 
either Gag or dgp41 antibodies and anti-rabbit or anti-human IgG-HRP, respectively. Proteins 
were detected via chemiluminescence (ImmunoCruz Luminol Reagent, Santa Cruz). 
 
Immunoplaque Assays 
Immunoplaque assays were performed in 6-well dishes by infecting BSC-40s with 50 pfu 
of individual plaques. Once plaques were visible, the cells were fixed with 1:1 acetone:methanol 
for 30 min at -20° C, washed with PBS, then incubated with anti-p24 Gag polyclonal rabbit serum 
or 2F5 (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: from Dr. 
Hermann Katinger) at 1:1000 in 3% FBS-PBS. Secondary biotinylated antibodies for anti-rabbit 
IgG or anti-human IgG from Vectastain ABC Kits (Vector Laboratories, Inc.) were used for 
detection with DAB peroxidase substrate (Vector Laboratories, Inc.) per manufacturer’s protocol. 
After counting positive plaques, cells were stained with Coomassie blue dye to count the number 
of negative plaques. Percentages were calculated by dividing positive plaques by total plaques 
per well. The plaque with the highest percentage of positives was used for further purification until 
a plaque with >98% purity was identified and used to grow stocks. 
 
Virus Stocks 
The final NYVAC-KC-Gag and NYVAC-KC-dgp41 plaques with >98% purity determined 
by immunoplaque assay were grown to CPE in BHK-21 cells in a 60 mm2 dish for the first 
passage (P1) stock. The P1 stock was titered in BSC-40s and used to infect five T150 flasks of 
BHK-21 cells at an MOI = 0.01 for the P2 stock. Cells were harvested at CPE, subjected to 
freeze-thaw and sonication, then cell lysates were placed on a 36% sucrose pad and centrifuged 
at 22,000 rpm for 80 min at 4° C with an SW28 rotor to pellet virions. Purified virions were 
resuspended in 10 mM Tris-HCl pH 9.0, their titer determined in BSC-40s, and were stored in 
aliquots at -80° C until further use. 
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Vaccinia in vitro VLP Production 
BSC-40 cells seeded in 100 mm2 dishes were infected at an MOI = 5. At 24 hpi, medium 
and cells were harvested and pelleted. Medium was subjected to 40% ammonium sulfate 
precipitation and resuspended in 1X PBS (140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM 
KH2PO4, pH 7.4). Aliquots were boiled and analyzed by SDS-PAGE for presence of Gag and 
dgp41 as described above. 
 
Expression in Plants of VLPs and their Purification 
HIV-1 Gag/dgp41 VLPs were expressed and purified as previously described (Kessans et 
al., 2013). Briefly, Gag transgenic N. benthamiana plants were infiltrated with Agrobacterium 
tumefaciens harboring pTM 602 with the dgp41 gene and leaf tissue was harvested 4-6 days post 
infiltration (dpi). Leaf tissue was crushed in a blender in extraction buffer (25 mM sodium 
phosphate, 100 mM NaCl, 1 mM EDTA, 50 mM sodium ascorbate, 1 mM PMSF, pH 7.8). VLPs 
were precipitated with 40% ammonium sulfate and resuspended in 1X PBS (140 mM NaCl, 2 mM 
KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4), then purified via iodixanol density gradient 
centrifugation. The VLP-containing 20% iodixanol fraction was concentrated on a 300 kDa 
molecular weight cut-off membrane (Sartorius) and quantified via immunoblot for immunizations 
as described in (Kessans et al., 2016). 
 
Antibodies 
The following antibodies were used for the indicated assays: anti-p24 Gag polyclonal 
rabbit serum (Kessans et al., 2013); human anti-MPER 2F5 (AIDS Reagent Program and the kind 
gift of Morgane Bomsel); goat anti-human IgG-HRP (Sigma) for immunoblot; goat anti-rabbit IgG-
HRP (Santa Cruz) for immunoblot; rabbit anti-human IgG-HRP (Santa Cruz) for ELISAs; rabbit 
anti-mouse IgG-HRP (Calbiochem) for ELISAs; mouse IgA-kappa (ICL Labs) for ELISAs; goat 
anti-mouse IgA (Sigma) for ELISAs. 
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Transmission Electron Microscopy (TEM) 
BSC-40 cells grown in T75 flasks were infected at an MOI = 5 and harvested by 
trypsinization 24 hpi. Cells were pelleted between all wash steps at 700 xg for 5 min at 4° C until 
embedded in agarose prior to secondary fixation. Pelleted cells were washed twice in 1X PBS 
(140 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.4). For primary fixation, cells 
were placed in 2% glutaraldehyde in PBS for 15 min at room temperature followed by a second 
incubation with fresh fixative for 1 hour at 4° C. Fixed cells were resuspended in 1% agarose and 
washed three times in PBS for 30 min each at room temperature. Cells were then fixed with 1% 
osmium tetroxide in PBS for 1 hour at room temperature followed by four 15-minute washes in 
water. A 0.2% uranyl acetate solution in water was used to stain en bloc overnight at 4° C 
followed by three 15-minute washes in water. An ethanol series from 20% to 100% (anhydrous) 
was used for dehydration, increasing the ethanol concentration by 20% every 10 min with three 
incubations in anhydrous ethanol. Spurr’s resin was gradually introduced through 4- to 8-hour 
incubations with 1:3, 1:1, and 3:1 ratios of resin:100% ethanol, followed by three 8 hour 
incubations in 100% resin. Cells were divided into several blocks of Spurr’s resin and polymerized 
at 60° C for 36 hours. Sections were cut at 70 nm thick, and were placed on formvar-coated 
copper slot grids followed by post-stain treatment with 2% uranyl acetate and 3% Sato’s lead 
citrate before imaging. 
 
Mouse Immunizations 
All animal experiments were done with approval from the Arizona State University 
Institutional Animal Care and Use Committee.  
For the initial study (Experiment 1), six-week-old C57BL/6 mice (Jackson Laboratories) 
were split into five groups. Three groups (n = 5) received virus prime (VV) followed by two boosts 
of either mock (Group 1), VLP (Group 2), or VV+VLP (Group 3). Group 4 (n = 3) received no virus 
prime and two VLP boosts and Group 5 served as the naïve control (n = 1). NYVAC-KC-Gag and 
NYVAC-KC-dgp41 P2 stocks, each at a dose of 5 x 105 pfu, were mixed together for a total dose 
of 1 x 106 pfu per mouse. Virus immunizations prepared in Tris HCl pH 9.0 were injected 
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intramuscularly (i.m.) into the thigh. Plant-produced, gradient-purified VLPs were prepared in 1X 
PBS pH 7.4 with 2 μg p24 and 1.2 μg MPER and mixed with Ribi adjuvant (Sigma) per 
manufacturer’s protocol to reach a final concentration of 2% oil [described previously in (Kessans 
et al., 2016)]. Mock mice were injected i.m. with Tris HCl pH 9.0 buffer in equivalent volumes. 
VACV and vehicle injections were delivered i.m. while VLPs were delivered intraperitoneally (i.p). 
Subsequent experiments were designed in a similar manner, but with different groups for 
comparison. The second NYVAC-KC study (Experiment 2) separated six-week-old C57BL/6 mice 
into six groups. Five groups (n = 5) were primed with NYVAC-KC-Gag and dgp41 virus (VV) 
mixed equally for a total of 1 x 107 pfu prepared in 1X PBS and delivered either via scarification or 
i.m. Only one group (n = 5) was primed with VLPs. VLPs were delivered i.p. and prepared as 
described above, only the pTM 901 (Dual Gemini +p19) vector described in Chapter 2 was used 
to produce VLPs. These VLP injections contained 2 μg p24 and 5.5 μg MPER. Scarification 
groups were as follows: VV/VV, VV/VLP, VV/VV+VLP, and VLP/VV+VLPs. The two additional 
groups (n = 5) receiving virus via the i.m. route were VV/VV and VV/VV+VLPs. A seventh group 
(n = 5) received mock i.m. injections of PBS and was shared with the Cop-VLP study described 
below. 
The third and final animal study (Experiment 3) was designed to compare the ability of a 
VACV vector simultaneously expressing Gag and dgp41 to boost and/or prime VLP Ab 
responses. This study utilized the Cop-VLP vector (abbreviated as Cop in figures shown here) 
that was described in Chapter 4. Cop-VLP was diluted in 1X PBS to administer 107 pfu i.m. VLPs 
generated with pTM 901 were prepared and delivered as described for Experiment 2. Four 
groups (n = 5/group) were assessed in this study: Cop/Cop, VLP/VLP, Cop/VLP, and VLP/Cop 
(where Cop = Cop-VLP). 
Three immunizations were given to mice at days 0, 45, and 90. Serum, fecal, and vaginal 
lavage samples were collected as previously described (Kessans et al., 2016) every 2 weeks at 
days 0, 14, 28, 42, 56, 80, and at the endpoint of day 97 for analysis of Ab production. One week 
post the final boost (day 97), spleens were collected for analysis of CD8 T-cell responses as 
described below.  
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Animals were monitored every 2-3 days for weight loss and other signs of illness, as a 
measure of vector safety. 
 
ELISA Detection of IgG and IgA 
Antibody production was measured via ELISA as previously described (Kessans et al., 
2016). Briefly, serum, fecal, and vaginal lavage samples were analyzed for IgG (serum) or IgA 
(mucosal sites) specific for Gag p24 or gp41 MPER regions. Samples were analyzed in threefold 
serial dilutions starting at 1:50, 1:2, and 1:5 for serum, fecal, and vaginal lavage samples, 
respectively. For mouse experiments where both vaginal IgG and IgA are assayed, lavage 
samples were initially tested at a 1:10 dilution. ELISAs were developed with either SIGMAFAST™ 
OPD (Sigma) and read at OD 490 nm (Experiment 1) or developed with 1-Step™ Ultra TMB-
ELISA Substrate Solution (Thermo Scientific) and read at OD 450 nm (Experiments 2 and 3). 
Endpoint titers were calculated as the reciprocal of the dilution factor at which the OD was equal 
to background levels (OD < 0.1). IgG1 and IgG2a isotypes were detected with the same ELISA 
protocol, but with goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP secondary 
antibodies (Santa Cruz Biotechnology) instead of total IgG. Purified mouse IgG1 kappa chain or 
mouse IgG2a kappa chain primary antibodies (Sigma) were used as controls. 
For anti-VACV ELISAs, 96-well plates were coated with 107 pfu/well of sucrose-purified 
NYVAC-KC overnight at 37° C. Wells were fixed in 2% paraformaldehyde in 1X PBS for 10 min at 
4° C to inactivate the virus. Wells were washed with buffer (150 mM NaCl, 0.5% Tween-20) then 
blocked with 5% non-fat milk in 1X PBST. Serum IgG was incubated in serial dilutions and 
detected as described for anti-p24 and anti-MPER ELISAs. 
 
Intracellular Cytokine Staining and Flow Cytometry 
Spleens were harvested in Hank’s medium (Corning Cellgro) and cells were strained 
through a 0.7 μm filter for resuspension in complete RPMI [cRPMI: 10% FBS, penicillin (100 
units/mL), streptomycin (100 μg/mL), 2 mM L-glutamine]. Red blood cells were lysed with ACK 
Lysing Buffer (Gibco) and splenocytes were resuspended in cRPMI at a concentration of 2 x 107 
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cells/mL. Cells were plated at 1 x 106 cells/well and incubated for 5 hours in the presence of 
GolgiPlug™ (BD Biosciences) and 50 μL of 1 μg/mL of one of five different immunodominant 
ZM96 Gag CD8 epitopes: LRSLYNTV (LRS8), VIPMFTAL (VIP8), AMQMLKDT (AMQ8), 
YSPVSILDI (YSP9), EVKNWMTDTL (EVK10) (synthesized by GenScript and resuspended 
according to manufacturer’s protocol). For the second and third studies, splenocytes were 
incubated with 50 μL of a Gag peptide pool containing a total of 5 μg/mL of peptides (1 μg/mL of 
each peptide listed above). 
Cells were stained with fluorescently conjugated antibodies: CD8-Pacific Blue or APC-
Cy7, TNFα-FITC, and IFNγ-PE (all from BD Biosciences). Fixation and permeabilization was 
performed with a Cytofix/Cytoperm™ Kit (BD Biosciences) with final resuspension in FACS Buffer 
(1% FBS in 1X PBS). Samples were analyzed by flow cytometry on an LSR Fortessa. Data was 
analyzed using FlowJo Data Analysis Software (FlowJo, LLC; Ashland, OR). 
 
Statistics 
All statistical analyses were performed in GraphPad Prism Software (GraphPad Prism 
Software Inc.; La Jolla, CA). All data were analyzed using a one-way ANOVA multiple 
comparison with Dunn’s post-test. Significance cut-off was defined as p < 0.05. 
 
Results 
Generation of Recombinant Vaccinia Virus Vectors 
NYVAC-KC-Gag, NYVAC-KC-dgp41, Cop-Gag, and Cop-VLP viruses were generated 
through in vitro recombination (see Materials and Methods) (Figure 30A-B, Figure 31A). Each 
gene was under control of a synthetic early/late VACV promoter, ensuring the genes were 
expressed at all stages of viral replication to maximize antigen production. Second round 
individual plaques were screened for expression via immunoblot by probing for either Gag or 
dgp41 expression. Immunoplaque assays for either Gag or dgp41 were performed to identify the 
plaque with highest purity for further selection. This process was repeated until a plaque with 
>98% purity was identified and then used to grow a P2 stock. The final sucrose-pad purified P2 
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stock show Gag and dgp41 expression in BSC-40 cell lysates at the proper size for NYVAC-KC-
Gag and NYVAC-KC-dgp41 (Figure 30C-D), and also for Cop-Gag and Cop-VLP (Figure 31B-C). 
It was noted during selection that viruses recombining with dgp41 plasmids had reduced plaque 
size and grew to much lower titers, suggesting that the HIV-1 gene makes the viral vector 
cytotoxic (discussed in Chapter 4).  
Gag is known to be sufficient and necessary for HIV-1 VLP formation and budding into 
the medium (Garoff et al., 1998). To test whether BSC-40-infected cells support VLP formation 
and budding, culture medium was analyzed for the presence of Gag and dgp41. Indeed, Gag 
protein was detected in culture medium of cells either infected with NYVAC-KC-Gag or co-
infected with NYVAC-KC-Gag and NYVAC-KC-dgp41 (Figure 30E, Lanes 2 and 4). In contrast, 
dgp41 was detected only in the medium from co-infected cells, not in medium from cells that were 
infected with NYVAC-KC-dgp41 alone (Figure 30E, Lane 4). The same results held true for Cop-
Gag and Cop-VLP vectors. Gag was detectable in the medium for both vectors while dgp41 was 
only present in Cop-VLP when both proteins are co-expressed from the same genome (Figure 
31D, Lane 4). This holds promise for in vivo production of dgp41-containing VLPs to enhance 
immunogenicity of the MPER. 
 
NYVAC-KC-Gag/dgp41 Show Cytotoxicity and in vitro VLP Production 
These results indicate that export of dgp41 to the medium depends on expression and 
export of Gag, suggesting that Gag VLPs and Gag/dgp41 VLPs are released, respectively, from 
cells that express Gag alone or co-express Gag and dgp41. We used TEM to test this possibility. 
BSC-40 cells that were infected (MOI = 5) with NYVAC-KC, NYVAC-KC-Gag, NYVAC-KC-dgp41, 
or co-infected with Gag/dgp4, were processed for TEM at 24 hpi.  
In cells infected with the parental NYVAC-KC strain, viral replication factories are clearly 
visible and all stages of viral replication are easily identified (Figure 32A). Mature virions 
(indicated by white arrows) are seen both intracellularly (Figure 32A-1) and extracellularly (Figure 
32A-2). Immature virions with and without incorporated genomes are also abundantly visible in 
this section (white and black triangles, respectively).  
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NYVAC-KC-Gag-, dgp41-, or co-infected cells have disorganized viral factories and 
mature viral particles are rare (Figure 32B-D). Many early crescent formations are visible (black 
arrow), along with what appears to be “unfilled” or empty virion shells (indicated by "E"). The rarity 
of mature virus particles corresponds well to the smaller plaques typical of these strains and their 
reduced titers, as noted above. Instead, these infected cells appear to have large protein 
aggregates or precipitates in their cytoplasm (“junk” indicated by "J"), mimicking a phenotype 
associated with palmitate deficiency (Greseth and Traktman, 2014). Additionally, NYVAC-KC-
dgp41-infected cells demonstrate nuclear condensation (Figure 32C-2, “nucleus” indicated by 
"N"), a classic sign of apoptosis (Duprez et al., 2009). Furthermore, the mitochondria (indicated 
by "M") in NYVAC-KC-Gag- and NYVAC-KC-dgp41-infected cells appear to be malformed, 
potentially indicating loss of structural integrity, which can also indicate occurrence of apoptosis 
(Li and Dewson, 2015).This phenotype seems far more drastic than that of NYVAC-KC-infected 
cells.  
Importantly, in cells that were infected with NYVAC-KC-Gag (Figure 32B-2) or co-infected 
with NYVAC-KC-Gag and NYVAC-KC-dgp41 (Figure 32D-2), particles of approximately 100 nm 
in diameter are seen budding at the cell surface (black stars). Based on their size and 
appearance, these particles are likely to be HIV-1 Gag or Gag/dgp41 particles budding out of the 
cell. This observation can explain the appearance of Gag and dgp41 in the media of these 
infected cells (Figure 30E). 
 
Experiment 1: Mouse Immunizations 
Six-week-old C57BL/6 mice were separated into five groups in order to assess different 
combinations of VACV and VLP immunization regimens (Figure 33A). Mice were given a total of 
three immunizations separated by 45 days to allow for memory responses to develop prior to 
boosting. Three groups (n = 5) were primed with the combination of NYVAC-KC-Gag and 
NYVAC-KC-dgp41 (denoted in all figures and text as VV), followed by two boosts with either 
vehicle (Group 1), VLPs alone (Group 2), or a combination of VV and VLPs (Group 3). A fourth 
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group (n = 3) received a mock (vehicle) prime followed by boosts with VLPs. The fifth group 
served as a naïve control (n = 1). 
Monitoring of weight revealed that none of the mice in any group lost weight (data not 
shown). This indicates little to no pathogenicity of the virus and is consistent with previous 
virulence data for NYVAC-KC (Kibler et al., 2011) and general safety of the plant-derived VLPs 
(Kessans et al., 2016). 
 
Serum IgG Responses to Gag and MPER 
Antigen-specific serum IgG responses were measured by ELISA using p24 subunit or 
MPER peptide to detect Gag and dgp41 Ab responses, respectively. Throughout, OD 450 nm 
values for the lowest dilution tested (1:50) are shown both over time (Figure 33B-C) and for 
individual animals at the endpoint, Day 97 (Figure 34A). Additionally, endpoint titers were 
calculated for the final serum samples and are shown in Figure 35A as the reciprocal of the 
dilution where the OD fell below background levels (OD < 0.1). 
Serum IgG responses against both p24 and MPER antigens remained undetectable in all 
groups until the first sample (Day 55) after the first boost. Titers increased gradually and were 
boosted after the final immunization with VLPs (Figure 33B-C), reaching significant levels at the 
endpoint analysis (Day 97) for both anti-p24 Gag and anti-MPER responses (Figure 34A). 
Endpoint Gag responses were highest in the group boosted with a combination of VV and VLPs 
(VV/VV+VLPs), while the group boosted with VLPs alone (VV/VLPs) also showed significant titers 
which were more variable responses among animals (Figure 35A). Anti-MPER serum IgG 
responses were lower than Gag titers but showed a similar trend, reaching significant levels in all 
groups receiving VLPs regardless of prime/boost regimen (Figure 34A). However, the endpoint 
titer calculations showed no difference between groups, consistent with low Ab responses (Figure 
35A). It is interesting to note that plant-produced VLPs appear to be largely responsible for Ab 
stimulation because no detectable levels of antibodies were present in the first 45 days after a 
single dose of VV and only reached detectable levels after the second immunization in those 
groups that received VLPs. 
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Mucosal IgA Responses to Gag and MPER 
Gastrointestinal IgA responses to the dgp41 (MPER) antigen (as determined by 
measuring the secreted Ab levels in fecal samples) were low but detectable (Figure 34B), 
whereas anti-MPER IgA levels in vaginal secretions were below our detection level irrespective of 
treatment (Figure 34C). Fecal anti-MPER IgAs were higher in groups that were immunized using 
the prime/boost VV/VLPs regimen than groups that were vaccinated with either VV or VLPs 
alone. Contrasting the two groups, those mice that were boosted with a combination of VV and 
VLPs exhibited marginally higher levels of fecal IgAs than those boosted with VLPs alone, but 
their fecal IgA levels were significantly higher than the group that was primed with VV only. 
Interestingly, levels of fecal and vaginal anti-p24 Gag IgAs were too low for detection in all 
groups. This contrasts sharply with the generally much higher titers of serum anti-p24 Gag IgGs 
as compared to serum anti-MPER IgGs. 
 
IgG Isotyping 
The two major IgG isotypes are IgG1 and IgG2a; the former is consistent with stimulation 
of a Th2 response for B cell activation, whereas the latter would be indicative of a Th1 response, 
which primarily results in inflammatory cytokine production and killing of intracellular pathogens 
(Snapper and Paul, 1987; Szabo et al., 2003). Our results so far indicate that the most important 
immunogens contributing to the elicitation of serum IgGs are the plant-derived VLPs. To further 
substantiate this conclusion, we determined the Ab isotypes contributing to this response, as 
protein-based vaccines (i.e. immune-complexes) usually elicit IgG1 (Martinez and Gordon, 2014; 
Mosser and Edwards, 2008).  
To this end, serum samples from the endpoint for the two groups which showed the 
highest serum IgG responses (VV/VLP and VV/VV+VLP) were analyzed for their IgG isotype 
content by isotype-specific ELISA (Figure 35A and B, respectively). Both groups show high levels 
of antigen-specific (either anti-p24 or anti-MPER) IgG1, but levels of IgG2a were too low for 
detection, in agreement with our hypothesis and data shown in Chapter 3. 
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Anti-vector Antibody Responses 
Having substantiated the contribution of the Gag/dgp41 VLPs for the elicitation of serum 
Ab responses against the two HIV-1 antigens, the question arose whether or not the viral vector 
induced production of anti-vector (i.e. anti-VV) serum Abs. Not surprisingly, mice belonging to 
Group 3 that received a total of three doses of VV (prime plus two boosts) showed significant 
levels of anti-VV serum IgG at the endpoint (Day 97, Figure 36). However, a single dose of VV at 
Day 0 was not enough to induce a potent anti-vector response (Group 1). 
 
Gag-specific CD8 T Cell Responses 
A major rationale to include Gag in an HIV-1 vaccine, especially a live-vectored one, is its 
excellent ability to induce cellular responses. To test induction of CD8 T cell responses, the ability 
of peptides corresponding to known Gag T-cell epitopes to stimulate proliferation of CD8 T-cells 
was tested among splenocytes obtained from vaccinated animals. One week after the final boost, 
splenocytes were harvested and stimulated with five CD8 ZM96 Gag peptides that were 
previously determined to be dominant in C57BL/6 mice (Chowell et al., 2015). Peptides were 
assessed individually in order to obtain a better resolution of their responses. CD8 T cells were 
analyzed for IFN-γ or TNF-α production in response to peptide stimulation using cytokine staining 
and flow cytometry. Little to no TNF-α production was seen in the flow cytometry analysis (data 
not shown); however, IFN-γ production was detectable in several groups. The group boosted with 
both VV and VLPs showed significant production of IFN-γ with two of the five Gag peptides, 
AMQ8 and EVK10, at 2.6 x 105 CD8+ IFN-γ+ T cells (3.5% of CD8+ T cells) and 1.91 x 105 CD8+ 
IFN-γ+ T cells (2.4%), respectively (Figure 37A-B). The other three peptides, LRS8, VIP8, and 
YSP9 showed a similar trend as AMQ8 and EVK10 but with slightly lower responses of CD8+ 
IFN-γ+ T cells at 1.73 x 105 (2.4%), 1.61 x 105 (2.1%), and 1.67 x 105 cells (2.3%), respectively, 
but failed to reach significance (Figure 37C-E). When responses from all five peptides are added 
together, the VV/VV+VLPs group has a total CD8 Gag-specific mean response of 9.53 x 105 
CD8+ IFN-γ+ T cells (12.7% of CD8 T cells, Figure 37F). The total Gag-specific CD8 responses of 
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the other groups show minute differences between groups at 8.0% in Tris/VLP, 5.6% in VV/VLP, 
and 4.2% in VV/Tris. This suggests that VLPs may be providing some component of the T cell 
response and potentially boosting the initial VV-primed T cell responses. Future experiments plan 
to distinguish the roles in these responses. 
 
Experiment 2: VLPs used for Ab Priming and CD8 T Cell Boosting 
The results of the initial NYVAC-KC experiment described above showed that the viral 
vectors were inefficient at inducing Ab responses (Figure 33), and mucosal responses were quite 
low (Figure 34). Furthermore, priming with protein-based vaccine components has been shown to 
induce Ab responses that are more protective than priming with a viral vector (Bessa et al., 2012; 
Link et al., 2012). Additionally, the groups in the initial study did not effectively assess whether 
VLPs were responsible for partially boosting the VV primed CD8 T cell responses (Figure 37). 
Therefore, a second experiment was devised to answer whether the VLPs could prime for higher 
Ab titers and boost VV primed CD8 T cell responses (Figure 38A). 
Three groups of C57BL/6 mice (n = 5/group) were given VV prime at a higher dose (107 
pfu) than the initial study (106 pfu) to increase responses, and the vector was administered via 
scarification (scar.) in an effort to improve Ab production at mucosal sites via access to 
Langerhans dendritic cells in the epidermis. These groups were boosted with either VV (Group 2-
1), VLP (Group 2-2), or VV+VLP (Group 2-3). A fourth group received a VLP prime followed by 
VV+VLP boosting (VV given via scar., Group 2-4) to mimic the most successful group from 
Experiment 1 and to compare to a VV prime and VV+VLP boost (Group 2-3). Comparison 
between VV/VV and VV/VLP will permit analysis of the capacity of VLPs to successfully boost 
VV-primed CD8 T cell responses. The final two groups were given VV primes via the i.m. route 
and boosted with either VV alone (Group 2-5) or VV+VLPs (Group 2-6) to compare any difference 
in viral delivery route on T cell and Ab responses. 
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VLPs Prime Ab Responses More Efficiently than VV 
Consistent with Experiment 1, the group receiving VLP priming (purple triangles) was the 
only group to have detectable Ab responses to both Gag (Figure 38B) and dgp41 (Figure 38C) 
prior to the first boost at Day 45. And this group had consistently higher serum IgG levels 
throughout the course of the experiment, therefore confirming that VLPs are primarily responsible 
for the Ab responses. However, groups primed with VV and then subsequently boosted with 
VLPs or VV+VLPs maintain a steadier OD450 after boosting when comparing Gag-specific serum 
IgG (Figure 38B). Furthermore, administering the VV via scarification actually appears to diminish 
the serum IgG responses, because groups primed with VV and boosted with either VLPs alone 
(red squares) or VV+VLPs (green triangles) display lower OD 450 nm upon boosting than those 
receiving VV i.m. (black circles, Figure 38B-C). Overall, responses to MPER were exceedingly 
transient compared to Gag serum IgG (Figure 38B-C). Though the group primed with VLPs had 
the highest detectable responses, all groups had detectable MPER-specific serum IgG at the 
endpoint, with the exception of the two VV/VV (scar. and i.m.). Thus, further implicating that the 
NYVAC-KC vectors do not elicit strong Ab responses when administered alone, but are capable 
of maintaining steadier levels of Gag-specific serum IgG upon boosting with VV+VLPs (black 
circles/green triangles, Figure 38B). 
Furthermore, ELISA data from endpoint serum samples show that the only groups 
achieving a 100% responses rate (5/5 mice) for both Gag (Figure 39A & C) and MPER (Figure 
39B & D) responses are those groups which primed with VLPs or VV (i.m.) and boosted with 
VV+VLPs (purple triangles/black circles). However, VV scarification prime followed by VLPs 
alone (red squares) or VV+VLPs (green triangles) was still able to achieve an 80% response rate 
for Gag (Figure 39A & C) and 100% for MPER (Figure 39B & D). Interestingly, though the OD 
values show that the scarification viral administration may reduce responses (Figure 39A-B), all 
responding groups achieved similar endpoint titers for both Gag (Figure 39C) and MPER (Figure 
39D). 
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Mucosal Responses for Fecal IgA and Vaginal IgA/IgG 
Endpoint (Day 97) fecal samples were analyzed for Gag- (left) and MPER- (right) specific 
IgA, and vaginal lavage samples were assessed for both antigen-specific IgA and IgG (Figure 
40). Administering NYVAC-KC vectors via scarification did not improve the ability to elicit mucosal 
responses at any site measured. No detectable responses were achieved above mock 
background levels for either vaginal IgA (Figure 40C-D) or IgG (Figure 40E-F) for either Gag or 
MPER; thus re-affirming the results of Experiment 1 (Figure 34C). The only case where any 
group reached a higher mean OD450 was VV/VV+VLPs (i.m.) for MPER-specific fecal IgA (black 
circles, Figure 40B), however, this difference was not statistically significant. Interestingly, this is 
the same group which had significant MPER-specific fecal IgA in Experiment 1 (Figure 34B). No 
Gag-specific fecal IgA was detected in this study (Figure 40A), also aligning with results in 
Experiment 1. Therefore, there was no significant advantage to changing viral administration 
route, dose, or VLP expression vector in eliciting Ab responses at mucosal sites. 
 
Gag-specific CD8 T Cell Responses are Improved with Scarification and VLP Boosting 
One week after the final boost, Gag-specific CD8 T cell responses in the spleen were 
assessed using a peptide pool of five immunodominant ZM96 Gag epitopes for C57BL/6 mice 
(Figure 41). CD8 T cell populations were analyzed via flow cytometry for TNF-α and IFN-γ 
expression, and results are shown as the percentage of all CD8 T cells which are expressing one 
or both cytokines analyzed. 
VLPs are capable of significantly boosting VV-primed T cell responses, noting that VV/VV 
(blue) achieved 3.1% cytokine-expressing Gag-specific CD8 T cells, and VV/VLP (red) reached 
5.7%. Interestingly, the VV/VLP group had the highest CD8 T cell responses overall (5.7% of 
CD8 T cells) when scarification is used for the virus prime. After a scarification virus prime, 
boosting with VLPs alone (red) actually induced higher CD8 responses than boosting with both 
VV+VLPs (green), thus contrasting with the results of the Experiment 1. However, the second 
highest Gag-specific CD8 T cell responses were achieved by priming with VLPs and boosting 
with VV+VLPs (purple), reaching 4.5% Gag-specific CD8 T cells. There is no difference between 
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VV/VV and VV/VV+VLPs for either the i.m. or scarification route. However, scarification achieve 
slightly higher CD8 T cell responses at 3.1% and 2.7% for VV/VV and VV/VV+VLPs, respectively, 
compared with 1.8% Gag-specific CD8 T cells for both VV/VV and VV/VV+VLPs when 
administered via the i.m. route. Though this contrasts with the previous study, it is possible that 
the increase in dose also increased the anti-vector response, thus resulting in an overall 
reduction in Gag-specific CD8 T cells. 
 
Experiment 3: In vivo VLP Production by Cop-VLP to Enhance Vector-induced Ab Responses 
Several studies have shown that the MPER of gp41 must be in the context of a 
membrane to elicit bnAbs, and these responses are regulated by immune tolerance due to the 
self-reactivity of the bnAbs elicited by this region (Haynes et al., 2005; Haynes et al., 2016; 
Verkoczy et al., 2011; Verkoczy et al., 2013; Verkoczy et al., 2010; Williams et al., 2015; Zhang et 
al., 2016). Therefore, to enhance the immunogenicity of dgp41, a vector was generated which co-
expresses both Gag and dgp41 from the TK locus (Figure 31), as described above. Furthermore, 
due to toxicity of Gag and dgp41, described above and in Chapter 4, the only VACV strain in 
which both proteins were successfully introduced was Cop, the parental strain of NYVAC, thus 
generating Cop-VLP (i.e. co-expressing Gag/dgp41). This vector releases Gag/dgp41 VLPs in the 
medium of infected cells (Figure 31D), and since both proteins are present within the same viral 
genome, this permits VLP production in vivo without the need for viral co-infection to occur as 
with the NYVAC-KC-Gag and dgp41 vectors. Additionally, as shown in Experiments 1 and 2, 
NYVAC-KC-Gag and dgp41 administered together in a mixture do not induce Ab responses in the 
absence of VLP injections. Therefore, a third experiment (Experiment 3) was designed to assess 
whether Cop-VLP can effectively prime and/or boost VLP-induced Ab responses. 
Four- to six-week-old C57BL/6 mice (Jackson laboratories) were divided into four 
immunization groups and one mock group (n = 5/group, Figure 42A). The mock group received 
PBS i.m. injections and was shared with Experiment 2. Two groups received Cop-VLP (referred 
to as Cop in figures for brevity) priming with 107 pfu delivered via i.m. This dose was chosen due 
to the results of the dose-response experiment in Chapter 4 (Figure 28A). One group was boost 
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with Cop-VLP and the other with VLPs. VLP injections were prepared in PBS with Ribi adjuvant 
and administered i.p. The last two groups were both primed with VLPs and either boosted with 
VLPs or Cop-VLP. Comparison between groups will allow determination of the ability of in vivo 
vectored VLP production to both prime and boost Ab responses and whether it can achieve or 
surpass the high Ab titers known to be induced with the plant-produced VLPs alone (Kessans et 
al., 2016). 
 
Cop-VLP Efficiently Primes Ab Responses 
Serum IgG was monitored by ELISA at two week intervals for both Gag (Figure 42A) and 
MPER (Figure 42B). The OD450 is shown over the entire course of the experiment for both 
antigens and revealed that VLP priming induces much higher levels of Gag and MPER-specific 
responses, achieving a 100% response rate after a single dose (green and orange lines, Figure 
42B-C). On the contrary, only one of ten mice receiving Cop-VLP prime responded after a single 
dose, and only 20% responded (1/5 mice) after three doses at the endpoint for the Cop/Cop 
group. The Cop/Cop group was the only immunization regimen which did not achieve a 100% 
response rate after all three doses. This could suggest one of two things, either the dose is not 
sufficient to induce Ab responses when the virus is administered i.m., or the parental Cop virus 
has multiple immune modulators which are suppressing the Ab responses. Interestingly, Cop-
VLP did show efficient boosting of VLP-primed Gag responses, which continued to increase 
between the two boosts (orange line) as opposed to the decrease generally seen beyond two 
weeks post-boost with VLP immunizations (green line, Figure 42B). Consistent with this, the 
group primed with Cop-VLP and boosted with VLPs (Cop/VLP) sustained steadier levels of Gag-
specific serum IgG between the two boosts as well (purple line, Figure 42B). 
Furthermore, when looking at only the Day 97 serum IgG responses for Gag (Figure 43A) 
and MPER (Figure 43B), there is a general trend that groups boosted with VLPs achieve higher 
Ab levels than those boosted with Cop-VLP. However, while the VLP/Cop group reached OD 
levels similar to that of the VLP boosted groups, analysis of the endpoint titers for this group 
revealed that the Ab titers were in fact more similar to the Cop/Cop group for both Gag (Figure 
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43C) and MPER (Figure 43D). Interestingly, Cop-VLP priming was able to achieve Ab titers on-
par with those of three VLP immunizations for both antigens (Figure 43C-D). Therefore, based on 
the actual endpoint titers, Cop-VLP can prime antigen-specific serum IgG just as effectively as 
VLPs, though it is not as effective when used to boost VLP-induced Ab responses. Taken 
together, these results suggest that the best responses are achievable with heterologous prime-
boosting. 
 
Mucosal Responses to Gag and MPER for Cop-VLP Vectors 
Day 97 endpoint samples were analyzed for IgA and both fecal and vaginal sites in 
addition to IgG in vaginal lavages (Figure 44). Data is shown as the raw ELISA OD 450 nm 
values for all samples. Endpoint samples were assessed for fecal IgA to Gag (Figure 44A) and 
MPER (Figure 44B). Only one mouse had detectable Gag-specific IgA, and was surprisingly part 
of the Cop/Cop group which had lower serum IgG titers; however, this was a different mouse than 
the Gag-specific serum IgG responder in this group. Overall, mucosal responses to MPER were 
very low in fecal samples, however, the VLP/VLP group achieved a higher mean OD450 than the 
mock group, though this was not statistically significant. 
Vaginal lavage samples had undetectable IgA for both Gag (Figure 44C) and MPER 
(Figure 44D). Responses to MPER were also low for vaginal IgG (Figure 44F). However, Gag-
specific IgG was detectable in vaginal lavage samples with all groups achieving a higher mean 
than the mock (Figure 44E). For Gag-specific vaginal IgG, the VLP/VLP group achieved the 
highest mean. Unfortunately, results for individual mice within each group were too variable to 
detect statistical significance. 
 
VLPs Induce the Highest Gag-specific CD8 T Cell Responses 
One week after the final boost, Gag-specific CD8 T cell responses were assessed as 
described for Experiment 2 with a Gag peptide pool used for stimulation. The CD8 T cell 
population was analyzed for TNF-α and IFN-γ cytokine expressing and results are expressed as 
the percent of CD8 T cells expressing one or both cytokines (Figure 45). Results revealed that 
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the VLP/VLP group had the highest Gag-specific CD8 T cell responses, at 2.7%. All groups either 
boosted or primed with Cop-VLP did not achieve significantly higher responses than the mock 
background level. Therefore, it is likely that the Cop virus has genes which suppress the immune 
response that are deleted in the NYVAC-KC vector, thus accounting for its enhanced 
immunogenicity. 
 
Discussion 
The RV144 Thai Trial demonstrated the strength of prime/boost vaccination approach by 
effectively combining two components that were previously shown to be ineffective on their own: 
a live (albeit non-replicating) canarypox viral vector (ALVAC) and a soluble protein boost 
(AIDSVAX). The low efficacy of the trial left much to be desired for widespread use as a vaccine 
while providing the conceptual basis for further improvement (Rerks-Ngarm et al., 2009). The 
vaccine design strategy presented here makes use of replicating, but highly attenuated, vaccinia 
virus NYVAC-KC and plant-produced HIV-1 Gag/dgp41 VLPs. 
Our approach reflects two hypotheses. First, it is suggested that in addition to their 
excellent facility in eliciting T cell responses, replicating vectors are expected to increase antigen 
load, resulting in improved immunogenicity. Second we propose that VLPs would improve 
presentation of relevant neutralizing determinants to the immune system.  
Live recombinant vectors based on viruses belonging to a wide range of families such as 
adenoviridae, poxviridae, and herpesviridae have been previously tested for their immunogenicity 
(Buchbinder et al., 2008; Hansen et al., 2013a; Huang et al., 2015; Rerks-Ngarm et al., 2009; 
Tartaglia et al., 1992a). Considering the relative success of ALVAC within the context of RV144, 
this study and others have decided to focus on poxviruses [see reviews (Gomez et al., 2012a; 
Jacobs et al., 2009; Pantaleo et al., 2010)]. ALVAC is based on canarypox, which like other 
avipoxviruses is naturally attenuated in humans due to its restricted replication in non-avian cells 
(Taylor and Paoletti, 1988; Taylor et al., 1988), accounting for ALVAC’s high safety profile (Corey 
et al., 2001; Nitayaphan et al., 2004). Similarly, when developing vaccinia-based vaccine vectors, 
efforts were initially focused on strains that are non-replicating in human cells (e.g. MVA and 
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NYVAC), due to safety concerns over potential complications with VACV infection in immune-
compromised individuals.  
NYVAC was originally designed as a highly attenuated vaccine vector by specifically 
deleting 18 open reading frames from its parental strain (Cop), thus preventing its replication in 
humans (Tartaglia et al., 1992b). NYVAC has been tested as an HIV-1 vaccine vector and was 
shown to induce robust, polyfunctional CD4 and CD8 T cell responses to Env and Gag-Pol-Nef 
(GPN) antigens in vaccinated individuals (Harari et al., 2008; Harari et al., 2012). Because 
mucosal immune responses are thought to be particularly important in protection against HIV-1, it 
was significant to note that such responses could be detected in the gut of NYVAC-immunized 
patients (Perreau et al., 2011).  
More recently, intensive research led to partial uncoupling of attenuation and replication 
in NYVAC-based vectors showing enhanced immunogenicity without compromising their safety. 
Specifically, re-insertion of two host-range genes yielded NYVAC-KC. This strain is capable of 
replicating in human cells and displays enhanced immune activation, yet remains highly 
attenuated in a mouse model of pathogenesis (Kibler et al., 2011; Quakkelaar et al., 2011), thus 
giving this particular vector many desirable traits of a vaccine vector and was chosen for use in 
the work presented here. 
A large focus of HIV-1 vaccine research is the envelope protein (Env/gp120), and 
variations thereof. However, gp120 is not highly conserved, and many critical neutralization 
targets are hidden or are only exposed upon conformational change during viral entry, thus 
limiting the effectiveness of any nAb response to this antigen (Decker et al., 2005; Labrijn et al., 
2003; Pancera et al., 2014). Protein engineering has attempted to resolve many of these issues, 
including the design of SOSIP trimeric gp140 variants of Env to make a more structurally 
accurate target necessary for eliciting specific types of nAbs, including a design to specifically 
target nAb germline B cells (Billington et al., 2007; Du et al., 2009; Jardine et al., 2013; Sellhorn 
et al., 2012; Wan et al., 2009). Unfortunately, to date, no successful clinical trials incorporating an 
engineered gp140 antigen have been conducted. The HIV-1 membrane protein gp41 contains the 
bnAb target known as the MPER. This region requires the context of a membrane in order to elicit 
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the partially auto-reactive bnAbs found in HIV-infected patients (Haynes et al., 2005; Verkoczy et 
al., 2013; Verkoczy et al., 2010; Zhang et al., 2016). In an effort to achieve such responses in 
vaccination platforms, VLPs offer desirable qualities of enveloped, native virion structure for 
displaying this important neutralization target. 
VLPs are safe, yet immunogenic, components of several vaccines and candidate 
vaccines for multiple infectious diseases [for a review see (Kushnir et al., 2012)]. The potential for 
success of VLP-based vaccines is indicated by the widespread use of the human papillomavirus 
(HPV) vaccines Gardasil® (Merck & Co., 2006) and Cervarix® (GlaxoSmithKline, 2014). To date, 
many plant-produced vaccines have been tested in animal studies for immunogenicity for both 
human and veterinary diseases (Rybicki, 2010; Scotti and Rybicki, 2013). The plant-produced 
HIV-1 VLPs described here have the advantage of displaying the MPER of gp41 in the native 
context of a Gag matrix, providing an immunogenic platform for humoral responses to both 
antigens (Kessans et al., 2013; Kessans et al., 2016). Additionally, HIV-1 VLPs have been shown 
to boost T cell responses primed by viral vectors (Pillay et al., 2010). CD8 T cell responses, often 
targeting the Gag protein, are known to be associated with reduced viral load, making this a key 
target for protective T cell immunity (Jiao et al., 2006; Kiepiela et al., 2007; Koup et al., 1994; 
Mudd et al., 2012; Stephenson et al., 2012). 
Data presented here shows that infecting susceptible cells with NYVAC-KC-Gag with or 
without NYVAC-KC-dgp41 releases, respectively, ~100 nm Gag or Gag/dgp41 VLPs into the 
extracellular medium (Figure 30E). Such particles can be seen by TEM budding out of the cell 
(Figure 32B-2 and D-2). Interestingly, dgp41 is detected in the medium only when co-expressed 
with Gag (Figure 30E), a result compatible with the notion the two proteins assemble at the 
plasma membranes of cells in culture to form VLPs. Although HIV-1 VLPs produced by other 
VACV-based vectors were previously shown to elicit both humoral and cellular immunity (Chen et 
al., 2005; Goepfert et al., 2011), in the experiments presented here, no Abs were detectable in 
any group until after the first plant-derived VLP immunization (Figure 33B-C, Figure 38B-C). 
Among several potential explanations, the simplest one is that production of Gag/dgp41 VLPs in 
vivo necessitates co-infection of the same cell by the two viruses; this is achievable under cell 
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culture conditions where high MOI can be ensured, but is unlikely to occur in an animal. In an 
effort to accomplish in vivo formation of Gag/dgp41 VLPs launched from a VACV vector, the 
NYVAC parental strain, Cop, was engineered to co-express both proteins from the TK locus of a 
single recombinant virus, denoted Cop-VLP (Figure 31A). Infection with Cop-VLP showed a 
similar release of Gag/dgp41 into the growth medium, yet does not require co-infection of two 
viruses, making this a promising vector for in vivo studies (Figure 31D). Indeed, Cop-VLP was 
able to both prime and, to a lesser extent, boost plant-produced VLP-induced Ab responses 
(Figure 42B-C, Figure 43C-D). However, this vector worked best in a heterologous prime/boost 
system, because three doses of Cop-VLP resulted in a 20% response rate with low Ab titers 
(Figure 43). 
Another possible reason for the limited functionality of the NYVAC-KC vectors is the poor 
replication and/or spread in mice, potentially due to the cytotoxicity represented by protein 
precipitates in the cytoplasm and nuclear condensation in NYVAC-KC-Gag-, dgp41- or co-
infected cells (Figure 32B-D, and Chapter 3). The toxicity seen with TEM strongly correlates to 
reduced plaque sizes and lower viral titers noted during viral selection (see Chapter 4). Gp41 is 
known to have a toxic cytoplasmic tail (Micoli et al., 2006; Postler and Desrosiers, 2013), and it is 
possible that this is responsible for the toxic effects seen in Figure 32. The cytotoxicity of full-
length gp160 has largely limited the use of gp41 in vaccine candidates despite the appealing, 
highly conserved target region of the MPER. Additionally, this is consistent with published data 
that NYVAC expressing HIV-1 Gag-Pol-Nef induces extensive apoptosis (Gomez et al., 2007). 
Currently, attempts to resolve this issue are being pursued through other VACV strains which are 
capable of limiting the toxic effects of the gp41 cytoplasmic tail in an effort to make it easier to 
produce vaccine candidates with full-length gp160 in its native, structurally accurate conformation 
(see Chapter 4). 
Despite the poor priming capacity of the VV in terms of eliciting Ab responses against 
Gag and gp41, upon boosting with plant-derived VLPs at Day 45, Ab production spiked with 
another increase after the final immunization at Day 97 (Figure 33B-C, Figure 38B-C). Endpoint 
anti-p24 Ab titers reached significant levels for serum IgG in the group boosted with just VLPs or 
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the combination of VV+VLPs (Figure 35A), and all groups boosted with any combination of VV 
and VLPs (Groups 2-4) reached significance for MPER-specific serum IgG (Figure 34A). As 
noted above, due to the lack of detectable Abs prior to boosting with VLPs, it seems that the 
plant-produced VLPs are largely responsible for boosting the Ab responses following sub-
responsive priming. This was confirmed with Experiment 2, where the only group with detectable 
Ab responses to either Gag or dgp41 prior to boosting was the group primed with VLPs (Figure 
38B-C). However, priming with VV (i.m.) and boosting with VV+VLPs resulted in Ab titers which 
were just as robust as when priming with VLPs and administering the same boost (Figure 39C-D). 
Though again, the viral vector appears to have little influence on the titer because the VV/VLP 
group reached similar Ab levels as those boosted with VV+VLPs (Figure 39). The main 
advantage with VV prime and including VV in the boost appears to be in the steadiness of the Ab 
responses over time (Figure 38B-C). It is clear that those groups do not experience a rapid 
decline in Ab responses beyond 14 dpi, thus implicating that the viral vector is somehow 
sustaining these responses (Figure 38B-C). These results were further corroborated with Cop-
VLP inducing a similar phenomenon in which the heterologous prime/boost groups maintain a 
steady state of Abs over time compared to the VLP/VLP group (Figure 42B-C). However, in this 
instance, VLP/Cop immunization resulted in much lower titers than the opposite Cop/VLP 
regimen (Figure 43C-D). For Experiment 1, in the groups with the highest responses, these Abs 
were shown to be entirely IgG1 with no detectable IgG2a (Figure 35B-C). This agrees with data 
presented in Chapter 3 showing that plant-produced HIV-1 VLPs stimulate a predominant Th2 
response through activation of M2b macrophages, thus inducing strong B cell Ab production. 
In the initial study (Experiment 1), Gag-specific CD8 T cell responses were highest in the 
group boosted with VV+VLPs (Group 3), reaching 12.7% of CD8 T cells expressing IFN-γ in 
response to the five Gag peptides (Figure 37). When a higher dose was employed in Experiment 
2, the Gag-specific T cell responses actually declined from the initial study, indicated anti-vector 
responses may have been too high to allow substantial Gag-specific responses to develop 
(Figure 41). However, the use of scarification revealed that VV/VLP and VV/VV+VLPs induced 
the highest Gag-specific CD8 T cell responses, at 5.7% and 4.5%, respectively (Figure 41). 
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Interestingly, the use of scarification appeared to reduce the ability of VLPs to boost Ab 
responses (VV/VLPs, VV/VV+VLPs scar., Figure 38B-C). It is possible that sedation of the mice 
is largely responsible for the more limited Ab responses seen with scarification than with i.m. 
delivery, though by the endpoint, titers between these groups achieved highly similar levels 
(Figure 39C-D). Furthermore, VLPs were able to substantially boost VV-primed CD8 T cell 
responses (compare scar. VV/VV and VV/VLPs, Figure 41), and the Cop-VLP experiment 
showed VLPs alone can elicit up to 2.7% Gag-specific CD8 T cells (Figure 45). Cop-VLP 
administration with or without VLPs induced very low Gag-specific CD8 responses (< 2%) and 
were not significantly higher than background levels (Figure 45). It is likely that the immune 
modulators present in Cop that were deleted during the generation of NYVAC are primarily 
responsible for evading detection, thus limiting its use a vaccine vector. Therefore, a 
heterologous prime/boost system with NYVAC-KC vectors and plant-produced VLPs achieved 
almost twice the CD8 T cell response of VV or VLPs alone, and serves as further support for the 
use of both vaccine components in an immunization regimen. 
While a non-replicating vector was not included in this study, these responses are higher 
than MVA-induced Gag-specific CD8 T cells (< 0.5%) in humans after two doses (Keefer et al., 
2011). Additionally, results here show higher Gag-specific CD8 T cell responses than seen in 
mice after DNA-NYVAC or DNA-MVA prime-boost regimen which elicit < 2% GPN/Env-specific 
CD8 T cells (< 0.5% Gag specific) and 12-15% GPN/Env-specific CD8 T cells (5.5% Gag-
specific), respectively (Garcia-Arriaza et al., 2013; Gomez et al., 2012b). Taken together, this 
may suggest that replication plays a role in increasing T cell responses. Results from NYVAC 
HIV-1 vaccines have shown proficiency for eliciting polyfunctional T cell responses (i.e. antigen-
specific T cells expressing multiple cytokines) which are primarily effector memory T cells 
(Garcia-Arriaza et al., 2011; Gomez et al., 2012b; Harari et al., 2008; Harari et al., 2012). This is 
important to explore in future experiments involving replicating vectors such as NYVAC-KC due to 
the association of polyfunctional T cells in the periphery with prevention of HIV-1 infection (Betts 
et al., 2006). Additionally, it is important to note than when Env is included in the MVA or NYVAC 
vector, T cell responses are skewed to be primarily Env-specific with minimal Gag recognition 
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(Garcia-Arriaza et al., 2013; Garcia et al., 2011; Gomez et al., 2012b; Harari et al., 2008; Harari et 
al., 2012; Mooij et al., 2009). Env-specific cytotoxic T lymphocyte (CTL) responses were not 
protective in clinical trials nor correlated with improved disease in natural infection (McMichael 
and Koff, 2014), while Gag-specific responses have been correlated with improved CD4 count 
and reduced viral load (Brander and Walker, 1999; Jiao et al., 2006; Kiepiela et al., 2007; Koup et 
al., 1994; Ogg et al., 1998; Stephenson et al., 2012) and have epitopes which are less prone to 
CTL escape (Goulder and Watkins, 2004). 
Here it was shown that the combination of NYVAC-KC-Gag/dgp41 replicating vaccinia 
virus vectors are immunogenic in mice and elicit the best responses when administered together 
in a regimen closely mimicking the RV144 clinical trial (VV/VV+VLPs). The NYVAC-KC vector is a 
replicating, but safe, live viral vector with which we can induce higher Gag-specific CD8 T cell 
responses than with non-replicating poxviral vaccine vectors.  Plant-produced VLPs show 
proficiency for eliciting high Ab titers and may boost T cell responses primed by the NYVAC-KC 
vectors, though this is the subject of future studies. These vaccine candidates show promise as a 
cost-effective, scalable vaccine production platform to take forward in an effort to build upon the 
known success of the RV144 clinical trial to find the elusive HIV-1 vaccine. 
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Figure 30 - Generation of Recombinant NYVAC-KC Viruses 
Plasmids were cloned to contain either full-length HIV-1 Gag (A) or dgp41 (B) as pTM 815 and 
816, respectively. The genes are located between homologous recombination arms for the VACV 
TK locus under the control of a synthetic early/late (E/L) promoter. Also included is the neomycin 
resistance gene fused to GFP (GFP-neoR). (C and D) SDS-PAGE shows full-length Gag (C) or 
dgp41 (D) expression in BSC-40’s of NYVAC-KC-Gag (Lane 2) and dgp41 (Lane 3) from the final 
P2 virus stock used in animal experiments. Parental NYVAC-KC shows no expression of either 
protein (Lane 1). (E) SDS-PAGE of ammonium sulfate precipitations from media of BSC-40 cells 
infected with: NYVAC-KC (WT, Lane 1), Gag (Lane 2), dgp41 (Lane 3), or a co-infection of 
Gag/dgp41 viruses (G/d, Lane 4). Samples were tested for both Gag (top) and dgp41 (bottom) 
expression. 
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Figure 31 - Generation of Recombinant Cop Viral Vectors 
A plasmid was cloned to co-express full-length HIV-1 Gag and dgp41 for insertion into the TK 
locus (A). Coumermycin selection was used to generate Cop-Gag with pTM 815 and Cop-VLP 
with pTK-Gag/dgp41 from the parental Cop-PGNR (Gyrase-PKR, neomycin resistance). 
Expression in BSC-40s is shown for both Gag (B) and dgp41 (C). (D) VLP release into the media 
is also shown for both Cop vectors for Gag (top) and dgp41 (bottom). Immunoblots were 
performed after ammonium sulfate precipitation of cellular growth medium of BSC-40s infected 
with the indicated vectors. 
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Figure 32 - Electron Microscopy of NYVAC-KC Infected BSC-40s 
BSC-40 cells were infected at an MOI of 5 and harvested 24 hpi and prepared for transmission 
electron microscopy. Cells were infected with either NYVAC-KC (A), NYVAC-KC-Gag (B), 
NYVAC-KC-dgp41 (C), or a co-infection with an MOI of 5 for each NYVAC-KC-Gag and NYVAC-
KC-dgp41 (D). All stages of VACV replication are present: mature virions (white arrow), immature 
virions (black triangle), immature virions with genome incorporated (white triangle), crescent 
formation (black arrow), and ‘unfilled/empty’ virions (E). Budding HIV-1 Gag VLPs (black star) are 
also seen in those cells infected with NYVAC-KC-Gag. In certain infections, an accumulation of 
cytoplasmic ‘junk’ (J) is visible. Other cellular features: mitochondria (M), nucleus (N). Scale bar: 
500 nm for all images, except (B-2) and (D-2) images are 100 nm for HIV-1 VLPs. 
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Figure 33 – Experiment 1: Mouse Immunization Schedule for NYVAC-KC Vectors 
(A) Six-week-old C57BL/6 mice were immunized at days 0, 45, and 90 with different combinations 
of recombinant vaccinia virus and plant-produced HIV-1 VLPs, represented as an image of a 
poxvirus or green-enveloped particles, respectively. Vaccinia virus doses (VV) consisted of 1 x 
106 pfu of equally mixed NYVAC-KC-Gag and NYVAC-KC-dgp41 delivered i.m. while plant-
produced VLPs were mixed with Ribi adjuvant and delivered i.p. with 2 μg p24 and 1.2 μg MPER. 
Serum, fecal, and vaginal lavage samples were collected once every 2 weeks (indicated by 
arrows). Serum samples were analyzed for antigen-specific IgG to p24 Gag (B), or the MPER 
region of dgp41 (C), shown over the length of the experiment as the ELISA OD 490 nm for the 
1:50 dilution (lowest tested). 
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Figure 34 – Experiment 1: Systemic and Mucosal Ab Production with NYVAC-KC Vectors 
 
Endpoint (Day 97) samples were analyzed for serum IgG (A), and mucosal IgA in fecal (B) and 
vaginal lavage (C) samples. Data is shown for both p24-specific (left) and MPER-specific (right) 
antibodies. Raw OD 490 nm values are shown for the lowest dilution factor tested (1:50). 
Statistically significant differences (p < 0.05) are indicated with an asterisk (*). Each marker 
represents a single animal. 
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Figure 35 - Experiment 1: Endpoint Serum IgG Titers and Isotyping 
(A) Endpoint titers were calculated as the reciprocal of the dilution factor that had background 
level of OD 490 nm (< 0.1). Isotypes were determined by ELISA for antigen-specific IgG1 (B) or 
IgG2a (C) for both p24 (left) and MPER (right) serum IgG. OD 490 nm readings are shown and 
clearly indicate a bias towards IgG1 production for both groups. Only endpoint (Day 97) serum 
samples were tested for these two groups because they had the highest responses. 
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Figure 36 - Experiment 1: Anti-VACV Responses in Serum at Endpoint 
Day 97 endpoint serum was analyzed by ELISA for anti-vector responses with endpoint titers 
calculated as for Gag and dgp41-specific serum IgG. The group which received a total of 3 doses 
of NYVAC-KC vectors shows significantly higher titers of VV-specific antibodies compared with 
any other group (purple triangles). (*** p < 0.001; **** p < 0.0001) 
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Figure 37 - Experiment 1: Gag-specific CD8 T Cell Responses 
One week after the final immunization, peak CD8 T cell responses were measured by intracellular 
cytokine staining and flow cytometry for 5 immunodominant ZM96 Gag epitopes: AMQ8 (A), 
EVK10 (B), LRS8 (C), VIP8 (D), and YSP8 (E). Number of IFN-γ+ CD8+ T cells in the spleen is 
shown for each peptide individually and the total response in the spleen (F) was calculated by 
adding the individual responses together for each group. The group boosted with VV and VLPs 
(purple) was significantly higher than the VV/Tris group (red) for two peptides and the overall 
response. (* p < 0.05; ** p < 0.01) 
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Figure 38 - Experiment 2: Mouse Immunization Schedule and Serum IgG Over Time 
(A) Four- to six-week-old C57BL/6 mice (n = 5/group) were immunized at days 0, 45, and 90 with 
107 pfu of mixed NYVAC-KC-Gag and dgp41 vectors either via scarification (scar.) or i.m. VLPs 
were mixed with Ribi adjuvant and delivered i.p. The mock group received i.m. injections of PBS 
and was shared with Experiment 3. Serum IgG specific for p24 Gag (B) or the MPER of dgp41 
(C) are shown as OD 450 nm at 2 week intervals. 
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Figure 39 - Experiment 2: Endpoint Serum IgG Responses for Gag and MPER 
Endpoint (Day 97) serum samples were analyzed for p24 Gag (left) or MPER (right) specific IgG. 
The raw ELISA OD 450 nm data is shown for both p24 (A) and MPER (B). Endpoint titers were 
calculated from this data as the reciprocal of the first dilution at which the OD 450 nm falls below 
background levels (OD < 0.1). Endpoint titers were log-transformed and are shown for both p24 
(C) and MPER (D). Statistical significance is indicated with an asterisk. (* p < 0.05; ** p < 0.01; 
**** p < 0.0001) 
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Figure 40 - Experiment 2: Mucosal Responses for Gag and MPER 
Endpoint (Day 97) fecal samples were analyzed for antigen-specific IgA and vaginal lavage 
samples were analyzed for both antigen-specific IgA and IgG. All ELISA data is shown as the raw 
OD 450 nm value. Each data point represents a single animal. Fecal IgA is shown for both p24 
Gag (A) and MPER (B). Vaginal lavage samples were assessed for p24-specfic IgA (C) and IgG 
(E) and MPER-specific IgA (D) and IgG (F). No statistical significance was found. 
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Figure 41 - Experiment 2: Gag-specific CD8 Responses in the Spleen 
One-week after the final boost, Gag-specific CD8 responses were measured by incubating 
splenocytes with a peptide pool consisting of five immunodominant Gag peptides followed by 
intracellular cytokine staining for TNF-α and IFN-γ. Total cytokine expressing CD8 T cells (i.e. 
expressing one or both cytokines) are shown as the percent of all CD8 T cells. Statistical 
significance between groups is indicated with an asterisk. (* p < 0.05; ** p < 0.01; *** p < 0.001) 
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Figure 42 - Experiment 3: Mouse Immunization Regimens and Antigen-specific Serum IgG 
Over Time 
 
(A) Four- to six-week-old C57BL/6 mice were immunized with the indicated regimens. Cop-VLP 
(shown as Cop) was administered at 107 pfu via the i.m. route. VLPs were prepared in Ribi 
adjuvant and delivered i.p. Antigen-specific serum IgG was analyzed every two weeks for p24 
Gag (B) or MPER (C) responses. Data is shown as the raw OD 450 nm at each time point. 
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Figure 43 - Experiment 3: Endpoint Serum IgG Responses to Gag and MPER 
Endpoint (Day 97) serum samples were analyzed for p24 Gag- (left) or MPER-specific (right) IgG 
responses. Raw ELISA OD 450 nm data is shown for both p24 (A) and MPER (B). Endpoint titers 
were calculated from OD 450 nm values as the reciprocal of the first dilution factor where the OD 
fell below background levels (OD < 0.1). The log of the endpoint titer is shown for p24 (C) and 
MPER (D) serum IgG responses. Statistical significance is indicated with asterisks. (** p < 0.01; 
*** p < 0.001; **** p < 0.0001) 
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Figure 44 - Experiment 3: Mucosal Responses to Gag and MPER for Cop Vectors 
Endpoint (Day 97) fecal samples were assessed for antigen-specific IgA and vaginal lavage 
samples were analyzed for both antigen-specific IgA and IgG. All data is shown as the raw OD 
450 nm values. Each data point represents a single animal. Fecal IgA to both p24 Gag (A) and 
MPER (B) are shown. Vaginal lavage samples were assessed for p24 Gag-specific IgA (C) and 
IgG (E) and for MPER-specific IgA (D) and IgG (F). No statistical significance was observed. 
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Figure 45 - Experiment 3: Gag-specific CD8 T Cell Responses in the Spleen 
One week after the final boost, CD8 T cell responses to Gag were analyzed by incubating 
splenocytes with a pool of five immunodominant Gag epitopes followed by intracellular cytokine 
staining for TNF-α and IFN-γ. Total cytokine expressing Gag-specific CD8 T cells (i.e. expressing 
one or both cytokines) is shown as the percentage of all CD8 T cells in the spleen. Statistical 
significance between groups is indicated by an asterisk. (* p < 0.05; ** p < 0.01) 
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Chapter 6 
SUMMARY AND OUTLOOK 
 
The HIV-1 pandemic is a steep burden on society, economically and socially. The 
millions of new infections each year are disproportionately affecting populations that do not have 
the infrastructure to properly curb the spread and help those already infected. In the absence of a 
vaccine, antiretroviral therapy has proven to be the most powerful, yet temporary solution, and 
treatments are expensive and lifelong. The modest 31% efficacy of the RV144 trial revived hope 
that an HIV-1 vaccine is achievable (Rerks-Ngarm et al., 2009). The combination of a non-
replicating canarypox vector with rgp120 boosting led many others to pursue other poxvirus 
vectors that were designed to be safe, yet highly immunogenic (Esteban, 2014; Gomez et al., 
2012a; Pantaleo et al., 2010). NYVAC represents one of these vectors, and it has shown much 
success in preliminary phase I/II clinical trials (Table 2). However, NYVAC is non-replicating, and 
it has been hypothesized that replication-competent viral vectors will enhance immunogenicity 
through increased antigen presentation and immune activation (Parks et al., 2013). Indeed, the 
only study in which a vaccine was able to clear an established SIV infection used a replication-
competent CMV vector (Hansen et al., 2013a), and this was shown to act through non-canonical 
MHC II antigen presentation to CD8 T cells (Hansen et al., 2013b). Thus, re-insertion of two 
genes into NYVAC generated NYVAC-KC, which is proposed as a replicating, immunogenic, and 
highly attenuated HIV-1 vaccine candidate (Kibler et al., 2011; Quakkelaar et al., 2011). 
To further enhance immunogenicity, NYVAC-KC was used in conjunction with plant-
produced HIV-1 Gag/dgp41 VLPs to replace the rgp120 used in RV144. These VLPs were 
previously shown to be immunogenic in mice and are capable of eliciting mucosal responses 
(Kessans et al., 2016). VLPs represent large immune complexes with high antigen density, as a 
safe alternative to attenuated HIV-1 vaccines and a more structurally accurate presentation of 
viral proteins than the soluble gp120 used in RV144, which has since been shown to not engage 
germline B cell precursors to bnAb lineages (Hoot et al., 2013; McGuire et al., 2014). The HIV-1 
transmembrane protein gp41 is proposed here as a more highly conserved target than gp120 
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(Modrow et al., 1987), which contains the bnAb target MPER (Huang et al., 2012; Purtscher et al., 
1994; Zwick et al., 2001). It has been suggested that bnAbs to the MPER are difficult to elicit due 
to their partial autoreactivity resulting in immune tolerance (Alam et al., 2007; Alam et al., 2009; 
Haynes et al., 2005; Haynes et al., 2016; Verkoczy et al., 2011; Verkoczy et al., 2013; Verkoczy 
et al., 2010; Zhang et al., 2016), in addition to the high affinity maturation and somatic mutations 
found in these B cell lineages (Kepler et al., 2014; Klein et al., 2013a; Liao et al., 2011; Mascola 
and Haynes, 2013). Therefore, a strong immunogen presenting MPER in the context of a 
membrane will likely be required in order to effectively elicit prolonged Ab responses that could 
lead to bnAbs. In studies presented here, NYVAC-KC vectors were successfully used in 
combination with Gag/dgp41 VLPs to elicit high titer Ab responses and CD8 T cell responses. 
Furthermore, the interaction of VLPs with the innate immune system was successfully 
characterized in addition to developing production methods in which the amount of MPER 
associated with Gag VLPs is increased to provide a higher antigen density. 
Other groups have previously expressed full-length p55 Gag in N. benthamiana with low 
yield [44 μg/kg FW, (Meyers et al., 2008)], though this can be substantially increased when 
expressed in chloroplasts [over 500 mg/kg FW, (Scotti et al., 2009)]. Here efforts achieved 
enhanced cytoplasmic expression of p55 Gag VLPs, up to 1 mg/kg FW, using either transgenic 
plants or transient expression with Gemini vectors co-expressing dgp41 and a gene silencing 
suppressor protein. However, the most promising outcome from comparing different expression 
vectors was that the ratio of MPER:p24 can be substantially increased when co-expressing Gag 
and dgp41 transiently with a Dual Gemini +p19 vector. A molar ratio ranging from 1.7-11.8 
MPER:p24 Gag, thus achieving the goal of increasing the available antigenic spikes for MPER. 
VLPs produced with this vector produced 1-2 log higher Ab titers than those produced with the 
TMV-based vector in our final vaccination studies when immunizations are standardized based 
on the amount of p24 Gag (compare Experiment 1 with Experiments 2 and 3 in Chapter 5). 
Future studies will determine whether this increased antigenic sites have any effect on 
neutralization capacity. 
166 
Additionally, plant-produced VLPs were shown to induce Ab responses through a TLR-
dependent pathway that results in a Th2-biased response through a CD11b+ population, at least 
partially consisting of M2b alternatively activated macrophages. Surprisingly, VLP stimulation of 
all TLRs was detectable, and ex vivo experiments with splenocytes from TICAM-/- and MyD88-/- 
mice suggest that both adaptor proteins are involved in the observed activation. Thus, based on 
known signaling pathways (Kawai and Akira, 2010; Takeda et al., 2003), TLR4 is likely the 
primary target of the VLPs, and implicates A. tumefaciens-derived LPS as the primary PAMP; 
however, this has yet to be determined in TLR4-/- mice or LPS-deficient VLPs and/or A. 
tumefaciens. Nucleic acids were also detectable encapsulated within the VLPs, confirming 
previous reports of Gag VLPs non-specifically incorporating host mRNA (Valley-Omar et al., 
2011). It would be interesting to determine whether these RNA species are derived from the plant 
or the viral expression vector, because Gag VLPs from uninfiltrated plants did not stimulate the 
nucleic acid TLRs. Future studies should also address whether the RNA remains functional in 
mammalian cells (i.e. whether translation can occur), and delineate whether the VLPs are being 
endocytosed and autophagocytosed to deliver the nucleic acids to the endosomal TLRs. 
Furthermore, an interesting characteristic of both DC and macrophage activation was the 
up-regulation of CD40 induced by the VLPs. CD40 is a main co-stimulatory molecule for DC and 
macrophage regulation of the T cell response (Grewal and Flavell, 1998; Quezada et al., 2004; 
Schonbeck and Libby, 2001; Summers deLuca and Gommerman, 2012). In binding to CD40L, 
APCs can initiate a Th1 response to initiate CD8 T cells or a Th2 response for B cell activation 
through differential cytokine secretion (Mosmann and Coffman, 1989). Soluble CD40L has been 
used in multiple vaccination studies (Hanks et al., 2005; Lefrancois et al., 2000), including as a 
type of adjuvant for an HIV-1 poxvirus vaccine (Gomez et al., 2009), to efficiently enhance 
immunogenicity. Future studies should delineate whether the observed CD40 up-regulation is 
required for VLP-induced Ab production and CD8 T cell responses. 
Interestingly, the VLPs bias the immune response toward Th2, thus potently activating B 
cells to produce IgG1, as shown in Chapter 3. However, despite the clear Th2 bias in B cell 
responses, CD8 responses primed by NYVAC-KC vectors were effectively boosted by VLPs 
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alone, and these were more robust than boosting with NYVAC-KC (Chapter 5, Experiment 2). 
These characteristics indicate an inherent adjuvancy for the plant-produced VLPs that has not 
been previously described. Though baculovirus (Buonaguro et al., 2008) and yeast (Tsunetsugu-
Yokota et al., 2003) based Gag VLPs have reported innate immune activation, only the latter was 
traceable to TLR2 stimulation. TLR-based adjuvants are of increasing interest for use in vaccines 
due to the immunological link between TLR activation and adaptive responses (Akira et al., 2001; 
Hjelm et al., 2014; Nagpal et al., 2015; Nemazee et al., 2006; Pasare and Medzhitov, 2004; 
Pasare and Medzhitov, 2005; Schnare et al., 2001; Steinhagen et al., 2011; van Duin et al., 
2006). B cells can even be activated in a T-independent manner when binding an antigen while 
receiving signals from TLRs (Pasare and Medzhitov, 2005). These data suggest that adjuvants 
and antigens could be strategically matched for tailoring the immune response toward Th1 or Th2 
based on the needs of the vaccine. For HIV-1, both potent CD8 T cell and B cell responses will 
likely be required for long-lived protection, thus the VLPs should be adjuvanted to enhance Th1 
responses in an effort to further improve Gag-specific CD8 T cell frequency. Furthermore, a Th2 
response results in IgG1, IgG3, and IgG4 isotype switching, but not IgG2a (Fujieda et al., 1995). 
Based on the comparison between VAX003 and RV144, it is now known that excessive protein 
boosting can lead to conversion of IgG3 protective Abs toward IgG4 inhibitory responses (Chung 
et al., 2014). Data here indicated strong bias toward IgG1, per the Th2 response, however, future 
isotyping should be pursued to characterize the difference in the heterologous prime/boosting 
regimens on the ratio of IgG3 to IgG4, in addition to determining Ab effector functions and 
neutralization capacity. 
Vaccination studies with the NYVAC-KC vectors revealed that high doses of NYVAC-KC 
are necessary to induce higher CD8 T cell responses, and that the vectors alone are not good 
inducers of Ab responses. It is possible that some of this is due to the toxicity to infected cells and 
the viral vector. The observed toxicity seems to be a result of ER stress from recombinant protein 
expression and resulting activation of a TBK1-dependent IRF3 pathway. Interestingly, though 
inhibition of TBK1 abrogates IRF3/IFN-β and PERK signaling, this was unable to rescue viral 
growth and eIF2α phosphorylation. There are many upstream kinases for eIF2α (de Haro et al., 
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1996; Donnelly et al., 2013), thus, it appears there may be redundant pathways involved in 
inhibiting NYVAC-KC replication when expressing HIV-1 antigens. Furthermore, addition of 10 
extra genes in NYVAC-KC (NYVAC+12), including the TBK1 inhibitor C6L (Unterholzner et al., 
2011), did not rescue IRF3 phosphorylation. Even Cop-Gag, which contains all genes missing 
from NYVAC-KC, still displayed IRF3 activation, though this vector was able to induce more 
potent CD8 T cell responses to Gag at lower doses than NYVAC-KC-Gag. Therefore, while C6L 
may not be sufficient to rescue IRF3 in vitro, NYVAC+12-ZM96 CD8 T cell responses should be 
directly compared to NYVAC-KC-Gag in a dose response experiment in order to assess the 
significance of this gene in vivo. Others have demonstrated that deletion of C6L from MVA 
actually enhances immunogenicity (Garcia-Arriaza et al., 2013; Garcia-Arriaza et al., 2011), 
however, MVA and NYVAC have different genetic deletions, thus the interaction of C6L with 
immunogenicity of NYVAC-KC should be assessed. 
Two genes outside of the K1L to C7L fragment which may be involved in the reduced 
viral titers for NYVAC-KC-Gag and dgp41 could be B13R and B14R. B13R is an inhibitor of 
caspase-dependent apoptosis (Dobbelstein and Shenk, 1996; Kettle et al., 1997), while B14R is 
an inhibitor of NFκB, but not apoptosis (Chen et al., 2008; Graham et al., 2008). Specifically, 
B14R is of great interest due to its ability to bind to and inhibit IKKα/β and NEMO (Chen et al., 
2008), which have been shown to regulate TBK1/IRF3 activation in TNF death receptor and TLR 
signaling cascades (Clark et al., 2011). The same study also demonstrated a direct interaction 
between TBK1 and NEMO (Clark et al., 2011), thus the absence of B14R may be the primary 
reason why the K1L-C7L gene fragment did not rescue signaling. This could further explain why 
MRT inhibition of TBK1/IRF3, but not IKKα/β regulation of NFκB, results in inability to rescue 
growth. Future work should include genetic knockouts for TBK1/IRF3 in addition to NFκB and up-
stream kinases, especially STING, to delineate the exact pathway activated here. STING is a 
primary target, because it is involved in inflammasome activation through RIG-I/MAVS at the 
mitochondria interface, interacts with the secretory pathway from the ER for potential regulation of 
ER stress through calcium flux, and its ability to stimulate both NFκB and TBK1/IRF3 signaling 
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pathways (Ishikawa and Barber, 2008), thereby connecting STING to PERK, caspase activation 
(B13R function), and transcription factor regulation (B14R function). 
The final vaccination trials with NYVAC-KC and plant-produced VLPs revealed that VLPs 
are the primary inducer of Ab responses, but viral vectors can prime and boost VLP-induced B 
cells responses. In contrast to a single dose of Cop-VLP, Abs could be detected, though the 
repetitive high dose seemed to decrease Gag-specific CD8 T cell responses compared to a 
single dose. Thus, the genes deleted from Cop to make NYVAC-KC seem to greatly alter 
immunogenicity and further support the use of NYVAC-KC as a vaccine vector. Additionally, a 
VLP prime is supported by reports that VLPs and not soluble antigen are capable of inducing 
follicular transport of antigen by DCs to enhance presentation to B cells (Bessa et al., 2012; Link 
et al., 2012), and that NYVAC is a more efficient boosting component than priming immunization 
(Bart et al., 2014). VLP priming should be directly compared to the common DNA priming used in 
the EuroVacc NYVAC phase I/II trials to determine whether the stronger Ab prime by VLPs could 
greatly enhance immunogenicity. Furthermore, an intriguing result showed that heterologous 
prime/boosting actually seemed to induce a more steady-state Ab response upon boosting than 
when VLPs were used alone. Similar recent studies using NYVAC and a gp120 boost have 
shown greatly enhance T cell and Ab responses, as described here (Asbach et al., 2016; Garcia-
Arriaza et al., 2015; Hulot et al., 2015; Mooij et al., 2015). Some of these studies even used GPN 
VLPs with gp140 spikes (Garcia-Arriaza et al., 2015; Perdiguero et al., 2015). Such vectors would 
be interesting to pursue to determine the effect on the neutralization profile induced by an Env 
spike lacking a gp41 cytoplasmic tail (CTT), as others have reported significant morphological 
changes to gp120 when altering the CTT of gp41 (Durham et al., 2012; Kalia et al., 2005; Vzorov 
et al., 2016). Based on all of the studies above and results described throughout, it is proposed 
that VLPs should serve as the prime followed by a viral vector plus protein boost to elicit high 
titer, steady release Ab responses and to elicit more potent CD8 T cell responses than a viral 
vector prime. 
Overall, this dissertation supports the heterologous prime/boost system of plant VLPs 
and NYVAC-KC HIV-1 vectors as a safe, immunogenic vaccine candidate with unique properties 
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for high density of MPER antigen on the surface of VLPs, unique innate immune stimulation, and 
ability to induce robust Ab and CD8 T cell responses. Results described here spawned the 
pursuit of similar strategies for emerging infectious diseases, including Ebola and Zika vaccines. 
Zika is an especially intriguing prospect because VACV has been used to produce VLPs in vivo 
for a Zika relative, Japenese encephalitis virus (JEV), which were shown to be protective in mice 
(Kanesa-thasan et al., 2000; Konishi et al., 1992). Ebola is an interesting concept as well 
because passive immunization with ZMapp, a plant-produced cocktail of monoclonal Abs, was 
protective in non-human primates and aided treatment efforts in the recent Ebola outbreak (Qiu et 
al., 2014). Others have also shown that Ebola VLPs are protective in non-human primates 
(Warfield et al., 2015), suggesting that the strong Ab induction of VLPs represents desirable 
platform for an Ebola vaccine. The ability of poxvirus vectors to elicit Ab responses is becoming 
an increasing focus point for vector research (Draper et al., 2013), thus, enhancing the Ab 
production by NYVAC-KC would provide a further boost to a heterologous vaccine, and 
identifying the genes responsible for the in vitro and in vivo attenuation of NYVAC-KC HIV-1 
antigen-expressing vectors should a priority. Thus, NYVAC-KC and plant-produced VLPs have a 
promising future not only for HIV-1 vaccines, but for many other emerging infectious diseases 
which require rapid, large-scale production of attenuated, but highly immunogenic constituents 
capable of inducing potent Ab and T cell responses. 
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